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1
Noonan Syndrome is a multisystem genetic disorder with an estimated incidence of 1 in 
1.000 to 1 in 2.500 live births (1, 2). Noonan syndrome is diagnosed clinically by observation 
of key features. The cardinal features of Noonan syndrome are characteristic facies, 
congenital heart defects, short stature, skeletal abnormalities, cryptorchidism, lymphatic 
dysplasia, and variable degrees of development delay (3-6). Noonan syndrome is an 
autosomal dominant condition. In approximately 50% of cases, Noonan syndrome occurs 
as the result of a de novo mutation in one of the Noonan syndrome genes. The clinical 
features present in a person with Noonan syndrome can be extremely variable (7, 8). 
History
In retrospect, Kobylinski described the first patient with features of Noonan syndrome 
over 130 years ago (9). He published his report ‘Ueber eine flughautahnliche Ausbreiting 
am Halse’ [About a flight membrane-like extension in the neck] referring to the webbing 
seen in Noonan syndrome patients (Figure 1). 
Figure 1   Kobylinski’s patient Leisar Eischikmann, possibly the first illustration of  
a patient with Noonan syndrome (10).
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In 1938, Henry Turner described a series of older women with typical facial features, 
webbed neck, short stature, cubitus valgus, and sexual infantilism (11). The essential features 
of the complex were independently described by Ullrich in 1949 (12). He recognized both 
females and males with a similar phenotype, which he named ‘status Bonnevie-Ullrich’, 
after Bonnevie’s work on mice. As a result of these publications, different denominations 
were used to describe this phenotype, and the eponym ‘Ullrich-Turner’ syndrome was 
born. 
 New cytogenetic techniques developed simultaneously in several laboratories during 
1959 and disclosed monosomy X as the chromosome abnormality in female Ullrich-Turner 
syndrome. However, as mentioned above by Ullrich, and additionally in other studies, 
male patients were also reported with similar features and were mentioned as having 
‘Male Turner syndrome’ or ‘Turner phenotype with normal chromosomes’, the latter based 
on chromosome studies in males (13-15). 
 In 1959 Dr. Jacqueline Noonan was appointed as the first pediatric cardiologist at 
 the University of Iowa, where she conducted a clinical study with Dorothy Ehmke. 
They studied 833 children with congenital heart disease for the presence of additional 
extra-cardiac anomalies. In nine of these children, they recognized a similar clinical 
presentation, consisting of valvular pulmonary stenosis, characteristic facies, and short 
stature (16). Her subsequent paper described 19 patients (12 males and 7 females) with 
typical facial features, congenital heart disease, and clinical features of Turner’s Syndrome 
with normal chromosomes and labeled this syndrome: ‘Hypertelorism with Turner 
phenotype’ (17). In subsequent publications, the eponym ‘Ullrich-Noonan’ syndrome was 
also used. 
 Dr. John M. Opitz, a medical student and first year resident in Professor Noonan’s 
department, suggested that the term Noonan’s syndrome should be used for this 
condition and confirmed Noonan’s syndrome as a nosologic entity (18, 19). This name 
gradually changed over the years from Noonan’s syndrome to Noonan syndrome. 
The clinical phenotype of Noonan syndrome
Diagnosis of Noonan syndrome is primarily based on clinical findings. Several scoring 
systems are described to guide the diagnostic process. In 1994, van der Burgt et al. 
developed a scoring system that was updated in 2007 (Table I) (6). These criteria are of 
particular value in the research domain and are embedded in management guidelines 
developed by Dyscerne in the United Kingdom (20). This clinical management guideline also 
provides details of recommended baseline investigations and age-specific management.
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Craniofacial features 
The facial dysmorphisms show variability in expression (figure 1) and considerable change 
with age, being more prominent in childhood and more subtle in the adult. Important 
facial features in the newborn are a broad and high forehead, hypertelorism, epicanthic 
folds, and downslanting palpebral fissures, a short and broad nose with a depressed root 
and upturned tip, deeply grooved philtrum with high, wide peaks of the vermilion border 
of the upper lip, micrognathia, low-set posteriorly rotated ears with a thick helix, high 
arched palate, a short neck with excess nuchal skin and a low posterior hairline. In infancy, 
the head appears relatively large with a tall and prominent forehead and prominent 
eyes with thick-hooded eyelids, hypertelorism and/or ptosis. The nose has a wide base, 
depressed root, and bulbous tip. In childhood, features often appear coarse with elongation 
of the face. In adolescents and young adults, the face often appears myopathic, eyes are less 
prominent, and the nose is high bridged and thin with a wide base. The neck appears longer, 
accentuating the webbing or prominent trapezius. Older adults have prominent nasolabial 
folds, a high anterior hairline, thick-hooded eyelids (21), and wrinkled skin (3, 4, 22-24). 
Table I  Scoring system for Noonan syndrome*
Feature A = Major B = Minor
1 Facial  Typical face dysmorphology Suggestive face dysmorphology
2 Cardiac Pulmonary valve stenosis,  
HOCM and/or typical ECG 
Other defect
3 Height <3th centile <10th centile
4 Chest wall Pectus carinatum/excavatum Broad thorax
5 Family history First degree relative with definite 
Noonan syndrome
First degree relative with 
suggestive Noonan syndrome
6 Other  Mental retardation, cryptorchidism 
and lymphatic dysplasia
One of mental retardation, 
cryptorchidism, or lymphatic 
dysplasia
HOCM: hypertrophic obstructive cardiomyopathy; ECG: Electrocardiogram
*Definite Noonan syndrome: 1A plus one of 2A-6A or two of 2B-6B; 1B plus two of 2A-6A or three of 2B-6B. 
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Cardiovascular anomalies
Congenital heart defects occur in 66%–87% of Noonan syndrome cases, depending upon 
patient selection   and the method of screening (3, 25-27). The most common cardiac 
anomalies are stenosis of the pulmonary valve (which is often dysplastic (32%–74%), 
hypertrophic cardiomyopathy (HCM) (8%–33%) (3, 4, 7, 25-30), atrial septal defect (ASD) 
(3%–30%) (3, 21, 25-27), and ventricular septal defect (VSD) (5-10%) (3, 26, 27). Other heart 
defects, like coarctatio aortae (CA), peripheral pulmonary branch stenosis, atrioventricular 
canal, aortic stenosis, mitral valve anomalies, tetralogy of Fallot, patent ductus arteriosus 
(PDA), and coronary artery anomalies have also been noted (4, 7, 25-27, 30). Patients with 
Noonan syndrome who have HCM have a worse risk profile at presentation compared 
with other children with HCM, resulting in significant early mortality (22% at 1 year) (31). 
 The electrocardiogram (ECG) of people with Noonan syndrome commonly shows 
left axis deviation, small R waves in the left precordial leads, abnormal Q waves and a wide 
QRS complex (26, 30, 32, 33).
Figure 2   Facial characteristics of six children with Noonan syndrome who participated 
in our studies (published with permission).
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Growth
Growth has been thoroughly investigated in Noonan syndrome. Between 50% and 70% 
of people with Noonan syndrome have short stature (1, 2, 4). Nevertheless, some affected 
people have normal stature, and therefore, the range of adult height is wide (34, 35). 
In the literature, several studies have been performed which described Noonan syndrome- 
specific growth charts (34-38). At birth, weight and length are usually normal or slightly 
subnormal. In the first year of life, a rapid decline in height standard deviation score (SDS) 
is seen. From 2 to 4 years of age, mean height in males and females follows the third 
percentile/-2 SDS until approximately 12 years and 10 years of age, respectively. Thereafter, 
height falls below the normal range due to late puberty. A growth spurt indicating 
puberty occurs with a delay of approximately 2 years, and final height is eventually 
reached at the end of the second decade. After the age of 5 years, bone age tends to be 
delayed by approximately 2 years (34, 39). A mean final height of 157.4.0-169.8 centimeters 
in males and 148.4-153.3 centimeters in females has been found (7, 34, 35, 38). Weight- to-
height ratio did not show evidence of a deviation from normal (34). BMI levels have been 
found to be normal or lower in people with Noonan syndrome (36, 38). Various mechanisms 
of stunted growth in Noonan syndrome have been reported, namely intrinsic, as a 
consequence of dysregulation of the RAS/MAPK signaling itself, insufficient growth 
hormone secretion, and growth hormone resistance (40-42). Growth hormone stimulation 
tests were reported as being normal (41). The Food and Drug Administration (FDA) 
approved treatment with recombinant human growth hormone for patients with Noonan 
syndrome in 2007 in the USA. In the Netherlands, short children with Noonan syndrome 
are treated with growth hormone if they are growth-hormone deficient.
 Musculoskeletal features and (psycho)motor performance
The classical sternum change seen in Noonan syndrome is pectus carinatum superiorly 
and pectus excavatum inferiorly (70%–95%). The thorax is broad with a large internipple 
distance, and in childhood, the upper chest appears to lengthen. The shoulders are 
often rounded with scapula alata. Spinal/vertebral deformities are common in Noonan 
syndrome, whereby scoliosis is seen most frequently. Other orthopedic features include 
cubitus valgus, joint contractures, radio-ulnar synostosis, and hand anomalies, such as 
syndactyly, clinobrachydactyly and blunt fingertips, talipes equinovarus, pes planus, 
joint hyperextensibility, pigmented villonodular synovitis, osteopenia/osteoporosis, and 
hypotonia (3, 4, 7, 24, 43-45). Giant cell lesions of the jaw, such as those seen in cheburism, 
are also reported in Noonan syndrome patients (46). 
 Problems with motor performance are frequently reported in Noonan syndrome. 
A high incidence of chronic pain is found (54%–65%). Pain can be located in joints, 
extremities, the back, or muscles (44, 47, 48). Literature on visual-motor integration in 
Noonan syndrome revealed inconsistent results, varying from delayed visual-motor 
coordination (49) to average visual-motor abilities in children with Noonan syndrome (50) 
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to no differences between adults with Noonan syndrome and healthy controls on a test 
for visuo-constructive ability (51). A motor developmental delay has been reported by 
parents in 26%–46% of infants with Noonan syndrome (3, 52, 53). In other studies, parents 
of children with Noonan syndrome report clumsiness, often referred to as a developmental 
coordination disorder (49, 54, 55). Tests for motor coordination in Noonan syndrome 
showed an impaired score in 51%–72% of tested children (55-58). Stevenson et al. (2012) 
found a significantly decreased handgrip strength in people with Noonan syndrome (59). 
Neurology and psychological health
Structural brain abnormalities are found at relatively low frequency in patients with 
Noonan syndrome, where Arnold-Chiari malformation type 1 and hydrocephaly are most 
common. However, percentages were not mentioned. The mean head circumference is in 
the normal range; however, some Noonan syndrome patients can be microcephalic or 
macrocephalic. Other neurologic manifestations are epilepsy, peripheral neuropathy, and 
craniosynostosis (8, 60, 61). 
 Noonan syndrome patients show intelligence scores ranging from mentally retarded 
to superior, with a mildly lowered average level (mean full scale intelligence quotient (IQ) is 
85) (50, 55). Learning problems are present in approximately one third of cases and are 
usually mild. Verbal and performance capacities are more or less equally divided or show a 
significant difference with an inconsistent pattern (50, 55, 57). Language development is 
often delayed, with frequent articulation problems. When language is sufficiently learned 
in adulthood, problems in language impairment seem to resolve (54). Other problems seen 
in Noonan syndrome are attention problems (a lack of selective and sustained attention 
and attention deficit/hyperactivity disorder), issues with executive function (organizational 
and planning weakness), memory (impaired visual memory, working memory, and 
memorizing) mood disturbances (fidgety or stubborn spells, irritability, depression and/or 
anxiety), social difficulties (diminished insight in social situations, lack of interaction with 
peers, disturbed emotional perception of self and others, problems in verbalizing and 
explaining experiences), and alexithymia (an ineffective regulation and expression of 
emotions) (62, 63). Depression was found and treated in almost half of an adult cohort of 
persons with Noonan syndrome (47). Despite a low-average mean intelligence, almost half 
of the children with Noonan syndrome have special educational needs (7). However, most 
children with Noonan syndrome can be raised with parental support alone (54). 
Genitourinary system
Male pubertal development and subsequent fertility may be normal, delayed, or in- 
adequate with associated deficient spermatogenesis (64). Male gonadal dysfunction has 
been reported and is suggested to be caused by primary Sertoli cell dysfunction rather 
than cryptorchidism (65). Cryptorchidism, unilateral or bilateral, is seen in up to 80% of 
male Noonan syndrome patients (4). Puberty may be delayed in females; however, normal 
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fertility is expected (64). Urinary tract malformations are present in approximately 10% of 
patients with Noonan syndrome, mostly pyelo-ureteric stenosis and/or hydronephrosis (2, 4). 
Lymphatics
Lymphatic vessel dysplasia, hypoplasia, or aplasia is a well-known finding in Noonan 
syndrome (20%). Peripheral lymphedema is the most common manifestation. It can occur 
in infants and resolves in the first few years of life, or it can develop in adolescence or 
adulthood (66). Less common abnormalities include generalized lymphedema, intestinal 
or pulmonary lymphangiectasia, chylous effusions in pleural or peritoneal spaces, 
anomalous thoracic cage lymphatic vessels, aplasia or absence of the thoracic duct, 
hypoplastic inguinal and iliac lymphatic vessels, and localized lymphedema of the scrotum 
or vulva (24).  Chylous effusion is a known complication of thoracic surgery (5, 67). Also, 
varying degrees of prenatal edema and hydrops are present, manifesting itself as increased 
nuchal translucency, distended jugular lymphatic sacs, cystic hygroma, hydrops fetalis, 
and pleural effusion (68).
Other signs and symptoms, not mentioned in the Scoring System of van der Burgt et al. 
(1994), are mentioned below:
 Hearing loss is usually a mild conductive loss secondary to recurrent otitis media 
(15%–40%). Sensorineural hearing loss is less common, but roughly 10% of affected 
individuals have auditory deficits in the low frequency range and 25% in the high 
frequency range (69). Inner ear structural abnormalities, including temporal bone 
abnormalities, have occasionally been reported (70, 71). 
 Ocular anomalies are among the most common findings in Noonan syndrome. 
Frequently found anomalies are strabismus (40%–63%), refractive errors (40%–61%), 
amblyopia (32%–33%), anterior segment changes (63%–72%), limited ocular motility 
(40%), prominent corneal nerves (72%), and posterior embryotoxon (32%). Less frequently 
found anomalies are fundal abnormalities (20%), nystagmus (10%), and optic nerve 
hypoplasia (4%) (52, 72). 
 Skin manifestations seen in Noonan syndrome are abnormalities of pigmentation 
(pigmented nevi (25%), cafe-au-lait spots (10%), and lentigines (3%)), ulerythema 
ophryogenes (14%) (which may lead to a lack of eyebrows), and keratosis pilaris on the 
upper arms. Prominent fetal fingertip pads are often seen (67%).  Approximately one third 
of patients have thick, curly hair, and 10% have thin, sparse hair (4). 
 Gastro-intestinal findings are hepatomegaly (25%) and splenomegaly (50%) in 
infancy, unrelated to cardiac failure and without organ dysfunction. The cause is likely 
related to subclinical myelodysplasia (73). Feeding problems are seen in 40%–76% of 
infants (4, 7, 53). The main described problems are poor suckling, refusal to drink or eat 
solids, recurrent vomiting, abdominal distention, constipation, and abdominal pain. Half 
of the infants studied had evidence of gastro-esophageal reflux. Feeding problems 
517840-L-bw-croonen
Processed on: 6-3-2018 PDF page: 18
18
Chapter 1
appear to be the result of delayed gastro-intestinal motor development, which showed 
patterns of foregut dysmotility similar to that seen in premature infants. 
 Hemato-oncological abnormalities are common in Noonan syndrome. Bleeding 
disorders, which refer to a history of bleeding and/or abnormal hemostatic laboratory 
results, are seen in 50%–89%. A positive bleeding history is mentioned in 20%–72% of 
people with Noonan syndrome and an abnormal hemostatic laboratory result is found in 
30%–74%. However, only 10%–42% of people with Noonan syndrome have both a history 
of bleeding diastases and an abnormal hemostatic laboratory result. Current knowledge of 
bleeding disorders suggests four etiologies: clotting factor deficiencies (factor XI (37%), 
XII (16%), VIII (12%), V (5%), and XI deficiency (4%)), platelet function defect (27%), thrombo-
cytopenia (6%), and Von Willebrand disease. Mixed bleeding disorders are common. 
Nevertheless, there is only a weak correlation between bleeding tendency and the results 
of laboratory studies in people with Noonan syndrome. Because many patients undergo 
one or more operations, special care is required for prevention and/or treatment. Therefore, 
it is important that physicians recognize and understand this, so proper action is taken 
(74-76). 
 The presenting types of cancer during childhood are juvenile myelomonocytic 
leukaemia (JMML), acute lymphoblastic leukemia (ALL), lymphoma, neuroblastoma, 
(embryonal) rhabdomyosarcoma, pheochromocytoma, and central nervous system 
tumors (77).  Acute leukemia and myeloproliferative and myelodysplastic disorders have 
been described, particularly during childhood at a proportion slightly above that in the 
general population (78, 79). JMML associated with Noonan syndrome tends to have an 
earlier onset and milder presentation than in non-Noonan syndrome JMML patients, and 
spontaneous remission may occur.  Giant-cell granulomas and bone and joint anomalies in 
Noonan-like/multiple giant-cell lesion syndrome are recognized to be part of the Noonan 
syndrome spectrum. A recently published study of the cancer spectrum and frequency of 
cancer among children with Noonan syndrome showed that they had an eightfold greater 
risk of developing childhood cancer than those without Noonan syndrome (80). 
 Prenatal features of Noonan syndrome are increased nuchal translucency, distended 
jugular lymphatic sacs, cystic hygroma, hydrops fetalis, pleural effusion, polyhydramnios, 
congenital heart disease, and renal abnormalities (68).   
Etiology
Noonan syndrome is an autosomal dominant disorder, genetically heterogeneous, and 
the most common syndrome among the RASopathies. The RASopathies are a clinically 
defined group of medical genetic syndromes caused by germline mutations in genes that 
encode components or regulators of the Ras/mitogen-activated protein kinase (MAPK) 
pathway. The RAS/MAPK pathway plays an essential role in regulating the cell cycle and 
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cellular growth, differentiation, and senescence, all of which are critical to normal 
development. Therefore, it is not surprising that RAS/MAPK pathway dysregulation has 
profound deleterious effects on both embryonic and later stages of development (81). 
 The RAS/MAPK pathway is activated by extracellular input in the form of growth 
factors. RAS genes constitute a multigene family that includes HRAS, NRAS, and KRAS. Ras 
proteins are small, guanosine nucleotide-bound GTPases that function as a critical 
signaling hub within the cell. They are activated through binding of growth factors to 
receptor tyrosine kinases (RTKs), G-protein-coupled receptors, cytokine receptors, and 
extracellular matrix receptors. Ras proteins cycle between an active, guanosine 
triphosphate (GTP)-bound form and an inactive, guanosine diphosphate (GDP)-bound 
form. Activation through RTKs occurs with the binding of a growth factor that causes 
RTK autophosphorylation and interaction with the adaptor protein growth factor 
receptor-bound protein 2 (GRB2). GRB2 is bound to son of sevenless (SOS), which is then 
recruited to the plasma membrane. SOS proteins are guanosine nucleotide exchange 
factors (GEFs) that increase the Ras nucleotide exchange rate of GDP for GTP, thereby 
increasing the level of active GTP-bound Ras (81-83). 
 In 2001, a missense mutation in the PTPN11 gene on chromosome 12q24.1 was found 
as a major cause for Noonan syndrome (84). The PTPN11 gene encodes the non-receptor 
protein tyrosine phosphatase, SHP-2. This enzyme is concerned with many intracellular 
signal cascades downstream of receptors for growth factors, cytokines, and hormones 
and is required in several developmental processes. The SHP-2 enzyme is composed of 
two src homology domains, N-SH2 and C-SH2, a central phosphotyrosine phophatase 
(PTP) domain, and a carboxy terminal. Most mutations cluster in interacting portions of 
the amino N-SH2 domain and the PTP domain, especially in exons 3,7,8, and 13. The 
mutations stabilize SHP-2 in the active form, inducing a gain of function. In approximately 
50% of Noonan syndrome patients, a mutation in the PTPN11 gene was found, which 
implicated genetic heterogeneity in this syndrome (85). In subsequent years, several other 
activating germline mutations in different genes of the RAS/MAPK pathway have been 
identified as causes of Noonan syndrome. In almost 80% of cases with clinical Noonan 
syndrome, a germline mutation in one of the known Noonan syndrome genes is found: 
PTPN11 in 50%; SOS1 in 10%–15%; RIT1 and RAF1 in 5%; KRAS in <5%; and NRAS, BRAF, and 
MAP2K1 in <2% each (73). The latest Noonan syndrome genes to be elucidated are SOS2, 
A2ML1, RASA2, LZTR1, and RRAS (86). 
The other RASopathies found in subsequent years include neurofibromatosis type 1 (NF1), 
caused by loss of function mutations in NF1; Noonan syndrome-like syndromes, namely 
Noonan syndrome with loose anagen hair, caused by activating mutations in SHOC2 and 
CBL-mutation associated syndrome caused by mutation in CBL; Noonan syndrome with 
multiple lentigines (NSML; formerly named LEOPARD syndrome), caused by loss of 
functions mutations in PTPN11 and RAF1; Costello syndrome (CS), caused by activating 
mutations in HRAS; cardio-facio-cutaneous (CFC) syndrome, caused by mostly activating 
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mutations in BRAF, MAP2K1 (MEK1), and MAP2K2 (MEK2); and NF1-like syndrome (Legius 
syndrome) caused by inactivating mutations in SPRED1 (Figure 3) (81, 86, 87).
Because of the common underlying RAS/MAPK pathway dysregulation, the RAS - opathies 
exhibit numerous overlapping phenotypic features. This overlap of phenotypic features 
can make the clinical differential diagnosis challenging, and molecular confirmation of a clinical 
diagnosis is often necessary (81, 86). 
 Besides these germline mutations, somatic mutations in genes encoding RAS/MAPK 
components also occur frequently in many tumors, making the RAS/MAPK signaling 
pathway a critical pathway in human cancer. The RAS/MAPK pathway has been well 
Figure 3   RAS/MAPK cascade and disorders involving germline mutations of related genes. 
MAPK: mitogen-activated protein kinase; NF1: neurofibromatosis type 1; NS: Noonan syndrome. 
*Indicates possible causative genes that have been reported since 2013. Adapted from Aoki et al. 2016 (86).
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studied in cancer and is an attractive target for small-molecule inhibition to treat various 
malignancies. In approximately one third of all human cancers, the RAS/MAPK pathway is 
deregulated by a somatic mutation. As Noonan syndrome is caused by a germline 
mutation in the RAS/MAPK pathway, the question can be raised if there is an association 
between Noonan syndrome and cancer, as mentioned before. As mentioned earlier, a 
recently published study of the cancer spectrum and frequency of cancer among children 
with Noonan syndrome showed that they have an 8-fold greater risk of developing a 
childhood cancer than those without Noonan syndrome (80). However, this does not 
warrant a specific cancer surveillance program because there is no correlation with a 
specific type of malignancy and no correlation with a specific type of mutation. 
 Because the RAS/MAPK pathway has targets for inhibition in cancer treatment, many 
small-molecule therapeutics are in development or undergoing clinical trials. The use of 
systemic therapies after birth to reduce RAS/MAPK activity in the RASopathies could 
potentially ameliorate the progression of signs and symptoms associated with these 
disorders (81). No results of clinical trials using RAS/MAPK pathway inhibitors in Noonan 
syndrome have been published so far. Therefore, further research is needed.  
Aim and outline of the thesis
The aim of this thesis is to support and improve the recognition of Noonan syndrome and 
the clinical care of subjects with Noonan syndrome throughout life. In this thesis, we focus 
on answering clinical questions, from both a doctor’s and a patient’s perspective, 
regarding the diagnosis of Noonan syndrome and perceived problems in the daily lives of 
subjects with Noonan syndrome. 
Doctor’s perspective: The diagnostic process
Prior to genetic testing (before 2001), Noonan syndrome was diagnosed solely on the 
basis of clinical characteristics. However, in the last decade, much research has been 
conducted to search for germline mutations that affect components of the RAS/MAPK 
pathway involved in the pathogenesis of Noonan syndrome. Despite these developments, 
at this moment, no mutation can be detected in 20% of clinically diagnosed subjects. 
In Chapter 2, we conduct a genotype-phenotype analysis of 33 subjects with a clinical 
diagnosis of Noonan syndrome who do not carry a PTPN11 mutation. In 19 subjects, 
no mutation was found in the other (then) recognized genes of the RAS/MAPK pathway 
involved in Noonan syndrome. Their clinical features are compared with those of the 
 mutation-positive patients with Noonan syndrome. 
 Neurofibromatosis type 1 (NF1) is a well-known genetic condition caused by loss- of-
function mutations in the NF1 gene, which also has a role in the RAS/MAPK pathway. 
Because of the common underlying RAS/MAPK pathway dysregulation, there is some 
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overlap in the clinical features of Noonan syndrome and NF1. This overlap of phenotypic 
features can make the clinical diagnosis challenging, whereby molecular confirmation of 
the clinical diagnosis often seems necessary. However, in Chapter 3, we present the first 
case report of a child with a clinical diagnosis of Noonan syndrome and not NF1 but with 
an NF1 gene mutation. 
 Subjects with Noonan syndrome are most frequently diagnosed in childhood on 
the basis of clinical findings using scoring systems. However, prenatal characteristics have 
also been seen by ultrasound examination in children with Noonan syndrome, namely 
increased nuchal translucency, distended jugular lymphatic sacs, cystic hygroma, hydrops 
fetalis, pleural effusion, polyhydramnios, congenital heart disease, and renal abnormalities. 
Until recently, no scoring system, i.e. protocol, was available to guide the diagnostic 
process prenatally. Chapter 4 describes the prenatal findings by ultrasound and provides 
a protocol for prenatal Noonan syndrome testing to serve as a useful aid to facilitate 
parental counselling and targeted DNA testing. 
 Congenital heart defects are present in more than half of all children with Noonan 
syndrome. The most common cardiac anomalies are stenosis of the pulmonary 
valve, hypertrophic cardiomyopathy, atrial septal defect, and ventricular septal defect. 
The electrocardiogram (ECG) of subjects with Noonan syndrome frequently shows a 
characteristic pattern with left axis deviation, small R waves in the left precordial leads, 
abnormal Q waves and/or a wide QRS complex. However, it is not known if these ECG 
characteristics are related to the involved gene mutation and/or the diagnosed congenital 
heart defect or are an independent diagnostic entity. In Chapter 5, we quantify these 
characteristic ECG findings and analyse if the ECG characteristics are related to the 
presence of a PTPN11 gene mutation, are related to the presence of a cardiac abnormality 
found by echo cardiography, or are an independent diagnostic entity. These findings give 
insight into the role of ECG in the clinical evaluation of subjects with Noonan syndrome. 
Patient’s perspective: Perceived problems in daily life
Feeding problems and failure to thrive are important problems for parents with a newborn 
child with Noonan syndrome. At birth, weight and length are usually normal or slightly 
subnormal. In the first year of life, a rapid decline in growth is seen. Feeding problems are 
present in more than 50% of children with Noonan syndrome. Various mechanisms of 
stunted growth in Noonan syndrome have been reported namely, intrinsic, as a 
consequence of dysregulation of the RAS/MAPK signaling itself, insufficient growth 
hormone secretion, and growth hormone resistance. Nutritional input during the first 
year of life has been postulated as the principal regulator of growth, with a minimal 
contribution of growth hormone starting during the second half of the first year. However, 
the relation between stunted growth and feeding problems in Noonan syndrome in the 
first year of life has never been investigated. In Chapter 6, we assess the question ‘Is growth 
decelerating in the first year of life because of feeding problems or because of other 
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Noonan syndrome related variables?’ The answer may support healthcare providers and 
parents with respect to nutrition guidelines in children with Noonan syndrome in daily 
practice.
 In daily life, many people with Noonan syndrome report motor impairments, decreased 
muscle strength, and pain in muscles and joints. Despite the frequently reported problems 
with motor performance, the majority of people with Noonan syndrome and/or their 
relatives do not feel heard and supported by healthcare professionals. To provide more 
insight into the perceived problems in daily life, we evaluate in Chapter 7 the motor 
performance problems experienced by people with Noonan syndrome themselves and/
or their relatives, the major consequences they suffer, the benefits of interventions they 
experience, and their experiences with healthcare professionals. In addition, to validate 
the motor performance problems of children with Noonan syndrome in daily life, we 
investigate in Chapter 8 whether motor performance in children with Noonan syndrome 
differs from that in the reference population and whether a specific profile of motor 
performance in these children with Noonan syndrome can be seen. The findings will 
support people with Noonan syndrome and healthcare professionals in clinical practice. 
 In Chapter 9, future prospects are discussed, and in Chapter 10, the results are 
summarized.
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Chapter 2
Abstract
Noonan syndrome is an autosomal dominant disorder characterized by facial dysmorphisms, 
short stature and congenital heart defects. The disorder is genetically heterogeneous and 
shows clinical overlap with other RASopathies. These syndromes are caused by mutations 
in a variety of genes leading to dysregulation of the RAS/MAPK pathway: PTPN11, KRAS, 
SOS1, RAF1, CBL, SHOC2, NRAS, BRAF, MAP2K1, MAP2K2, HRAS, NF1 and SPRED1. 
 In this study, we conduct a genotype-phenotype analysis of 33 patients with a clinical 
diagnosis of Noonan syndrome without a PTPN11 mutation. Mutation analysis of the genes 
involved in RASopathies was performed, except for NF1 and SPRED1. 
 In 14 (42%) Noonan syndrome  patients, a mutation was found, 7 (21%) had a mutation 
in SOS1 , 3 (9%) in RAF1 and 1 (3%) in KRAS , MAP2K2 , BRAF and SHOC2 each. The phenotype 
of these mutation-positive cases corresponded to that described in the literature. In the 
cases with a BRAF and MAP2K2 mutation, the diagnosis cardio-facio-cutaneous syndrome 
was made. The patient with the SHOC2 mutation had features compatible with ‘Noonan- 
like syndrome with loose anagen hair’. Three major clinical features of Noonan syndrome 
– a typical face, short stature and a pulmonary valve stenosis – were less frequently 
present in the group without a mutation. 
 Missense mutations in genes encoding proteins of the RAS/MAPK pathway cause 
Noonan syndrome. The 3 major clinical features of Noonan syndrome were less frequently 
present in the mutation negative patients, which stresses the importance of the syndrome- 
specific symptoms of the face, heart and short stature in Noonan syndrome. However, 
all mutation-negative cases met the Noonan syndrome criteria, indicating that the 
involvement of novel genes is to be expected.
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Introduction
Noonan syndrome is a well-known autosomal dominant disorder with an estimated 
incidence of 1: 1,000–2,500 live births (1). Excellent reviews of Noonan syndrome have 
been published and have commented on clinical and molecular findings (2-4). 
 The cardinal features of Noonan syndrome are characteristic facies, short stature, 
congenital heart defects, skeletal abnormalities, cryptorchidism, and variable development 
delay (2, 5, 6). The facial dysmorphisms show considerable change with age, being more 
prominent in childhood and less conspicuous in the adult (7). Congenital heart defects 
occur in 66–87% of cases (5, 8-10). The most common cardiac anomaly is a stenosis of the 
pulmonary valve, which may be dysplastic (32–74%). Hypertrophic cardiomyopathy occurs 
in 8–33% (5, 6, 8-13). The electrocardiogram (ECG) of Noonan syndrome patients commonly 
shows left axis deviation, small R waves in the left precordial leads, abnormal Q waves, and 
a wide QRS complex (9, 10, 14-16). 
 Noonan syndrome is genetically heterogeneous and shows a considerable clinical 
overlap with Costello syndrome, LEOPARD syndrome (multiple lentigines – ECG conducting 
abnormalies – ocular hypertelorism – pulmonic steonsis – abnormal genitalia – retardation 
of growth – sensorineural deafness) and cardio-facio-cutaneous (CFC) syndrome. Neuro-
fibromatosis type 1 (NF1) and Legius syndrome have more specific features: café-au-lait 
spots in Legius syndrome (SPRED1 gene) and neurofibromas in NF1 (NF1 gene) (17, 18). 
These syndromes all belong to RASopathies, a specific class of developmental disorders 
caused by germline mutations in genes encoding proteins of the Ras-mitogen-activated 
protein kinase (RAS/MAPK) pathway (19). About 50% of known Noonan syndrome cases 
have a gain-of-function mutation in the PTPN11 gene (20, 21). Heterozygous gain-of- 
function mutations in other genes encoding proteins of the RAS-MAPK pathway have also 
been identified in Noonan syndrome and other RASopathy syndromes: KRAS (22, 23), SOS1 
(24, 25), RAF1 (26, 27), MAP2K1 (28), BRAF (29), SHOC2 (30), NRAS (31), and CBL (32). Two genes are 
only associated with Costello and CFC syndrome, respectively, HRAS (33) and MAP2K2 (34). 
 The purpose of this study was to identify the disease causing mutation in 33 patients 
with a clinical diagnosis of Noonan syndrome without a PTPN11 gene mutation, by analysis 
of 10 genes involved in the RASopathies. The mutation-positive Noonan syndrome 
patients are compared to known cases from literature and to those with an unknown 
genetic cause, with the aim to ascertain whether there are important clinical differences 
between the groups.
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Patients and Methods
Patients
We included 33 patients with Noonan syndrome, clinically diagnosed at one tertiary center 
using the cardinal features delineated by van der Burgt et al. (1994) (35). Mutation analysis 
of the PTPN11 gene was negative in all cases.
Electrocardiogram
A pediatric cardiologist who was blinded for mutation status and the presence of a cardiac 
abnormality judged the ECG. The ECG was scored on 4 characteristic ECG findings (36):
(1)  Left axis deviation: the QRS axis less than the lower limit of normal for the patient’s 
age.
(2)  Small R waves in the left precordial leads: the R/S ratio in lead V6 is lower than the 
lower limits of normal and the R wave voltage in leads V5 and V6 is less than 50% of 
the mean.
(3)  Wide QRS-complex: a QRS duration of more than 0.08 s under the age of 3 years, 
above 0.10 s between 3 and 12 years and above the upper limit for QRS duration of 
0.12 s from 12 years on.
(4)  Abnormal Q wave: the Q voltage is greater than the upper limit of normal and wider 
than 0.04 s.
DNA Analysis
DNA of all patients was tested by Sanger sequencing in a routine DNA diagnostic setting 
for mutations in the coding regions of the genes PTPN11, KRAS, HRAS, NRAS, BRAF, RAF1, 
SOS1, MAP2K1, MAP2K2, SHOC2, and CBL (for primer sequences and PCR conditions see 
supplementary material). Classification of sequence variants was according to the CMGS 
practice guidelines for the interpretation and reporting of unclassified variants in clinical 
molecular genetics (http://www.cmgs.org/BPGs/pdfs%20current%20bpgs/UV%20GUIDELINES 
%20ratified.pdf). Only mutations classified as unclassified variants 3 or 4 were reported. 
The study was performed according the regulations of the local medical ethical 
committee. 
Statistical Analysis
The data were analyzed with SPSS, version 16.0. Because of the small number of patients 
only descriptive analysis was performed.
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Results
Mutation-Positive Noonan syndrome Patients
In figure 1, the distribution of the different genes involved in our Noonan syndrome 
cohort is shown. Tables I and II show the mutations and their patient characteristics. 
In 14 of the 33 Noonan syndrome patients without a mutation in PTPN11 (42%), a mutation 
in one of the other 10 genes that were analyzed could be identified. 
 Seven patients had a SOS1 mutation (21%). Six of these mutations were described earlier 
in other Noonan syndrome cases, namely c.797C>A (p.Thr266Lys), c.806T>C (p.Met269Thr), 
c.806T>G (p.Met269Arg), c.1644T>C (p.Ser548Arg), c.1656G>C (p.Arg552Ser), and c.2104T>C 
(p.Tyr702His) (24, 25, 37). The mutations c.797C>A (p.Thr266Lys) and c.2104T>C (p.Tyr702His) 
were found to be de novo in the patient, whereas the c. 806T>C (p.Met269Thr) mutation 
was present in 2 affected brothers, and the c.1656G>C (p.Arg552Ser) mutation was 
inherited from the affected mother. For the other patients with a previously described 
SOS1 mutation, no family history of Noonan syndrome was noted, but family studies have 
not been performed. One novel de novo mutation was identified: c.2183A>T (p.Lys728Ile), 
Figure 1   Distribution of the different genes involved in our cohort of patients with  
a clinical diagnosis of Noonan syndrome.
SOS1
21%
56% 9%
6%
3%
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3%
RAF1
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BRAF
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located in the REM domain of the SOS1 gene. The clinical features of this patient have been 
described elsewhere (38). 
 Three patients had a RAF1 mutation (9%). These mutations, c.781C>G (p.Pro261Ala), 
c.1457A>G (p.Asp-486Gly) and c.1837C>G (p.Leu613Val) were described earlier in Noonan 
syndrome patients (26, 27). For none of these patients parental studies could be performed, 
but no family history of Noonan syndrome was described. 
 One patient had a KRAS mutation (3%): c.40G>A (p.Val14Ile). The same mutation was 
present in her affected twin brother, but the parents did not have the mutation. This mutation 
is previously described as a pathogenic mutation by Schubbert et al. (2006) (23). 
 In one case (3%) a de novo BRAF mutation, c.736G>C (p.Ala246Pro), was identified. 
This mutation was published by Nava et al. (2007) and Niihori et al. (2006) in CFC patients 
(28, 29). The clinical features of our patient are consistent with CFC syndrome (Figure 2). 
In one patient (3%) we identified a MAP2K2 mutation, c.401A>G (p.Tyr134Cys), which was 
first published by Rodriguez-Viciana et al. (2008) in a CFC patient (34). The mutation was 
found in a 20-year-old man with an Noonan syndrome phenotype. This patient was born 
with a pulmonary valve stenosis and cryptorchidism. He had neonatal feeding difficulties 
and a developmental delay. At 20 years, his height was 1.95 m and weight 82 kg. He had 
multiple pigmented nevi and easy bruising. Neuropsychological testing yielded an IQ of 
70. The patient presented with characteristic facial features including hypertelorism and 
low set ears (Figure 3). One half-sister died after 9 months, who had a severe pulmonary 
valve stenosis. The father is clinically affected, but no mutation analysis has been done. 
 In one patient (3%) we found the previously reported pathogenic mutation c.4A>G 
(p.Ser2Gly) in the SHOC2 gene. This mutation was first reported by Cordeddu et al. (2009) 
(30). The parents were not available for testing. 
Figure 2   Clinical features of the patient with the BRAF mutation, consistent with  
CFC syndrome.
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Mutation-Positive versus Mutation-Negative Patients
A typical dysmorphic appearance was seen most in mutation-positive patients (93% 
(13/14) vs. 74% (14/19)). Small stature (height < –2 SD) was observed more often in mutation- 
positive patients (79% (11/14) vs. 63% (12/19)). Also heart defects were more prevalent 
in mutation-positive patients (79% (11/14) vs. 56% (10/18)), with pulmonary stenosis as 
most common (64% (9/14) vs. 39% (7/18)). Other heart defects were more frequent in the 
mutation- negative group (33% (6/18) vs. 14% (2/14)). Noonan syndrome patients with 
a mutation had an aberrant ECG twice as often as Noonan syndrome patients without a 
mutation (46% (5/11) vs. 23% (3/13)). Figure 4 shows a Noonan syndrome patient without 
a known mutation. 
Figure 3   Clinical features of the patient with the MAP2K2 mutation, consistent with  
CFC syndrome.
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Discussion
Analysis
Because of the small cohort, we only applied descriptive analysis. When comparing the 
characteristics of all Noonan syndrome patients known in literature, no evident differences 
were found (5, 6, 10). 
 All mutation-positive cases fulfil the criteria declined by van der Burgt et al. (1994) for 
the diagnosis of Noonan syndrome (35). We found a SOS1 mutation in 7 out of 33 (21%) 
patients, analogous to the literature (17–28%) (24, 25, 37). In line with these same reports, 
we found a similar spectrum of congenital heart defects with a high prevalence of 
pulmonary valve stenosis, facial characteristics (ptosis, downslanted palpebral fissures and 
low set ears), curly hair and pectus deformities. Two reports identified a high frequency 
(50–58%) of ectodermal anomalies which is not the case in our study (2/7; 29%) (25, 37). 
Interestingly, we noticed a height below –2 SD in all Noonan syndrome patients with a 
SOS1 mutation (compared to 13–52% in literature), mental retardation and/or need for 
special education in 57% (4/7) (compared to 6–27% in literature), macrocephaly in 14% 
(1/7) (compared to 56% in literature), and cryptorchidism in none of the patients (ref. 
45–50%) (24, 25, 37). The phenotypic differences between the SOS1 positive patients in this 
study and the previously reported cases are likely to be explained by differences in the 
way the patients are included, selected, characteristics are described as well a variation in 
the included type of mutations. 
Figure 4   Clinical features of one of the mutation-negative patients, who still meet  
the clinical criteria for Noonan syndrome.
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We found KRAS mutations in 1 out of 33 (3%) patients, analogous to the literature (22, 23). 
These reports describe patient characteristics comparable to our patient. Several cases 
described in the literature present a severe Noonan syndrome condition, eventually with 
features overlapping Costello syndrome and CFC syndrome. 
 We observed a RAF1 mutation in 3 of 33 patients (9%), analogous to the literature 
(8.4–17%) (26, 27). In line with these same reports, we found a similar spectrum of charac-
teristics. However, they demonstrate that RAF1 is the major gene associated with 
hypertrophic cardiomyopathy in Noonan syndrome (76–82%). In our cohort, only one 
Noonan syndrome patient with an RAF1 mutation had hypertrophic cardiomyopathy. 
 BRAF mutations are predominantly described in CFC syndrome (28, 29, 39). However, 
BRAF mutations are also found in Noonan syndrome and LEOPARD syndrome (40, 41). In 
our cohort, we found one mutation in BRAF. Using our criteria, we misdiagnosed Noonan 
syndrome in this patient at early age. The clinical features of the patient with the BRAF 
mutation are consistent with CFC syndrome (Table I , Figure 2). She had the typical facial 
features, nevi, developmental delay, short stature, hearing and visual disorders, and a 
valvular pulmonary stenosis with an atrial septal defect. Her ECG registration showed left 
axis deviation and small R waves in left precordial leads. 
 Mutations in the MAP2K2 gene are so far only described in patients with CFC syndrome 
(34, 42). Our patient was first diagnosed with Noonan syndrome. In retrospect, the 
presence of multiple pigmented nevi and an IQ of 70 do also suspect CFC syndrome in 
this patient as well ( fig. 3 ). However, a height of almost 2 m is a striking finding in CFC 
patients and in a broader context, in all the related disorders known as RASopathies. 
 In 2009, Cordeddu et al. published the involvement of the c.4A>G (p.Ser2Gly) mutation 
in SHOC2 in 25 patients with the diagnosis Noonan-like syndrome with loose anagen hair 
(30). They revealed a consistent phenotype with characteristic craniofacial appearance 
(macrocephaly, a prominent forehead, hypertelorism, ptosis, low set and posteriorly 
rotated ears, and loose anagen hair with sparse and/or absent scalp hair), pectus anomalies 
and a darkly pigmented skin with eczema or ichthyosis. They also showed cognitive 
deficits, reduced growth, frequently associated with growth hormone deficiency, and 
cardiac anomalies (pulmonary valve stenosis and hypertrophic cardiomyopathy). Some of 
these characteristics were seen in our patient with a SHOC2 mutation, such as the 
craniofacial appearance, sparse and thin scalp hair, short stature, intellectual disability and 
hyperpigmented skin. Macrocephaly and hyperactive behavior were not observed. 
Growth hormone values were never measured; however, his adult height was 167.5 cm 
(<–2 SD). According to these characteristics, these patients had clinical features that were 
compatible with Noonan-like syndrome with loose anagen hair.
The RASopathies
Noonan syndrome, LEOPARD syndrome, CFC syndrome, and Costello syndrome are – together 
with NF1 and Legius syndrome – related disorders known as RASopathies (19). Several 
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genes involved in the RAS-MAPK pathway are associated with these syndromes. Nyström 
et al. (2008) concluded in their study that the molecular and clinical overlap between CFC 
and Noonan syndrome is more complex than previously suggested and that these 2 
syndromes might even represent allelic disorders (39). Despite attempts made to 
discriminate overlapping RASopathies, such as phenotypic lists of overlap between 
Noonan syndrome, CFC and CS presented by Roberts et al. (2006), it will be very hard to 
diagnose the ‘right syndrome’ in all patients (43). All the Noonan syndrome patients 
included in our study fulfil the criteria of van der Burgt et al. (1994) (35). However, in 
retrospect, 2 of them were diagnosed as having CFC. Based on these findings, we believe 
that the sensitivity of the criteria of van der Burgt is low because patients with CFC also 
fulfil these criteria, which can be explained by overlap of clinical characteristics which are 
used as criteria for diagnosis (35, 44). On the other hand, the specificity is high, which 
means no Noonan syndrome patient will be missed according to the criteria. We believe 
the discrepancy in diagnosis will continue because of these significant clinical overlaps 
and the large intra- and interfamilial variability of expression in each of the RASopathies. 
 We had no reasons to change the clinical diagnosis in the other patients of our cohort. 
In the group of mutation-negative patients, all 3 major clinical features of Noonan 
syndrome – typical face, short stature and a pulmonary valve stenosis – were less 
frequently present. This observation stresses the importance of these 3 major features for 
the diagnosis of Noonan syndrome. However, all mutation-negative cases still meet the 
clinical criteria for Noonan syndrome. The facial features of one of these patients are 
shown in figure 4 . Since in several typical Noonan cases the underlying genetic defect has 
not yet been identified, the involvement of novel genes is to be expected.
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Supplemental data  Primers en PCR set up.
PTPN11 BRAF CBL
01 F gctgacgggaagcaggaagtgg EXON F/R Sequentie (5’-3’) 01 F cttcacgccctgcttctct
01 R atgaccctggcacccgtggttccctc 01 F cagctctccgcctcccttcc 01 R ccccactgacttcccagtta
01 R atgaccctggcacccgtggttccctc 01 R gagctggcccgagaaggtgg 02 F tggggttatggatctgcttc
02 R cagcaagctatccaagcatggt 02 F tactgtgatgtagttgt 02 R acgtcatccatggcaacc
03 F cgacgtggaagatgagatctga 02 R tcctaatcccacctcctaaaa 03 F catcctcaacagcgcatttc
03 R cacgtaccaagtatatgcaggaatg 03 F ccctatcaactggtgaaaag 03 R ccaaagccaggaaatacatacac
04 F gattgatcaatcccttggaggaatg 03 R ttcctgtatgacatggatgc 04 F ggctctccttcctttccttg
04 R gtcaccagacccaacgtggtg 04 F ggtgttgtatctgacctagt 04 R gctttctcttcaccgaagtagc
05 F ctgcagtgaacatgagagtgcttg 04 R cctacagtatttcttcaggc 05 F ttggttgtacatctgacctgaa
05 R gttgaagctgcaatgggtacatg 05 F ccaaacctccctcactgtta 05 R gaagaataaatctctttgcgtca
06 F tgcattaacaccgttttctgt 05 R gcctctaggagggtattttc 06 F gctgcagtgagctgagattg
06 R gtcagtttcaagtctctcaggtc 06 F gaacccccggttttcatttt 06 R tccaggacctgaaggtcaaa
07 F gaacatttcctaggatgaattcc 06 R accctcacagacttttagac 07 F cttacaccacgttgcccttt
07 R ggtacagaggtgctaggaatca 07 F ggtatatgaagcttctgggt 07 R tgggtcctattttaagtctcca
08 F gacatcaggcagtgttcacgttac 07 R agttcaagaagcatgtcact 08 F ggtttcactttaaa ccctggag
08 R ccttaaagttactttcaggacatg 08 F cagctttggcagtattggat 08 R ggccaccccttgtatcagta
09 F gtaagctttgcttttcacagtg 08 R atcagagagaaaccagaagc 09 F ctggcttttggggttaggtt
09 R ctaaacatggccaatctgacatgct 09 F cagtgttatcgctactctct 09 R ggtcttcggcaaattcctta
10 F gcaagacttgaacatttgtttgttgc 09 R gtctgttacttgaaagaggc 10 F tgccctcttatggtgacaca
10 R gaccctgaattcctacacaccatc 10 F ccatcctttccaaaaggtct 10 R ttatgaagggagccagaagc
11 F caaaaggagacgagttctgggaac 10 R tggctgtgacttctaagaag 11 F gttccctcaagtgcttctgc
11 R gcagttgctctatgcctcaaacag 11 F cctctcaggcataaggtaat 11 R aggctggtctcgaaatcctc
12 F gctccaaagagtagacattgtttc 11 R ttttggaggagtcctgaaac 12 F taaggcccctaagcgtttg
12 R gactgttttcgtgagcactttc 12 F gtatggagttagggctatga 12 R ctgggttttctcaattttctgc
12 R gctaatagttgctaccactg 13 F gcacctttggtcagttgaaag
13 F taccgacagactactttggt 13 R tgaggttctcatgttgctgag
13 R atccttatgttcctggacag 14 F acacctataacttgccacaagag
14 F ctttacacccccaagtatgt 14 R tcccagctacagaagaattttg
14 R tctcctatacatgcatgcac 15 F ctgcagtgttggtgcagatt
15 F ctaacacatttcaagcccca 15 R cttgggactttcctcccatt
16 F caggtgcatggtatatttagaagg
16 R tatccacagagagggcaag
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Supplemental data  Primers en PCR set up (continued).
SOS1 RAF1 KRAS
01 F ctgttccgcgctgcgagctc 01 F gcccgagccaagttagaag EXON F/R Sequentie (5’-3’)
01 R agaaagacggccctgcgcgc 01 R atgacctgagtgggatgtgggaactc 02 F gtctgcagtcaactggaatt
02 F ggccacaaacccacattttt 02 F tgctgatgaatgcaggagg 02 R ccaaggaaagtaaagttccc
02 R gagagagcaaattctttccc 02 R atgacccaaaggaagacattccaggc 03 F gcatcttttcaggtgcttag
03 F ccacatgtgaaaagctctac 03 F tggacattcaggttgtttcg 03 R acagggatattacctacctc
03 R atcatagcatcccttctcac 03 R cagagcaagactccacctca 04 F ggtgtagtggaaactaggaa
04 F ttgttggtaagcacaggcct 04 F gggctttggagttcaacaga 04 R tgaccaccaaagccaaaagcagtac
04 R ctggagatattccccaacac 04 R ttgccttactgtaaacaacagca 05a F gaacaaaccaggattctagc
05 F gatgctggcaatatatccaa 05 F tttttggaggccaagaaatg 05a R gtagttctaaagtggttgcc
05 R catgaattaagtcccacaac 05 R tgaatgccaccaaacctagc 05b F cagttgcctgaagagaaaca
06 F gtacacctttgcagaaggaa 06 R caagttccacagaagcagca 05b R ccaaaactctgggaatactg
06 R gctggaaagaagtaagactc 07 F tacaggtagagtttgcccttaagc
07-08 F attgtgctcgcatagtcgtg 07 R cagagacctgagaaagtgttgc
07-08 R aaattcacacttgaatatgttacaaa 08-09 F ggccactgatatttgctgaa
09 F cactgctaatcttggtcttt 08-09 R caagtgtgccaaaaatgacag
09 R tcattgtttacttgaggagg 10 F atgggttgatcctttgatgc
10a F cccttacttacatgagctct 10 R catgacccatgtgcagactg
10a R cgatattctgcattgctagc 11 F ctgtgtaggtatgtgattctttgg
10b F agccaaacatgagagacaca 11 R acatccctttgctctcaagg
10b R aggcacaataaacccatgca 12 F tgatggcccagtgaactaatg
11 F ccttctacttggcaaaacat 12 R ccagctggaacctgaacaac
11 R tctgaaaaggatcttagctc 13 F tgatgtgaaccaggctgaac
12 F gctgactggtgaaaacgttt 13 R ggacaggccaagcctactaa
12 R cttgtttgggaaaggtcctt
13 F gtattgtactgtgcattgtg
13 R acatcttacattactgagcc
14 F cgggaaatggaaaaggagaa
14 R tgaaaaccctataaggcagaaa
15 F cacagacctttctgttggta
15 R cctatgtgacagagcaaaac
16 F agttatactatcgccacccc
16 R gctgggacctgtgaatacat
17 F ctgttgtatttgggcgtttc
17 R ctgctggcatattacacatg
18 F gagccttggttcttttgttt
18 R ccctataaaataaacctgcc
19 F ggcaggtttattttataggg
19 R tttatttggaaggaagtggg
20 F ccaggcacatatagaaaaac
20 R ggtggagtttagaatttgtc
21 F catccagctgaactttttgc
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Supplemental data  Primers en PCR set up (continued).
SOS1 RAF1 KRAS
21 R ccaagaagagttttagcagg
22 F gcaatttccagctaagactt
22 R cctagtgagaactaaactag
23a F cctgccaatagcatgtttga
23a R tgtttgggaagaaggcattg
23b F cacctgatgttttctcaagc
23b R ttttaactcctcagtgctgg
Supplemental data  Primers en PCR set up (continued).
MAP2K1 MAP2K2 SHOC2
F gggtccactgagaccgctac 01 F cttcatccctccgtctcctc 01-02 F gtaggatctttgtctcttcatctt
01 R ccagacgtacgtgacaaacc 01 R ctgcctcgtgcactcctc 01-02 R gagggactgcaatttgttactg
02 F gacctggagctttctttcca 02 F gcaggaatccagtctgtg
02 R cagtcttccttctaccctggtc 02 R cgtgctagctttctgggaat
03 F acctgtttctcctccctctacc 03 F ttggtcttgaccactgttgg
03 R caccaggaatactgcccact 03 R tcgactgccttgagaaggat
04 F gatctcggctcactgcaag 04 F agtcacgcaactgattcgag
04 R cttgtccatttcttaccgactc 04 R ccttggccactctctttctg
05 F tgaaactgcgtctcaaaggag 05-06 F acagcctgaaatggttcctg
05 R ggtaggagttgctgcctcag 05-06 R cccacgaaatagttgggaaag
06 F aagggccttggtgtacagtg 07 F ttagccatggagagggtgac
06 R tgctccaaggcctaagaaag 07 R tcactgcttccagctctgtc
07 F caggaggccaaattcaagag 08 F atttaggctggcatgtggag
07 R gcatccagggacagagaatc 08 R gtttcagtgagccgagaagg
08 F ttgtccatgaccctgttctg 09 F ggaaggaagcaagtgacgac
08 R aaactgctgggattacaggc 09 R acagctctgggaaaaggaatc
09 F cattaggcccaacctcttca 10 F accaaagtgcagaggtggat
09 R actctgcctgcagaagcaat 10 R caggatggcttctctcatgg
10 F tgtgggcatgatactgtgc 11 F ttctgtcccgtaccatctgc
10 R ctgatgggagagcaaaggag 11 R cttcatcccttgacccaaag
11 F cgagtaggctccaagaggtg
11 R cttggcacatgctgtgttct
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Supplemental data  Primers en PCR set up (continued).
HRAS NRAS
02 F gtaaaacgacggccagtctgtgggtttgcccttcaga 2 F agaaccaaatggaaggtcaca
02 R ctagaggaagcaggagacag 2 R cccaaaataactttttactttctctcc
03 F gcatgaggggcatgagaggt 3 F gcaatttgagggacaaacca
03 R acatgcgcagagaggacagg 3 R caatgtcaaacaacctaaaacca
04-05 F cctgtcctctctgcgcatgt 4 F cactgtacccagcctaatcttgttt
04-05 R acactctggggacaagaggg 4 R atggatcacatctctaccag
06-07 F cttgatcccacagcagggag 5 F agtccacataaagagatacaaatgcaa
06-07 R ggcctgaggttccgacatac 5 R accagacaataacaccagcactcct
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Summary
A 10 and a half year-old boy was born at full term, the second child of nonconsanguineous 
parents. Pregnancy and parturition were uncomplicated. Breast feeding was complicated 
because of nasal regurgitation. He developed a positional plagiocephaly, and had a 
inguinal hernia and right-sided cryptorchidism, which were both corrected when he was 
9 weeks old. 
 Because of poor movements at the age of 4 months, physiotherapy was started and 
he was examined by a neurologist. Facial dysmorphisms (epicanthus, hypertelorism, down- 
slanted palpebral fissures, ptosis, small right orbit, low-set ears and webbed neck), pectus 
excavatum with a wide internipple distance, head lag, poverty of movement and plagio- 
cephaly were present. At 8 months, a delayed development with a tonic dysregulation 
was noted. Fine motor, adaptive and personal social behaviour were adequate. At the age 
of 34 months, speech therapy showed a language and speech development delay of, 
respectively, 4 and 10 months. 
 At 5 years of age, he was diagnosed with Noonan syndrome by a clinical geneticist 
because of the typical facial dysmorphisms as mentioned above (Figure 1), a height below 
-2,5 SD, pectus excavatum with a wide internipple distance, developmental delay and a 
corrected cryptorchidism (Table I). He was bruising easily. Hearing was normal and an 
amblyopia was corrected. His behaviour indicated attention deficit, for which Ritalin was 
Figure 1   Patient at the age of 10 years and 6 months showing typical facial 
dysmorphisms: epicanthus, hypertelorism, down-slanted palpebral fissures, 
ptosis and low-set ears.
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given, and he attends primary school with extra support. Physical examination also 
indicated cafe´-au-lait spots (six >0.5 cm, six <0.5 cm), which did not alter during follow-up 
until the age of 10 years and 6 months (Figure 2). No other diagnostic criteria of neuro-
fibromatosis type 1 (NF1) were present (Table I). 
Figure 2   Patient at the age of 10 years and 6 months old with six café-au-lait spots 
larger than 0.5cm: one on his left buttock, one on his right buttock/thigh,  
one between the anal cleft, two on the left side of his back (one lateral and 
one paravertebral) and one on his abdomen. Also, six cafe´-au-lait spots 
smaller than 0.5 cm were found, of which four are shown: two on his right 
buttock, one on the lower left side of his back and one on his abdomen.
Table I  Diagnostic criteria by diagnosis.
Noonan syndrome (1)
Typical face + one major or two minor clinical characteristics
Suggestive face + two major or three minor clinical characteristics 
A = Major
-     Typical face
-     PVS, HOCM and/or typical ECG
-     Growth <P3
-     Pectus carinatum/excavatum
-     First degree relative with definite NS 
-     All three: Mental retardation, lymphatic  
      dysplasia  and cryptorchidism (in boys)
B = Minor
-     Suggestive face
-     Other cardiac defect
-     Growth <P10
-     Broad thorax
-     First degree relative with suggestive NS
-     One of mental retardation, lymphatic 
      dysplasia and cryptorchidism (in boys)
Neurofibromatosis type 1 (2)
Two or more criteria
-     6 or more café-au-lait spots (<0.5 cm in children or >1.5 cm in adults)
-     2 or more cutaneous/subcutaneous neurofibromas or one plexiform  neurofibroma
-     Axillary or groin freckling
-     Optic pathway glioma
-     2 or more Lisch nodules
-     Bony dysplasia
-     First degree relative with NF1
PVS: Pulmonary valve stenosis; HOCM: Hypertrophic obstructive cardiomyopathy; ECG: Electrocardiogram; NS: Noonan 
syndrome; NF1: Neurofibromatosis type 1; (1): van der Burgt et al., 1994; (2): Stumpf et al.,1988
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Investigations 
Metabolic investigation, radiograph of the skull, MRI cerebrum, echocardiogram and ECG 
showed no abnormality. Ultrasound of the bladder and kidneys indicated a double system 
on both sides: an ureterocele on the right and a small ureterocele on the left. An additional 
micturition cystography and renography were normal. Growth hormone stimulation tests 
showed no growth hormone deficiency. 
 DNA analysis for Noonan syndrome did not result in the identification of a pathogenic 
mutation in PTPN11, RAF1, KRAS, SOS1, BRAF, MAP2K1, NRAS, SHOC2 and CBL. Mutation analysis 
of all coding exons and exon/intron boundaries of NF1, using direct sequence analysis and 
multiplex ligation dependent probe amplification analysis, resulted in the identification of 
the sequence variant p.Leu1196Phe (c.3586C>T, NM_000267.3) in NF1 exon 27. This variant 
was classified as an ‘unclassified variant’ because the mutation had not been described in 
the literature and there is only a small physicochemical difference between leucine and 
phenylalanine. However, the location in the Ras GTPase-activating protein domain of NF1, 
the evolutionary conservation of the leucine at position 1196 and the fact that another 
mutation of the same amino acid (p.Leu1196Arg) was described as a pathogenic mutation 
indicated that the p.Leu1196Phe variant in our patient was likely to be pathogenic. Indeed, 
1 year later, the unclassified variant was reclassified as a pathogenic variation based on the 
fact that the variant appeared to be de novo (both parents were negative for the mutation) 
in our patient and p.Leu1196Phe was also found to be de novo in a second patient with 
Neurofibromatosis type 1  from an unrelated family.
Discussion
We present the first documented case of a patient with an NF1 mutation who fulfils the 
diagnostic criteria for Noonan syndrome and not for Neurofibromatosis type 1. 
 One of the latest reviews presents a clear overview of the clinical features, diagnosis 
and management guidelines in Noonan syndrome (3). The cardinal features of Noonan 
syndrome have been reported by Van der Burgt et al. (1994) (1) (Table I). Gain-of-function 
mutations are found in genes involved in the RAS/MAPK pathway called PTPN11, KRAS, 
SOS1, BRAF, RAF1, SHOC2, NRAS, MAP2K1 and CBL (3-5). Neurofibromatosis type 1  is caused 
by a single mutated gene: NF1, which is located on chromosome 17 (6). Neurofibromatosis 
type 1 is a highly variable disorder in which characteristics develop over time. By the age 
of 10 years, almost 100% of the Neurofibromatosis type 1 patients fulfil the criteria (7). 
Because of the extremely variable presentation, formal diagnostic criteria were established 
in 1988 (Table I) (2). Upadhyaya et al. (2007) presented a cohort with a c.2970-2972del AAT 
mutation in exon 17 of the NF1 gene, which is associated with a mild Neurofibromatosis 
type 1 phenotype without cutaneous neurofibromas or clinically obvious plexiform 
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neurofibromas (8). Patients who fulfil the diagnostic criteria for Neurofibromatosis type 1 
and have features of Noonan syndrome are described in the literature as having the neu-
rofibromatosis-Noonan syndrome (NFNS) (9). In these patients, mutations in NF1 are found 
(10, 11). One NFNS patient has been describe with both a NF1 and a PTPN11 gene mutation. 
Her relatives with only a NF1 gene mutation had only the clinical diagnosis of Neurofibro-
matosis type 1 (12). These findings support the finding that NFNS is caused by mutations 
of the NF1 gene. Only one case in literature had both NF1 and PTPN11 mutation, leading to 
expression of both syndromes (Neurofibromatosis type 1 and Noonan syndrome) in this 
patient.
Conclusion
Here, we report a patient who has the clinical diagnosis of Noonan syndrome, but a 
molecular diagnosis of Neurofibromatosis type 1.
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Abstract
In recent studies on prenatal testing for Noonan syndrome in fetuses with an increased 
nuchal translucency (NT) and a normal karyotype, mutations have been reported in 
9–16% of cases. 
 In this study, DNA of 75 fetuses with a normal karyotype and abnormal ultrasound 
findings was tested in a diagnostic setting for mutations in (a subset of) the four most 
commonly mutated Noonan syndrome genes. A second group, consisting of anonymized 
DNA of 60 other fetuses with sonographic abnormalities, was tested for mutations in 10 
Noonan syndrome genes.
 A de novo mutation in either PTPN11, KRAS or RAF1 was detected in 13 fetuses (17.3%). 
Ultrasound findings were increased NT, distended jugular lymphatic sacs (JLS), hydrothorax, 
renal anomalies, polyhydramnios, cystic hygroma, cardiac anomalies, hydrops fetalis and 
ascites. In the second study group, five possible pathogenic mutations have been 
identified (in PTPN11 (n=2), RAF1, BRAF and MAP2K1 (each n=1)). 
 We recommend prenatal testing of PTPN11, KRAS and RAF1 in pregnancies with an 
increased NT and at least one of the following additional features: polyhydramnios, 
hydrops fetalis, renal anomalies, distended JLS, hydrothorax, cardiac anomalies, cystic 
hygroma and ascites. If possible, mutation analysis of BRAF and MAP2K1 should be 
considered.
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Introduction
Noonan syndrome is an autosomal dominant condition with an incidence of 1:1000–2500 
live births. It is characterized by characteristic facies, short stature, congenital heart defects 
(CHD), skeletal abnormalities, cryptorchidism and variable development delay (1-3). NS is 
one of the ‘RASopathies’, a specific class of developmental disorders, caused by germline 
mutations in genes, encoding proteins of the RAS–mitogen-activated protein kinase 
(RAS/MAPK) pathway. This pathway has an essential role in the control of the cell cycle, 
differentiation, growth and cell senescence. Dysregulation has profound developmental 
consequences. About 50% of known Noonan syndrome cases have a mutation in the 
PTPN11 gene (4, 5). Heterozygous gain-of-function mutations in other genes perturbing 
RAS/MAPK signaling have also been identified in Noonan syndrome patients: KRAS, SOS1, 
BRAF, RAF1, MAP2K1, NRAS, SHOC2 and CBL (6-13). Several of these genes are also involved in 
Cardio-Facio-Cutaneous (CFC) syndrome and Costello syndrome (14-16). Because of the 
high variability of clinical symptoms and the genetic heterogeneity establishing a 
diagnosis of one of these syndromes is often difficult. Patients are most frequently 
diagnosed postnatally, but also prenatal characteristic findings are described. Costello 
syndrome is associated with polyhydramnios, fetal overgrowth, a relative macrocephaly 
and to a lesser extent with nuchal thickening, hydrops, ventriculomegaly, pyelectasia and 
fetal atrial tachycardia/arrhythmia (17-19). 
 Prenatal features of Noonan syndrome are increased nuchal translucency (NT), 
distended jugular lymphatic sacs (JLS), cystic hygroma, hydrops fetalis, pleural effusion, 
polyhydramnios, CHD and renal abnormalities (20-24). The first prenatal DNA diagnosis of 
Noonan syndrome in a fetus with massive cystic hygroma, pleural effusion and ascites 
showed a mutation in the PTPN11 gene (25). Lee et al. (2009) performed a retrospective 
review of prenatal PTPN11 testing (26). The two most common indications for testing in 
this study were increased NT (44%) and cystic hygroma (48%). PTPN11 mutations were 
identified in 9% of fetuses (2 and 16% of fetuses with increased NT and cystic hygroma, 
respectively). In a prospective DNA diagnostic study on fetuses with a normal karyotype 
and an increased NT, we previously identified a de novo mutation rate of 15.8% (3/19 
fetuses) by parallel sequencing of PTPN11 and KRAS (27). 
 In the present study, we  investigated the DNA of 56 additional fetuses with a normal 
karyotype and one or more abnormal ultrasound findings for a mutation in one or more 
of the Noonan syndrome genes in a diagnostic setting. Parallel sequencing of PTPN11, 
KRAS, SOS1 and RAF1 was offered, as these are the most frequent mutated genes in patients 
diagnosed with Noonan syndrome after birth. The actual number of genes tested in each 
fetus depended on the amount of DNA available for testing (chorionic villi or amniotic 
fluid, cultured or uncultured cells). In an attempt to define whether parallel sequencing of 
these four genes revealed the highest mutation frequency in fetuses with an abnormal 
ultrasound, we investigated in a second anonymized study the DNA (amplified by whole 
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genome amplification to allow a sufficient amount of DNA) of 60 other fetuses with 
increased NT, hydrops fetalis and/or CHD and a normal karyotype, for mutations in 10 genes 
of the RAS/MAPK pathway. 
 The aim of this study is to provide a protocol for prenatal Noonan syndrome testing, 
to serve as a useful aid to facilitate parental counselling and targeted DNA testing.
Materials and methods
Patients
The first, diagnostic, study group consisted of 75 fetuses with a normal karyotype and 
one or more abnormal ultrasound findings. This group contains all fetuses sent to our 
laboratory from different clinical genetics centers in the Netherlands for a period of 
2 years. Part of the positive cases have been described in case reports (24, 27). Ultrasound 
findings considered as indication for prenatal sequencing were increased NT (greater than 
the 95th percentile (p95)), cystic hygroma, distended JLS, ascites, hydrops fetalis, pleural 
effusion, polyhydramnios, CHD and renal abnormalities. 
 From all mutation-negative cases the ultrasound findings provided by the referring 
physician were marked, and ultrasound findings that were not mentioned were regarded not 
to be present. From all the mutation-positive cases the applicants were asked to deliver 
detailed information about gestational age (GA) and corresponding ultrasound findings. 
Blood of both parents was available for testing of detected mutations and variants.
 The second, anonymized, study group consisted of 60 other fetuses with increased 
NT, hydrops fetalis and/or CHD and a normal karyotype. Medical records of these cases 
were reviewed before anonymizing the samples. Because of the anonymous design of 
the study, parents could not be tested and results were not communicated to the parents.
Sequence analysis
In the diagnostic study group, parallel sequencing of the coding regions and splice sites 
of PTPN11, KRAS, SOS1 and RAF1 was performed. The number of genes tested depended on 
the amount of DNA available for testing (chorionic villi or amniotic fluid, cultured or 
uncultured cells) and the GA of the pregnancy. In 15 fetuses only PTPN11 was tested, 9 
fetuses were tested for PTPN11 and KRAS, 11 fetuses were tested for PTPN11, KRAS, and SOS1. 
In 40 fetuses all four genes were analyzed. The order of genes tested in case not enough 
DNA was available (PTPN11, KRAS, SOS1, RAF1) is based on the reported mutation frequency 
in postnatally diagnosed Noonan syndrome cases. 
 In the anonymized study group, 10 ng of fetal DNA was amplified using the Illustra 
Genomiphi V2 DNA amplification kit (GE Healthcare, Piscataway, NJ, USA), according to the 
manufacturer’s protocol. The coding regions and splice sites of 10 genes were sequenced: 
PTPN11, KRAS, RAF1, SOS1, BRAF, NRAS, SHOC2, MAP2K1, MAP2K2, and HRAS. Mutations were 
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confirmed on the unamplified fetal material. Primers and PCR/sequencing conditions are 
available upon request.
Interpretation of sequence variants
For all detected variants that were not previously described in literature, an insilico-based 
method (Alamut software version 2.0, Interaction Biosoftware, Rouen, France) was used to 
assess the effect of the mutation. Parameters used in this program include the Grantham 
score, SIFT and PolyPhen analysis, PhyloP score and analysis of frequency of the mutation 
in the population. 
Statistical analysis
The data were collected in SPSS 16.0. For statistical analysis we used the Student’s t-test 
and the Fischer’s Exact test. A statistically significant two-sided threshold was set at P<0.05. 
Because of the small number of fetuses also descriptive analysis was performed.
Results
Diagnostic study group
The diagnostic study group included 75 fetuses with a normal karyotype and abnormal 
ultrasound findings, described in Noonan syndrome. 
 Table I shows the prenatal ultrasound findings in the total group and classified by the 
presence or absence of a mutation. The most frequently identified prenatal characteristics 
are increased NT (n=50; 66.7%), cystic hygroma (n=17; 22.7%), cardiac anomalies and 
hydrops fetalis (each n=15; 20.0%), distended JLS (n=12; 16.0%), hydrothorax (n=9; 12.0%), 
renal anomalies (n=7; 9.3%), polyhydramnios (n=3; 4.0%) and ascites (n=1; 1.3%). No 
postnatal information of the mutation-negative cases is present. However, we never 
received a request for testing of the remaining Noonan syndrome genes once the baby 
was born, suggesting that no Noonan syndrome-specific features were present. However, 
it cannot be excluded that part of the pregnancies has been terminated because of the 
abnormalities seen on the ultrasound. 
 In 13/75 (17.3%) fetuses a mutation was detected. Table II shows their pre- and postnatal 
clinical characteristics. The mutations and clinical features of four of these fetuses have 
also been described elsewhere; case 1 has been described by Bakker et al. (2011) and cases 
9, 12 and 13 have been described by Houweling et al. (2010) (24, 27). Nine fetuses had a de 
novo mutation in PTPN11, three in RAF1 and one in KRAS. Eight of the 12 different mutations 
detected in this study have been described earlier in postnatally identified Noonan 
syndrome patients: PTPN11; c.174C4G (p.Asn58Lys) (28), c.182A4G (p.Asp61Gly) (4), c.184T4G 
(p.Tyr62Asp) (5), c.205G4C (p.Glu69Gln) (28), c.417G4C (p.Glu139Asp) (5), and c.854T4C 
(p.Phe285Ser) (5), RAF1 c.770C4T (p.Ser257Leu) (10), and KRAS c.173C4T (p.Thr58Ile) (6). 
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One mutation has been previously described in a patient with the clinical diagnosis of 
LEOPARD syndrome: PTPN11 c.1381G4A (p.Ala461Thr) (29). The remaining three mutations 
had not been described in literature before the detection in this study: RAF1 c.775T4C 
(p.Ser259Pro), PTPN11 c.181G4C (p.Asp61His) and PTPN11 c.227A4T (p.Glu76Val). These 
mutations were considered to be pathogenic as the mutations were not present in both 
the parents. Furthermore, they affect highly conserved amino acids, and in silico analysis 
(Alamut software) predicts a pathogenic effect. Additionally, further evidence for patho- 
genicity of these mutations is given by the fact that the c.181G4C and c.227A4T mutations 
in PTPN11 were detected as somatic events in malignancies (30). As the Ser259 residue is 
critical for auto inhibition of RAF1, mutations affecting this residue facilitate binding of 
RAF1 to GTP-bound RAS and its activation (9).
 Twelve fetuses with a mutation had an increased NT with a mean NT of 8mm at GA of 
11–14 weeks (range 4.2–14mm). The NT value of case 6 was not measured at this term. 
Apart from the increased NT, all mutation-positive fetuses had one or more other 
sonographic abnormalities. These were, in order of frequency: distended JLS (n=7; 53.8%), 
hydrothorax (n=7; 53.8%), renal anomalies (n=6; 46.2%), cardiac anomalies (n=5; 38.5%), 
cystic hygroma (n=4; 30.8%), hydrops fetalis (n=4; 30.8%), polyhydramnios (n=3; 23.1%) 
and ascites (n=1; 7.7%). In three fetuses limb anomalies were described (syndactyly of the 
4th and 5th finger, clubfeet and short femura). In five fetuses, facial characteristics such as 
low-set ears, uplifted earlobes, small nose, sloping forehead and brachycephaly were 
noted. Twelve of 13 pregnancies were terminated after extensive counselling. One woman 
had a planned caesarean section at GA 32 weeks, but the neonate deceased suddenly 
1 day post partum.
Table I  Prenatal findings of 75 fetuses with a normal karyotype.
Findings Total group
(n=75) (%)
Mutation 
 positive group 
(n=13) (%) 
Mutation 
 negative group 
(n=62) (%) 
P-value
Increased NT
   Mean NT (mm) at 11-14 weeks
50/75
7.3
(66.7) 
(3.6-14)
13/13
8.0
(100) 
(4.2-14)
37/62
6.5
(59.7)
(3.6-11.9)
0.003*
0.854#
Cystic hygroma 17/75 (22.7) 4/13 (30.8) 13/62 (21.0) 0.475*
Distended JLS 12/75 (16.0) 7/13 (53.8) 5/62 (8.1) 0.000*
Ascites 1/75 (1.3) 1/13 (7.7) 0/62 (0.0) 0.173*
Hydrothorax 9/75 (12.0) 7/13 (53.8) 2/62 (3.2) 0.000*
Cardiac anomalies 15/75 (20.0) 5/13 (38.5) 10/62 (16.1) 0.120*
Renal anomalies 7/75 (9.3) 6/13 (46.2) 1/62 (1.6) 0.000*
Hydrops fetalis 15/75 (20.0) 4/13 (30.8) 11/62 (17.7) 0.279*
Polyhydramnion 3/75 (4.0) 3/13 (23.1) 0/62 (0.0) 0.004*
*: Fisher’s Exact test; #: Student’s T test; NT: nuchal translucency; JLS: jugular lymphatic sacs
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An increased NT, distended JLS, hydrothorax, renal anomalies and polyhydramnios were 
significantly more common in the mutation-positive group (Table I). The mean NT at GA 
11–14 weeks was 8mm in the mutation-positive group versus 6.5mm in the mutation-neg-
ative group, which is not statistically significant (P=0.854). In the mutation-positive group 
a tendency of increasing NT with advancing GA was observed in the group as a whole 
(Figure 1). This trend is not seen in the mutation-negative group. 
Anonymized study group
Our second study group consisted of anonymized DNA from 60 fetuses with abnormal 
prenatal ultrasound findings including increased NT, hydrops fetalis and/or cardiac 
anomalies, referred to our department for routine chromosomal analysis. 
 Indications for karyotyping were increased NT in 17/60 fetuses (28.3%), cardiac 
anomaly in 35/60 (58.3%), hydrops fetalis in 7/60 (11.7%) and in one fetus both a cardiac 
anomaly and hydrops fetalis were indications for testing (1.7%). Other characteristic 
ultrasound findings were cystic hygroma/distended JLS (n=2; 3.3%), ascites (n=5; 8.3%), 
hydrothorax (n=5; 8.3%), renal anomalies (n=3; 5.0%) and polyhydramnios (n=3; 5.0%) 
(Table III). All karyotypes were normal.
 In five fetuses (8.3%) a mutation in one of the 10 Noonan syndrome genes was found. 
Besides the previously described pathogenic mutation c.854T4C (p.Phe285Ser) in PTPN11 (5), 
four unclassified variants were identified: PTPN11 c.430C4T (p.Pro144Ser), RAF1 c.935T4G 
(p.Val312Gly), BRAF c.1150A4G (p.Arg384Gly) and MAP2K1 c.1039G4A (p.Ala347Thr). Although 
these variants have not been described before and de novo occurrence could not be 
tested, we hypothesize that these mutations are likely to be causative as the in silico 
analysis predicts a deleterious effect. Although the frequency of these variants has not 
been tested in healthy controls, the absence of these mutations in postnatally tested cases 
in our laboratory (B100 for RAF1, B150 for BRAF and MAP2K1, and B1700 for PTPN11), and in 
public databases (NHLBI GO Exome Sequencing project, and dbSNP XML build 135), 
supports the fact that these changes are not frequently identified polymorphisms. 
However, in the absence of parental DNA, further evidence on the pathogenicity of these 
unclassified variants can only be generated by biochemical and/or functional  characterization.
 To provide further evidence for the involvement of BRAF and MAP2K1 mutations 
(that were not tested in the diagnostic study group), we anonymized 27 DNA samples 
(all samples with sufficient DNA left) from that group and sequenced both genes. 
One sample contained a mutation in the MAP2K1 gene c.383G4A (p.Gly128Asp). Because 
of the anonimization of the samples, no clinical features of the fetus can be described, 
and the parents could not be tested. The exact mutation has not been described in 
literature, but is regarded to be pathogenic as a mutation of the same amino acid (p.
Gly128Val) has been reported in a patient with CFC Syndrome (31). 
 No significant differences in clinical characteristics were found between the mutation- 
positive and negative fetuses in this study group.
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Table II   Prenatal and postnatal findings of 13 mutation positive fetuses  
in the diagnostic study group.
Prenatal and  
Postnatal findings
Case 1(24) Case 2 Case 3 Case 4 Case 5 Case 6 Case 7
DNA Mutation RAF1 
c.770C>T (p.Ser257Leu)
de novo
PTPN11 
c.174C>G (p.Asn58Lys)
de novo
RAF1 
c.770C>T (p.Ser257Leu)
de novo
RAF1 
c.775T>C (p.Ser259Pro)
de novo
PTPN11 c.1381G>A 
(p.Ala461Thr)
de novo
PTPN11 
c.182A >G (p.Asp61Gly)
de novo
PTPN11 
c.854T>C
(p.Phe285Ser)
de novo
Prenatal findings
Increased NT (mm)
  
4.4 4.2 10.0 7.6 6.5 – 11.2 unknown 7.8
Cystic hygroma No No No Yes No Yes No 
Distended JLS No No Yes No No No Yes (8,5-14 mm)
Ascites No No Yes No No No No 
Hydrothorax No Yes (right side) Yes (both sides) Yes (both sides) Yes (left side) Yes (right side) No 
Hydrops fetalis No No Yes Yes Yes No No 
Polyhydramnios No Yes No Yes No Yes No 
Cardiovascular Anomalies Yes
mild TR, Malalignment VSD, 
Heart axis deviation, RV
dysfunction, PE
Yes
Ductus venosus agenesis
No No No No Yes
Hypoplastic left heart, 
retrograde flow aorta
Renal Anomalies Yes
Bilateral pyelectasis
No Yes
Bilateral
echogenicity
Yes
Hydronephrosis
No Yes
Unilateral pyelectasis
No 
Facial features Yes
Low set ears with 
uplifted earlobes, small 
nose, sloping forehead, 
brachycephaly
Yes
Mild ptosis
No 
Limb anomalies No Yes
Clubfeet
Yes
Syndactyly 4th and 5th 
finger
No
Indication for testing Increased NT, facial 
features
Increased NT, ductus 
venosus agenesis
Increased NT Increased NT Increased NT Increased NT Increased NT, distended 
JLS and hypoplastic left 
heart
Pregnancy course TOP GA 22+1 Planned Sectio Caesarea at 
GA 32, deceased suddenly 
one day post partum
TOP GA 17+3 TOP GA 20+2 TOP GA 16+4 TOP GA 23+3 TOP GA 16+1
Postnatal findings
Facial features Low set posteriorly
angulated ears, broad 
nose,
brachycephaly, 
Downslanted palpebral 
fissures, hypertelorism, low 
set posteriorly
angulated ears, broad 
neck, low anterior hairline
Deep nasal bridge, 
hypertelorism, low set 
posteriorly
angulated ears, anteverted 
nares, broad mouth, long 
philtrum
Low set ears Short nose, anteverted 
nares, low set posteriorly
angulated ears
Low set ears, retrognathia
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Table II   Prenatal and postnatal findings of 13 mutation positive fetuses  
in the diagnostic study group.
Prenatal and  
Postnatal findings
Case 1(24) Case 2 Case 3 Case 4 Case 5 Case 6 Case 7
DNA Mutation RAF1 
c.770C>T (p.Ser257Leu)
de novo
PTPN11 
c.174C>G (p.Asn58Lys)
de novo
RAF1 
c.770C>T (p.Ser257Leu)
de novo
RAF1 
c.775T>C (p.Ser259Pro)
de novo
PTPN11 c.1381G>A 
(p.Ala461Thr)
de novo
PTPN11 
c.182A >G (p.Asp61Gly)
de novo
PTPN11 
c.854T>C
(p.Phe285Ser)
de novo
Prenatal findings
Increased NT (mm)
  
4.4 4.2 10.0 7.6 6.5 – 11.2 unknown 7.8
Cystic hygroma No No No Yes No Yes No 
Distended JLS No No Yes No No No Yes (8,5-14 mm)
Ascites No No Yes No No No No 
Hydrothorax No Yes (right side) Yes (both sides) Yes (both sides) Yes (left side) Yes (right side) No 
Hydrops fetalis No No Yes Yes Yes No No 
Polyhydramnios No Yes No Yes No Yes No 
Cardiovascular Anomalies Yes
mild TR, Malalignment VSD, 
Heart axis deviation, RV
dysfunction, PE
Yes
Ductus venosus agenesis
No No No No Yes
Hypoplastic left heart, 
retrograde flow aorta
Renal Anomalies Yes
Bilateral pyelectasis
No Yes
Bilateral
echogenicity
Yes
Hydronephrosis
No Yes
Unilateral pyelectasis
No 
Facial features Yes
Low set ears with 
uplifted earlobes, small 
nose, sloping forehead, 
brachycephaly
Yes
Mild ptosis
No 
Limb anomalies No Yes
Clubfeet
Yes
Syndactyly 4th and 5th 
finger
No
Indication for testing Increased NT, facial 
features
Increased NT, ductus 
venosus agenesis
Increased NT Increased NT Increased NT Increased NT Increased NT, distended 
JLS and hypoplastic left 
heart
Pregnancy course TOP GA 22+1 Planned Sectio Caesarea at 
GA 32, deceased suddenly 
one day post partum
TOP GA 17+3 TOP GA 20+2 TOP GA 16+4 TOP GA 23+3 TOP GA 16+1
Postnatal findings
Facial features Low set posteriorly
angulated ears, broad 
nose,
brachycephaly, 
Downslanted palpebral 
fissures, hypertelorism, low 
set posteriorly
angulated ears, broad 
neck, low anterior hairline
Deep nasal bridge, 
hypertelorism, low set 
posteriorly
angulated ears, anteverted 
nares, broad mouth, long 
philtrum
Low set ears Short nose, anteverted 
nares, low set posteriorly
angulated ears
Low set ears, retrognathia
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Table II   Prenatal and postnatal findings of 13 mutation positive fetuses  
in the diagnostic study group (continued).
Prenatal and  
Postnatal findings
Case 1(24) Case 2 Case 3 Case 4 Case 5 Case 6 Case 7
Cardiovascular anomalies Subaortal stenosis, LVH, 
perimembrous VSD
No Deep interventricular 
fissure externally
HLH ASD type II, 
perimembranous VSD, 
mitral stenosis, aortic 
stenosis, hypoplasia aortic 
arch
Renal anomalies No No
Other features Redundant nuchal skin, 
generalized skin oedema
Severe hydrops, 
brachydactyly, virilized 
genital
Severe hydrops
Clubfeet
Hygroma colli
Table II (continued)   Prenatal and postnatal findings of 13 mutation positive fetuses  
in the diagnostic study group.
Prenatal and  
Postnatal findings
Case 8 Case 9 (27) Case 10 Case 11 Case 12(27) Case 13(27)
DNA Mutation PTPN11 
c.227A>T
(p.Glu76Val)
de novo
KRAS 
c.173C>T (p.Thr58Ile)
de novo
PTPN11 
c.184T>G (p.Tyr62Asp)
de novo
PTPN11 
c.205G>C (p.Glu69Gln)
de novo
PTPN11 
c.417G>C (p.Glu139Asp)
de novo
PTPN11 
c.181G>C (p.Asp61His)
de novo
Prenatal findings
Increased NT (mm)
    
11 14 5.1 8.5 5.2 8.2
Cystic hygroma Yes No No Yes (6,9 mm) No No
Distended JLS No Yes Yes (7,1x8,7 mm) Yes Yes Yes
Ascites No No No No No No
Hydrothorax Yes (left side) Yes (both sides) No No No No
Hydrops fetalis Yes No No No No No
Polyhydramnios No No No No No No
Cardiac Anomalies No No No Yes
Hypoplastic right  
heart with small arteriae 
pulmonalis
No Yes
Pericardial effusion, AVSD
Renal Anomalies No Yes
Bilateral pyelectasis (right 
9,6 mm, left 7,7 mm)
No No No Yes
Bilateral pyelectasis
Facial features Yes
Unclassified because of 
oedema
Yes
Low set ears
Yes
Low set ears
No
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Table II   Prenatal and postnatal findings of 13 mutation positive fetuses  
in the diagnostic study group (continued).
Prenatal and  
Postnatal findings
Case 1(24) Case 2 Case 3 Case 4 Case 5 Case 6 Case 7
Cardiovascular anomalies Subaortal stenosis, LVH, 
perimembrous VSD
No Deep interventricular 
fissure externally
HLH ASD type II, 
perimembranous VSD, 
mitral stenosis, aortic 
stenosis, hypoplasia aortic 
arch
Renal anomalies No No
Other features Redundant nuchal skin, 
generalized skin oedema
Severe hydrops, 
brachydactyly, virilized 
genital
Severe hydrops
Clubfeet
Hygroma colli
Table II (continued)   Prenatal and postnatal findings of 13 mutation positive fetuses  
in the diagnostic study group.
Prenatal and  
Postnatal findings
Case 8 Case 9 (27) Case 10 Case 11 Case 12(27) Case 13(27)
DNA Mutation PTPN11 
c.227A>T
(p.Glu76Val)
de novo
KRAS 
c.173C>T (p.Thr58Ile)
de novo
PTPN11 
c.184T>G (p.Tyr62Asp)
de novo
PTPN11 
c.205G>C (p.Glu69Gln)
de novo
PTPN11 
c.417G>C (p.Glu139Asp)
de novo
PTPN11 
c.181G>C (p.Asp61His)
de novo
Prenatal findings
Increased NT (mm)
    
11 14 5.1 8.5 5.2 8.2
Cystic hygroma Yes No No Yes (6,9 mm) No No
Distended JLS No Yes Yes (7,1x8,7 mm) Yes Yes Yes
Ascites No No No No No No
Hydrothorax Yes (left side) Yes (both sides) No No No No
Hydrops fetalis Yes No No No No No
Polyhydramnios No No No No No No
Cardiac Anomalies No No No Yes
Hypoplastic right  
heart with small arteriae 
pulmonalis
No Yes
Pericardial effusion, AVSD
Renal Anomalies No Yes
Bilateral pyelectasis (right 
9,6 mm, left 7,7 mm)
No No No Yes
Bilateral pyelectasis
Facial features Yes
Unclassified because of 
oedema
Yes
Low set ears
Yes
Low set ears
No
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Table II (continued)   Prenatal and postnatal findings of 13 mutation positive fetuses  
in the diagnostic study group (continued).
Prenatal and  
Postnatal findings
Case 8 Case 9 (27) Case 10 Case 11 Case 12(27) Case 13(27)
Limb anomalies No Yes
Short femura (<p5)
Indication for testing Hydrops fetalis Increased NT Increased NT Increased NT Increased NT, distended 
JLS
Increased NT, AVSD, short 
femura
Pregnancy course TOP GA 17+4 TOP GA 22+2 TOP TOP GA 21+5 TOP GA 23+5 TOP GA 16+0
Postnatal findings
Facial features Extremely low set 
posteriorly
angulated ears, 
hypertelorism
Hypertelorism, low set 
ears
Hypertelorism, low set 
left ear
Low set posteriorly
angulated ears, 
hypertelorism, webbing 
of the neck
Cardiac anomalies No Hypertrophy Hypertrophy 
interventricular septum
Complete AVSD
Renal anomalies No Bilateral pyelectasis
Other features Severe skin oedema Nuchal oedema Loose nuchal skin
AVSD: atrio ventricular septal defect; GA: gestational age; HLH: Hypoplastic left heart; JLS: jugular lymphatic sacs; 
LVH: left ventricular hypertrophy; NT: nuchal translucency; PE:  pericardial effusion; RV: right ventricle; TOP: termination 
of pregnancy; TR: tricuspid regurgitation; VSD: ventricular septum defect; *: Increased NT: measured at 11-14 weeks
Table III  Prenatal findings in 60 anonymous fetuses with a normal karyotype.
Prenatal findings Total group 
(n=60) (%)
Mutation  
positive group 
(n=5) (%)
Mutation  
negative group 
(n=55) (%)
P-value*
Indication DNA research
     Increased NT (>95th centile)
     Hydrops fetalis
     Cardiac anomaly
Other findings 
     Cystic hygroma/distended JLS
     Ascites
     Hydrothorax
     Renal anomaly
     Polyhydramnion
17/60
8/60
36/60
2/60
5/60
5/60
3/60
3/60
 
(28.3)
(13.3)
(60.0)
(3.3)
(8.3)
(8.3)
(5.0)
(5.0)
2/5
1/5
2/5
1/5
0/5
1/5
0/5
0/5
(40.0)
(20.0)
(40.0)
 
(20.0)
(0.0)
(20.0)
(0.0)
(0.0)
15/55 
7/55
34/55
1/55
5/55
4/55
3/55
3/55
(27.3)
(12.7)
(61.8)
 
(1.8)
(9.1)
(7.3)
(5.5)
(5.5)
0.616
0.524
0.380
0.161
1.000 
0.363
1.000
1.000
*: Fisher’s Exact test; DNA: deoxyribonucleic acid; NT: nuchal translucency; JLS: jugular lymphatic sacs
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Discussion
Analysis of the diagnostic study group consisting of 75 fetuses with a normal karyotype 
and one or more abnormal ultrasound findings suggestive for Noonan syndrome revealed 
a de novo mutation in 13 fetuses in one of the four tested genes known to be related to 
Noonan syndrome (PTPN11, KRAS, SOS1 and RAF1). This corresponds to a positive test rate 
of 17.3%. As part of this cohort (19 fetuses sent in by one of the Dutch medical centers) has 
previously been described by Houweling et al. (2010), we also have calculated the mutation 
frequency in the undescribed cases (27). In the additional 56 fetuses, 10 mutations have 
been identified, which corresponds to a mutation frequency of 17.9%. This slightly higher 
percentage is probably explained by the fact that in the first 19 cases only two genes have 
been tested. As no pathogenic mutations have been detected in the SOS1 gene, analysis 
of three genes (PTPN11, KRAS and RAF1) would have revealed the same mutation frequency. 
The fact that no SOS1 mutations have been detected, although SOS1 mutations underlie 
twice as much Noonan syndrome as do RAF1 mutations, is likely explained by the fact that 
the milder SOS1-related Noonan syndrome may be difficult to detect in utero with 
ultrasound. Lee et al. (2009) analyzed 134 fetuses with one or more sonographic findings 
suggestive of Noonan syndrome for PTPN11 mutations only and found a positive test rate 
Table II (continued)   Prenatal and postnatal findings of 13 mutation positive fetuses  
in the diagnostic study group (continued).
Prenatal and  
Postnatal findings
Case 8 Case 9 (27) Case 10 Case 11 Case 12(27) Case 13(27)
Limb anomalies No Yes
Short femura (<p5)
Indication for testing Hydrops fetalis Increased NT Increased NT Increased NT Increased NT, distended 
JLS
Increased NT, AVSD, short 
femura
Pregnancy course TOP GA 17+4 TOP GA 22+2 TOP TOP GA 21+5 TOP GA 23+5 TOP GA 16+0
Postnatal findings
Facial features Extremely low set 
posteriorly
angulated ears, 
hypertelorism
Hypertelorism, low set 
ears
Hypertelorism, low set 
left ear
Low set posteriorly
angulated ears, 
hypertelorism, webbing 
of the neck
Cardiac anomalies No Hypertrophy Hypertrophy 
interventricular septum
Complete AVSD
Renal anomalies No Bilateral pyelectasis
Other features Severe skin oedema Nuchal oedema Loose nuchal skin
AVSD: atrio ventricular septal defect; GA: gestational age; HLH: Hypoplastic left heart; JLS: jugular lymphatic sacs; 
LVH: left ventricular hypertrophy; NT: nuchal translucency; PE:  pericardial effusion; RV: right ventricle; TOP: termination 
of pregnancy; TR: tricuspid regurgitation; VSD: ventricular septum defect; *: Increased NT: measured at 11-14 weeks
517840-L-bw-croonen
Processed on: 6-3-2018 PDF page: 74
74
Chapter 4
of 9% (26). In our previous study parallel testing of PTPN11 and KRAS in fetuses with a 
normal karyotype and an increased NT showed a mutation frequency of 15.8% (27). The 
lower-positive test rate reported by Lee et al. might be due to the fact that only PTPN11 was 
tested (26). 
 In the present study, prenatal testing of PTPN11, KRAS, SOS1 and RAF1 was offered to 
parents carrying a fetus with a normal karyotype and ultrasound abnormalities as seen in 
Noonan syndrome. The actual number of genes tested depended on the amount of DNA 
available for testing. The prenatal findings of the mutation-positive fetuses found in our 
diagnostic study group were increased NT, distended JLS, hydrothorax, renal anomalies, 
cardiac anomalies, cystic hygroma, hydrops fetalis, polyhydramnios and ascites. An 
increased NT, distended JLS, hydrothorax, renal anomalies and polyhydramnios were 
significant more common in mutation-positive fetuses. However, features in the muta-
tion-negative fetuses that are not specifically mentioned were considered not to be 
present. Bakker et al. (2011) reviewed the literature on prenatal findings in Noonan 
syndrome and mentioned increased NT/cystic hygroma (35.7%), distended JLS (16.7%), 
hydrothorax (40.5%), renal anomalies (23.8%), cardiac anomalies (38.1%), scalp/skin edema 
(33%), polyhydramnios (50%) and ascites (14.3%) (24). Baldassarre et al. (2011) found most 
frequently polyhydramnios (38.3%) and increased NT (41%) (32). The two most commonly 
reported indications for prenatal testing reported by Lee et al. (2009) were increased NT 
(44%) and cystic hygroma (48%) (26). In our study mutation-positive fetuses showed an 
increased NT and at least one of the following additional features: polyhydramnios, 
hydrops fetalis, renal anomalies, distended JLS, hydrothorax, cardiac anomalies, cystic 
hygroma or ascites. Therefore, we recommend these characteristics as important 
indications for prenatal Noonan syndrome testing. Future studies should reveal whether 
testing of the Noonan syndrome genes in fetuses with isolated NT is worthwhile. 
 In the second study group of 60 anonymized fetuses with abnormal prenatal 
ultrasound findings, we detected a potential-positive test rate of 8.3%. No significant 
differences were found between mutation-positive and negative fetuses regarding 
prenatal findings. These two observations are different from the results in the first study 
group. However, a more detailed analysis of the difference in occurrence of features 
between the two cohorts is not possible, because the inclusion criteria in the two study 
groups are not the same. Furthermore, because of the anonymous nature of the second 
group the description of sonographic abnormalities on the request form might not be 
complete.
 The mutation rate could actually by higher than 8.3%, as false negative results cannot 
be ruled out. Both preferential amplification and allele dropout are known problems 
accompanying whole genome amplification (33), as all mutations have been verified on 
the original (unamplified) DNA, false-positive cases have been excluded. The lower-positive 
test rate can also be explained by the fact that a cardiac anomaly was the most common 
(60%) indication for testing in this study group. Two out of five fetuses with a mutation had 
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a cardiac anomaly (40%). The findings of both the diagnostic and the anonymized study 
group support the fact that cardiac anomalies alone will not differentiate between the 
presence or absence of a mutation in one of the Noonan syndrome genes and should 
thus not be the main indication for further investigation. Additionally, it is notable that 
cardiac anomalies are less common in our positive fetuses (38.5% in the diagnostic study 
group and 40.0% in the anonymized study group) compared with the general Noonan 
syndrome population (66–87%) (1, 34-36). Also Menashe et al. (2002) noted that heart 
malformations were evident prenatally only in a small group of Noonan syndrome patients 
(27%), which could be explained by the fact that the most common heart malformations, 
pulmonary valve stenosis and hypertrophic cardiomyopathy, develop during pregnancy 
or early childhood (22). This observation suggests that the cardiac anomaly in Noonan 
syndrome is a cryptic condition in early gestation and has an evolving phenotype in utero 
and in postnatal life (37). 
 Interestingly, we only know of an increased NT in two of the mutation-positive fetuses 
from the anonymized study group. The anonymous nature of this study group did not 
allow us to discriminate between the possibilities that in the other three mutation-posi-
tive fetuses from this group an increased NT was not present but not mentioned, or was 
not present at all. Therefore, it cannot be ruled out that mutations in the Noonan syndrome 
genes are found in fetuses with a normal NT.
 Although we are aware of the fact that prenatal testing for Noonan syndrome and 
the possibility to terminate a pregnancy is not common in all countries, based on our 
findings in the positive fetuses from the first cohort and current literature, we would 
recommend prenatal testing of Noonan syndrome genes when an increased NT is seen in 
combination with at least one of the following additional features: polyhydramnios, 
hydrops fetalis, renal anomalies, distended JLS, hydrothorax, cardiac anomalies, cystic 
hygroma or ascites. When chromosomal analysis has revealed a normal karyotype, parents 
should be referred to a clinical geneticist for counselling and an ultrasound examination 
at 16 weeks. If thereafter genetic testing for Noonan syndrome is indicated, it is advised to 
collect parental blood simultaneously with the fetal sample, as in case of the identification 
of a mutation in the fetus, the parental DNA can immediately be tested for de novo 
occurrence. This saves precious time and limits the uncertainty about pathogenicity of 
the mutation. The recommended genes for testing are PTPN11, RAF1 and KRAS. If sufficient 
time and DNA is left, mutation analysis of BRAF and MAP2K1 should be considered. For 
optimal decision-making by the parents, the results of the tests performed should be 
disclosed when the option of terminating the pregnancy (in the Netherlands at 24 weeks 
of gestation) is still open. We recently adapted our DNA diagnostic protocol according to 
the criteria described in this paper. Although parallel sequencing of these five genes is 
possible within two weeks on B2 mg of fetal DNA, there is a great need for other detection 
methods involving less DNA, more tests and a shorter turnaround time, to allow the 
analysis of more genes and thus to further increase the mutation detection rate. 
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Furthermore, future clinical studies of mutation-negative cases, both prenatally and 
postnatally, are necessary to better define the inclusion criteria for Noonan syndrome 
testing.
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Abstract
Noonan syndrome is a developmental disorder with distinctive facial features, short stature 
and cardiac abnormalities. 
 In this cross-sectional study, we evaluated characteristic electrocardiographic findings 
and cardiac abnormalities in 84 patients with Noonan syndrome.
 56 (67%) patients had a PTPN11 mutation. Pulmonary valve stenosis was the most 
common cardiac abnormality, followed by atrial septal defect and hypertrophic cardio- 
myopathy. The electrocardiogram (ECG) showed at least one characteristic finding in 
50% of cases including left axis deviation in 38 (45%), small R waves in the left precordial 
leads in 20 (24%) and an abnormal Q wave in 5 (6%) patients with Noonan syndrome. 
A wide QRS complex was not detected in any of these patients. The characteristic ECG 
findings of Noonan syndrome patients were not associated with a PTPN11 gene mutation, 
or with a (specific) cardiac anomaly.
 We conclude that there are characteristic ECG findings in Noonan syndrome, but the 
ECG pattern is neither a useful tool for the phenotype characterization of a PTPN11 mutation, 
nor for the presence or type of cardiac abnormality.
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Introduction
Noonan syndrome (OMIM 163950), an autosomal dominant disorder with an estimated 
prevalence of 1/1,000–2,500 live births, is characterized by distinctive facial anomalies, 
short stature, and cardiac abnormalities (1). About 50% of patients with Noonan syndrome 
have a mutation in the PTPN11 gene on chromosome 1 (2, 3). Recently, genetic 
heterogeneity is demonstrated by identifying heterozygous gain-of-function mutations 
in other genes encoding proteins of the RAS/MAPK pathway, like SOS1 in about 15% of 
patients, and KRAS and RAF1 in less than 5% of patients (4-6). 
 The most common cardiac abnormalities are pulmonary valve stenosis (31–74%), 
hypertrophic cardiomyopathy (HCM) (7–20%), and atrial septal defect (ASD) (3.2–30%) 
(7-9). The electrocardiogram (ECG) of patients with Noonan syndrome commonly shows 
left axis deviation, small R waves in the left precordial leads, wide QRS complex and 
abnormal Q wave (10, 11). 
 The purpose of this study was to conduct the first systematic analysis of the PTPN11 
gene mutation in relation to the characteristic ECG findings in patients with Noonan 
syndrome.
Patients and methods
Patients
We included all clinically diagnosed patients with Noonan syndrome (including affected 
parents) at one tertiary center using the cardinal features delineated by Van der Burgt et al. 
(1994) (1). Patients were excluded if PTPN11 gene testing had not been performed or if 
there was insufficient clinical information or if their ECG was not available.
Electrocardiogram
Two independent pediatric cardiologists who were blinded to the PTPN11 mutation status 
and the presence of a cardiac abnormality judged this first ECG. The ECG was scored on 
four characteristic ECG findings (10, 11) (Figure 1). The criteria include (12): 
(1)  Left axis deviation: QRS axis less than the lower limit of normal for the patient’s age. 
(2)  Small R waves in the left precordial leads: R/S ratio in lead V6 lower than the lower 
limits of normal and an R wave voltage in leads V5 and V6 less than 50% of the mean.
(3)  Wide QRS-complex: QRS duration of more than 0.08 sec under the age of three years, 
above 0.10 sec between three and 12 years and above the upper limit for QRS 
duration of 0.12 sec from 12 years on.
(4)  Abnormal Q wave: Q voltage greater than the upper limit of normal and wider than 
0.04 sec. Combinations of two or more characteristic ECG findings were possible.
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Statistical analysis
The data were analyzed with SPSS (version: 12.0.1). For statistical analysis the Fisher’s exact 
test, with a significance threshold of  P<0.05, was used. 
Results
In 84 (38%) of the 219 clinically diagnosed patients with Noonan syndrome, we performed 
PTPN11 gene mutation analysis; clinical information and ECG were available. Of these 
84 patients, 45 (54%) were boys, and the median age was 5 years. In 56 (67%) a PTPN11 
mutation was identified. In 62 (74%), one or more cardiac abnormalities were present. 
Pulmonary valve stenosis was the most common cardiac abnormality, that is, in 52 cases 
(62%), followed by ASD in 9 (11%) and HCM in 7 (8%) patients. The number of patients 
with a cardiac abnormality was 45 (80%) in the PTPN11 mutation-positive group and 17 
(61%) in the PTPN11 mutation-negative group (P=0.07). Pulmonary valve stenosis was the 
most common heart defect in both groups. However, a statistically higher prevalence of 
pulmonary valve stenosis was found in the mutation-positive group (71% vs. 43%; P=0.02). 
No statistically significant difference was found for ASD (P=0.26), but a significantly higher 
prevalence of HCM was observed in the mutation-negative group (21% vs. 2%; P<0.01). 
Characteristic ECG Findings – PTPN11 Gene Mutation
An ECG pattern with any of the four characteristic findings was present in 42 (50%) 
subjects. Left axis deviation was present in 38 (45%), small R waves in the left precordial 
leads were present in 20 (24%) and abnormal Q wave in 5 (6%) patients with Noonan 
syndrome. Wide QRS complex was not found. No significant difference in the frequency, 
Figure 1   Electrocardiogram of a 3 months old male Noonan syndrome patient, 
showing left axis deviation (see negative aVF) and small R waves in the left 
precordial leads (see small positive deflection inV5 and V6).
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number, and type of characteristic ECG findings was found between the PTPN11 mutation- 
positive and mutation-negative group (Table I). 
Characteristic ECG Findings – Cardiac Abnormality
The presence, number and type of characteristic ECG findings were not associated with the 
presence of a cardiac abnormality (Table II). Moreover, these findings were not associated 
with the presence of pulmonary valve stenosis, HCM, and ASD (data not shown).
Table I   Characteristic ECG abnormalities in PTPN11 mutation-positive and  
PTPN11 mutation-negative patients with Noonan syndrome.
Study group PTPN11 positive  
n=56
PTPN11 negative 
n=28
P-value*
Patients with characteristic ECG findings 30 (54%) 12 (43%) 0.49
Number of characteristic ECG findings
     1 ECG characteristic 16 (29%) 8 (29%) 1.00
     2 ECG characteristics 12 (21%) 3 (11%) 0.36
     3 ECG characteristics 2 (4%) 1 (4%) 1.00
     4 ECG characteristics 0    0    -
Type of ECG finding
     Wide QRS complex 0    0    -
     Left axis deviation 27 (48%) 11 (39%) 0.49
     Abnormal Q wave 3 (5%) 2 (7%) 1.00
     Small R waves in the left precordial leads 16 (29%) 4 (14%) 0.18
ECG: Electrocardiogram; *: Fisher’s exact test
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Discussion
The association between type of cardiac abnormality and PTPN11 gene mutation identified 
in our study corresponds with that documented by other studies (3, 9, 13). We investigated 
the four characteristic ECG findings commonly described in patients with Noonan 
syndrome: left axis deviation, small R waves in the left precordial leads, abnormal Q wave 
and wide QRS complex (10, 11). In healthy children without evidence of a cardiac 
abnormality the incidence of left axis deviation is about 1% (14). 
 In the present study, left axis deviation is present in 50% of patients with Noonan 
syndrome with a cardiac abnormality, and in 32% of patients without a cardiac abnormality. 
Only one patient had an atrioventricular canal defect, which could explain the left axis. 
Although left axis deviation was shown to be a common ECG finding in Noonan syndrome 
patients with cardiac abnormality, it was not found in patients with Noonan syndrome 
without a cardiac abnormality in a recent study (11). The pathophysiology of left axis 
deviation in Noonan syndrome patients is not fully understood. It appears to involve not 
only counterclockwise rotation of the heart, but also a disturbance in the conduction 
system, or possibly, an image of inferior pseudonecrosis due to absence of initial inferior 
forces (15). In our study, counterclockwise rotation was observed with certainty in 24 (29%) 
patients. Left axis deviation is very unusual in pulmonary valve stenosis with or without 
ASD and in HCM (12, 15). 
Table II   Characteristic ECG findings and presence of a cardiac abnormality in  
84 patients with Noonan syndrome.
Study group Cardiac
abnormality 
n = 62
No cardiac
abnormality 
n = 22
P-value*
Patients with characteristic ECG findings 34 (55%) 8 (36%) 0.21
Number of characteristic ECG findings
     1 ECG characteristic 18 (29%) 6 (27%) 1.00
     2 ECG characteristics 13 (21%) 2 (9%) 0.33
     3 ECG characteristics 3 (5%) 0    0.56
     4 ECG characteristics 0    0    -
Type of characteristic ECG finding
     Wide QRS complex 0    0   -
     Left axis deviation 31 (50%) 7 (32%) 0.21
     Abnormal Q wave 5 (8%) 0    0.32
     Small R waves in the left precordial leads 17 (27%) 3 (14%) 0.25
ECG: Electrocardiogram; *: Fisher’s Exact Test
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Small R waves in the left precordial leads were present in 24% of the cases compared to 
48% in the series of Sanchez-Cascos (1983) (10). An abnormal Q wave was found in five 
patients with Noonan syndrome, all with a cardiac abnormality. By definition, both small R 
waves in the left precordial leads and abnormal Q waves are rarely found in children 
without a cardiac abnormality. Moreover, these are not characteristic ECG findings in 
patients with pulmonary valve stenosis and ASD, but may be found in patients with HCM 
(12, 16). However, there was no association of these features with HCM in the present 
study. No wide QRS complex was found in our Noonan syndrome patients, in contrast 
with Sanchez-Cascos (1983) (10). Of the 21 Noonan syndrome patients with a cardiac 
abnormality he described, 6 had a wide QRS complex.
 In the present study, the characteristic ECG findings of Noonan syndrome patients 
were neither associated with a PTPN11 gene mutation, nor with a (specific) cardiac 
anomaly. This latter finding has already been noted by Bertola et al. (2000) (11). 
 One of the limitations of this study is that not all patients were evaluated at the same 
age and ECG registration may change over time. However, we included only five parents 
who had their first cardiac evaluation as an adult. Another limitation is the fact that 
sequencing for additional genes encoding proteins participating in RAS-MAPK signal 
transduction such as KRAS, SOS1, and RAF1 was not performed on PTPN11 mutation-nega-
tive cases. 
Conclusion
In patients with Noonan syndrome, the ECG pattern is neither a useful tool for the 
phenotype characterization of a PTPN11 gene mutation, nor for the presence or type of 
cardiac  abnormality. However, because of the presence of characteristic ECG findings in 
50% of patients, it remains a useful part of the clinical evaluation in patients who had not 
have genotyping.
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Abstract
Children with Noonan syndrome show rapid decline of growth in the first year of life and 
feeding problems are present in over 50%. The aim of this study was to explore whether 
growth decelerates because of feeding problems or other Noonan syndrome-related 
factors.
 We performed a retrospective, longitudinal cohort study of clinically and genetically 
diagnosed subjects with Noonan syndrome (n=143). Questionnaires about the phenotyp-
ic-genotypic profile and reported feeding problems were sent to eligible subjects. Data 
on first-year growth was obtained from growth charts. Ninety-one participants were 
excluded because of different criteria. 
 A total of 52 subjects with Noonan syndrome were included. The largest decline in 
weight and length standard deviation score (SDS) occurred in the first 2.5 months after 
birth (-1.93 and -1.15, respectively), with feeding problems causing a decline of 0.57 SDS in 
the remaining months. At one year, children with feeding problems were on average 290 
grams lighter and 0.8 centimeters shorter than children without feeding problems. Weight 
gain was also negatively influenced by having a PTPN11 mutation and a higher gestational 
age, whereas children of parents with Noonan syndrome and with a higher birth weight 
gained more weight. Growth in length was reduced by having cardiac surgery and a 
higher gestational age, but positively influenced by birth length and maternal height. 
 Growth in children with Noonan syndrome is impaired right after birth and only 
partially associated with feeding problems. In addition, several specific Noonan syn-
drome-related factors seem to influence growth in the first year. 
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Introduction
Noonan syndrome is a well-known autosomal dominant disorder with an estimated 
incidence of 1:1.000–2.500 live births (1). The cardinal features of Noonan syndrome are 
characteristic facies, congenital heart defects, and short stature (2-4). Noonan syndrome is 
caused by germline mutations in genes encoding proteins of the Ras-mitogen-activated 
protein kinase (RAS/MAPK) pathway (5). Several excellent reviews of Noonan syndrome 
have been published that have addressed clinical and molecular findings (2-4, 6-10).
 Growth has been investigated thoroughly in Noonan syndrome (1, 4, 11-18). Birth 
weight and birth length are usually normal or slightly subnormal. In the first year of life a 
rapid decline in length gain is seen after birth. The reason for this rapid decline in length 
gain is not known. The mechanism of stunted growth in Noonan syndrome has variously 
been reported to be intrinsic or a consequence of dysregulation of the RAS/MAPK 
signaling itself, insufficient growth hormone secretion, and growth hormone resistance 
(19-21). Nutritional input during the first year of life has been postulated as the principal 
regulator of growth, with a minimal contribution of growth hormone starting during the 
second half of the first year (22-24). Studies on feeding problems and growth in Noonan 
syndrome are scarce, although feeding problems in infancy were seen in more than 50% 
of children with Noonan syndrome (4, 25, 26). 
 Three studies have hypothesized an association between stunted growth in the first 
year of life and feeding problems in Noonan syndrome (16, 18, 25), but this has never been 
investigated. Therefore, it remains unclear what the association is between feeding 
problems and growth in the first year of life. Is growth decelerating because of feeding 
problems, or do other Noonan syndrome-related variables cause the decelerating 
growth? The aim of this study is to find an answer to this research question that may 
support healthcare providers with respect to nutrition guidelines for children with 
Noonan syndrome in daily practice. 
Methods
Study population
Subjects with Noonan syndrome were selected from a database, composed by a clinical 
geneticist since 1994, with all known individuals with Noonan syndrome clinically 
diagnosed at one tertiary center using the features delineated by van der Burgt et al. (1994) 
(27). Because Noonan syndrome is genetically heterogeneous and shows considerable 
clinical overlap with other RASopathies (5), we included only phenotypic subjects with 
Noonan syndrome with a positive mutation analysis. Subjects were excluded if they were 
18 years or over when the fourth Dutch growth study was performed (28), if incomplete 
or missing patient and/or address data were present, and if no informed consent was 
517840-L-bw-croonen
Processed on: 6-3-2018 PDF page: 96
96
Chapter 6
given. Secondary exclusion criteria were preterm birth (29, 30), small for gestational age (< 
-2 standard deviation score [SDS]) (31), and fewer than four data points for both length and 
weight in the first year of life. 
Methods of measurement
All (parents of) eligible subjects with Noonan syndrome were invited to participate in the 
study by means of a letter that explained the study aim. A questionnaire and a growth 
form were added to each invitational letter. Informed consent was obtained from all 
(parents of) participants with Noonan syndrome.  This article did not contain any studies 
with human participants performed by any of the authors. The Regional Committee on 
Medical Research Ethics approved the study.
Questionnaire
Phenotypic–genotypic profile
The questionnaire was used to collect general information about the phenotypic–
genotypic profile: gender, type of mutation, gestational age, birth weight and birth 
length, presence and type of congenital heart defect, cardiac operation in the first year of 
life, parent affected with Noonan syndrome, height of both parents, and developmental 
milestones. 
Feeding problems
Data on feeding problems in the first year of life were obtained through the questionnaire 
as well. Feeding problems were categorized by the parents according to the classification 
of Sharland et al. (1992) (4): 1) no feeding problems, 2) mild feeding problems (poor sucking, 
with each feeding on average taking over an hour to complete), 3) moderate feeding 
problems (very poor sucking and recurrent vomiting for more than 50% of the feedings), 
and 4) severe feeding problems (tube feeding required for two weeks or longer in a term 
infant). 
Growth measurements
Data on the first-year weight and length of the participants with Noonan syndrome were 
obtained retrospectively from growth charts in hospital files and/or from growth forms 
provided by the (parents of) participants. These growth data were compared to the data 
of the fourth Dutch growth study performed in 1997 (28).
Statistical analysis
Descriptive analyses were performed to check all continuous variables for normal 
distributions. To provide an overview of the characteristics of the study population divided 
by feeding problems, we dichotomized feeding problems into 1) no feeding problems 
and 2) feeding problems (2, 3, and 4 combined). These groups were compared by 
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calculating odds ratios with 95% confidence intervals (CI) and performing Student t-tests 
(Table I). For each growth measurement, we calculated the SDS according to the data of 
the fourth Dutch growth study (Software ‘Growth Analyser 3’, Dutch Growth Foundation, 
www.growthanalyser.org). Because data on birth weight and length are not included in 
the growth analyzer, we used a syntax developed  by Niklasson et al. (1991) (32) to convert 
these data into SDS values. Subsequently, we plotted the growth parameters of weight, 
weight SDS, length, and length SDS against age from birth through one year of age in 
order to show growth patterns. 
 To study the influence of feeding problems on growth, we performed linear mixed 
model analyses, with feeding problems as fixed effects and participants as random 
effects. Because of non-linear growth patterns, these analyses were done separately for 
the first 2.5 months after birth and the remainder of the first year. In the multivariable 
analyses, we initially included all potentially relevant variables from the questionnaire: 
gender, type of mutation (PTPN11 yes/no), presence of a congenital heart defect (yes/no), 
cardiac operation in the first year of life, parent with Noonan syndrome, height of both 
parents, birth weight, birth length, and gestational age. Variables were deleted from the 
model when exclusion did not change the effect estimate for feeding problems by more 
than 10%. The estimates with 95% CIs for the remaining variables are presented in Tables 
II and III. All statistical analyses were performed using IBM Statistics 22.0 for Windows (IBM 
SPSS Inc., Chicago, IL, USA). 
Results
General characteristics
In total, 143 individuals clinically and genetically diagnosed with Noonan syndrome were 
selected from the database. Twenty-four individuals were excluded because of incomplete 
or missing patient and/or address data, and five because they were deceased. In addition, 
10 subjects were excluded because they were born 18 years or more before the fourth 
Dutch growth study was performed. The remaining 104 (parents of) children and young 
adults with Noonan syndrome were invited to participate in the study. Of these, 19 did not 
respond and 14 were not interested in participating in the study and/or gave no permission 
to publish the data. 
 Of the 71 (parents of) children or young adults who responded positively to our 
invitation to participate in this study, 19 were excluded because of secondary exclusion 
criteria: one because of dysmaturity, 15 because of preterm birth, and three because fewer 
than four measurements of weight and length were available. Table I lists the characteris-
tics of the 52 study participants with Noonan syndrome.
517840-L-bw-croonen
Processed on: 6-3-2018 PDF page: 98
98
Chapter 6
Table I   Characteristics of the 52 study participants with Noonan syndrome divided by 
feeding problems in the first year of life.
Characteristics Children with 
feeding problems
(n=29)
Children without 
feeding problems 
(n=23)
Comparison of 
children with and 
without feeding 
problems
Number (%) Number (%) Odds ratio (95% CI)
Gender 
     Female
     Male 
18 (62.1 %)
11 (47.8 %)
11 (47.8 %)
12 (52.2 %)
1.8 (0.6 – 5.4)
Type of mutation
     PTPN11 
     SOS1
     RAF1 
     KRAS
23 (79.3 %)
3
2
1
16 (69.6 %)
5
2
0
1.7 (0.5 – 5.9)a
Congenital heart defectb
     Pulmonary valve stenosis
     Hypertrophic cardiomyopathy
     Septal defect
     Other 
24 (82.8 %)
17 (58.6 %)
4
7
2
15 (65.2 %)
12 (52.2 %)
2
3
2
2.6 (0.7 – 9.3)c
Cardiac surgery in 1st year 4 (13.8 %) 1 (4.3 %) 3.5 (0.4 – 33.9)
Parent with Noonan syndrome
     Father
     Mother
3 (10.3 %)
2
1
10 (43.5 %)
4
6
0.2 (0.04 – 0.6)
mean   (range) mean   (range) p-value
Parental height (n=50)
     Father (centimeters)
     Mother (centimeters)
182 (159 – 196)
171 (157 – 180)
180 (159 – 190)
167 (154 – 180)
0.38
0.05
Birth weight 
     Absolute value (grams)
     Standard deviation score
3598 (2310 – 4560) 
 0.42 (-2.21 – 1.98)
3405 (2770 – 4120)
-0.01 (-1.42 – 2.45)
0.18
0.16
Birth length (n=49)
     Absolute value (centimeters)
     Standard deviation score
 50.1 (45 – 54)
 -0.02 (-1.66 – 1.99)
 48.9 (45 – 52)
 -0.60 (-2.01 – 1.47)
0.07
0.05
Gestational age (weeks)  39.7 (37.0 – 42.4)  39.6 (37.6 – 42.9) 0.81
Age at time of study (years)  14.5 (1.6 – 33.1)  15.5 (2.1 – 32.8) 0.71
a  Odds ratio for having a PTPN11 mutation versus having another mutation 
b  As some children had more than one type of congenital heart defect, the total number of specific congenital heart 
defects exceeds the number of children with congenital heart defects
c  Odds ratio for having a congenital heart defect versus not having a congenital heart defect
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Growth patterns
In Figure 1A, the scatterplot of weight for age is presented for the 52 Noonan syndrome 
participants (382 data points, median 7 [4–15] measurements per child). Mean birth weight 
and estimated mean weight at the age of one year were 3513 (95% CI: 3370–3656) grams 
and 8410 (95% CI: 8217–8604) grams, respectively. Figure 1B shows a biphasic course of the 
weight SDS for age curve, with a steep decline until the age of 2.5 months and a more 
gradual decline thereafter. Mean birth weight SDS was 0.23 (95% CI: -0.07 – 0.53), while the 
estimated mean weight SDSs at 2.5 months and one year were -1.54 (95% CI: -1.81 – -1.27) 
and -1.93 (95% CI: -2.21 – -1.66), respectively.  
 In Figure 2A, the scatterplot of length for age is presented for the 52 Noonan 
syndrome participants (332 data points, median 6 [4–15] measurements per child). The 
mean birth length and estimated mean length at the age of one year were 49.6 (95% CI: 
48.9–50.2) engthtres and 73.3 (95% CI: 72.6–74.1) engthtres, respectively. Figure 2B again 
shows a biphasic course of the length SDS for age curve with a similar pattern. The mean 
birth length SDS was -0.27 (95% CI: -0.56–0.03), while the estimated mean length SDSs at 
the ages of 2.5 months and one year were -1.30 (95% CI: -1.58 – -1.02) and -1.66 (95% CI: -1.94 
– -1.37), respectively. 
Feeding problems
Feeding problems were reported for 29 (55.8%) of the Noonan syndrome children. Of 
these, three (10.3%) had mild feeding problems, nine (31.0%) moderate feeding problems, 
and 17 (58.6%) severe feeding problems. Children with feeding problems seemed to gain 
301 grams less weight in the first year of life compared to children without feeding 
problems (Table II). This estimate changed to -290 (95% CI: -554 – -26) grams after 
adjustment for confounding, which also elucidated that children with feeding problems 
were 0.25 (95% CI: -0.04 – 0.45) weight SDS lighter at the age of 2.5 months than those 
without feeding problems. From age 2.5 months to one year, feeding problems reduced 
the weight SDS further with -0.57 (95% CI: -1.00 – -0.14) compared to children without 
feeding problems. Even though the latter children were on average 1.2 cm shorter at 
birth, they were estimated to gain 0.8 (95% CI: 0.1–1.5) centimeters more during the first 
year than those with feeding problems (Table III). In the first 2.5 months of life, the presence 
or absence of feeding problems did not influence length SDS. However, children with 
feeding problems lost 0.57 (95% CI: 0.21–0.93) length SDS compared to those without 
feeding problems between 2.5 months and one year of age. 
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Figure 1   Scatterplots of weight versus age; A. weight in grams; B. weight in SDS.
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Figure 2  Scatterplots of length versus age; A. length in centimeters; B. length in SDS.
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Other relevant variables
Tables II and III also show the estimates for the independent effects of other factors on 
weight and length in the first year of life, respectively. Boys seemed to gain more weight 
and length over the first year than girls, but oddly enough showed a decline in both 
weight SDS and length SDS of around 0.5 in the first 2.5 months after birth. Children with 
a PTPN11 mutation were on average 246 (95% CI: -68–559) grams lighter at the age of one 
year, with most of the decline in SDS occurring in the period from 2.5 months to one year 
(weight SDS: -0.50; 95% CI: -1.01–0.00). The type of mutation did not have an effect on 
growth in length. Having cardiac surgery in the first year of life seemed to have a slight 
effect on weight gain (-264; 95% CI: -709–181) and led to -2.2 (95% CI: -3.5 – -0.9) centimeters 
reduced growth in length, mainly occurring between 2.5 months and one year (length 
SDS: -0.88; 95% CI: -1.52 – -0.23). Children with a parent with Noonan syndrome were an 
estimated 331 (95% CI: 50–613) grams heavier at one year of age than those without a 
parent with Noonan syndrome, mostly due to an increase in weight SDS of 0.57 (95% CI: 
0.10–1.04) between 2.5 months and one year. Birth weight and length also seemed to 
have independent effects on weight gain and growth, respectively, with every 100 extra 
grams of birth weight leading to 70 (95% CI: 32–108) extra grams of weight at one year and 
each centimeter at birth to 0.8 (95% CI: 0.6–0.9) extra centimeters a year later. Maternal 
height also influenced growth positively (SDS: 0.05 [95% CI: 0.03–0.08] per centimeter). 
Table II   Effects of feeding problems and other relevant factors on weight gain and 
weight SDS among 52 children with Noonan syndrome.
Effect on weight gain 
0 – 12 months 
in grams (95% CI)
Effect on weight SDS
0 – 2.5 months
(95% CI)
Effect on weight SDS 
2.5 – 12 months
(95% CI)
Feeding problems 
(unadjusted/adjusteda)
 -301 (-648 – 46)
 -290 (-554 – -26)
 0.25 (-0.37 – 0.87)
 -0.25 (-0.45 – 0.04)
 -0.55 (-1.06 – -0.04)
 -0.57 (-1.00 – -0.14)
Independent effects of other factors in the model for feeding problems adjusted for confoundingb
Gender – male  202 (-38 – 442)  -0.43 (-0.64 – -0.22) -
PTPN11 mutation  -246 (-559 – 68)  -0.16 (-0.44 – 0.11)  -0.50 (-1.01 – 0.00)
Cardiac surgery in 1st year  -264 (-709 – 181) - -
Parent + Noonan syndrome  331 (50 – 613) -  0.57 (0.10 – 1.04)
Birth weight (per 100 grams)  70 (32 – 108)  0.20 (0.16 – 0.23)  0.08 (0.02 – 0.14)
Birth length (per centimeter)  15 (-68 – 98)  0.07 (-0.00 – 0.14)  -0.03 (-0.16 – 0.11)
Gestational age (per week)  -76 (-172 – 19)  -0.25 (-0.33 – -0.17) -
Time (per month)  402 (389 – 414)  -0.77 (-0.87 – -0.67)  -0.04 (-0.06 – -0.03)
a Adjusted for confounding by all variables that contributed to the final model and are listed in the table. 
b Each factor was adjusted for all other factors in the final model.
- Factor did not contribute to the final model.
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Gestational age negatively influenced weight gain as well as weight and length SDS in the 
first 2.5 months only. The estimates for the independent influence of time clearly showed 
that the overall decline in weight SDS (-0.77; 95% CI: -0.87 – -0.67 per month) and height 
SDS (-0.46; 95% CI: -0.58 – -0.33 per months) predominantly occurred in the first few 
months after birth, as shown in Figures 1B and 2B.    
Discussion
This is the first study to investigate the effects of feeding problems on first-year growth in 
children with Noonan syndrome. In general, a major decline of the SDS curves in the first 
year of life was seen for both weight and length, with the largest decline in the first 2.5 
months. More than half of the included Noonan syndrome participants had feeding 
problems. Children with Noonan syndrome and feeding problems were clearly lighter 
and shorter and had a clinically relevant (delta SDS of 0.5 per year) lower weight and 
length SDS at the age of one year than children without feeding problems. Besides 
feeding problems, other Noonan syndrome-related variables had an independent, 
Table III   Effects of feeding problems and other relevant factors on growth in length 
and length SDS among 52 children with Noonan syndrome.
Effect on length growth 
0 – 12 months 
in cm (95% CI)
Effect on length SDS
0 – 2.5 months 
(95% CI)
Effect on ength SDS 
2.5 – 12 months 
(95% CI)
Feeding problems 
(unadjusted/adjusteda)
 -0.3 (-1.6 – 1.0)
 -0.8 (-1.5 – -0.1)
 0.42 (-0.15 – 0.98)
 -0.05 (-0.34 – 0.24)
 -0.31 (-0.83 – 0.22)
 -0.57 (-0.93 – -0.21)
Independent effects of other factors in the model for feeding problems adjusted for confoundingb
Gender – male  0.6 (-0.1 – 1.2)  -0.45 (-0.74 – -0.15) -
PTPN11 mutation -  0.10 (-0.27 – 0.48) -
Cardiac surgery in 1st year  -2.2 (-3.5 – -0.9) -  -0.88 (-1.52 – -0.23)
Birth weight (per 100 grams) -  0.05 (0.00 – 0.10) -
Birth length (per centimeter)  0.8 (0.6 – 0.9)  0.38 (0.28 – 0.49)  0.26 (0.18 – 0.34)
Maternal height (per 
centimeter)
 0.09 (0.04 – 0.14) -  0.05 (0.03 – 0.08)
Gestational age (per week) -  -0.28 (-0.39 – -0.17) -
Time (per month)  1.9 (1.8 – 1.9)  -0.46 (-0.58 – -0.33)  -0.03 (-0.06 – -0.01)
a Adjusted for confounding by all variables that contributed to the final model and are listed in the table. 
b Each factor was adjusted for all other factors in the final model.
- Factor did not contribute to the final model.
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clinically relevant effect on weight and growth in the first year of life. Weight gain was also 
negatively influenced by having a PTPN11 mutation and a higher gestational age, whereas 
children of parents with Noonan syndrome and with a higher birth weight gained more 
weight. Growth in length was reduced by having cardiac surgery and a higher gestational 
age, but positively influenced by birth length and maternal height. 
 In comparison with the known literature, we found similar results regarding the basic 
characteristics of our Noonan syndrome population: male–female ratio, type of mutation, 
and presence and type of congenital heart defect (5, 7, 8). Mean birth weight was slightly 
higher than found in other studies (4, 12, 15, 18), whereas birth length was analogous 
to the range found in the literature (12, 15, 17, 18). Near normal SDS values for birth weight 
and birth length were found compared to the Dutch reference (www.perinatreg.nl 
(28, 32)). The estimated mean length at the age of one year was 73.3 centimeters, which 
is comparable to the mean of 71.8 centimeters found by Ranke et al. (1988) (12). No exact 
values were mentioned in other studies. We observed a decline of approximately 1.5 SDS 
for growth in length and almost 2 SDS for weight gain in the first year, with a major decline 
in the first 2.5 months followed by a minor decline in the remainder of the year. Otten and 
Noordam (2009) converted the Ranke data in length SDS versus age using the Dutch 
references. They also found an early decline in length SDS in the first year of life (16). 
Only Witt et al. (1986) described the length development in the first year in more detail. 
They showed that children with Noonan syndrome dropped off the normal curve by 
three months of age followed by a mean length that remained consistently below the 
fifth percentile from three months through adulthood (13). Birth weight, birth length, 
maternal height, and gestational age seemed to have independent effects on weight gain 
and/or growth in the first year of life. These effects have never been investigated in 
Noonan syndrome before. 
 We found feeding problems in 56% of the included infants with Noonan syndrome, 
analogous to the known literature (4, 25, 26). Compared to Sharland et al. (1992), we found 
more severe feeding problems and fewer children with mild and moderate feeding 
problems (4). This could be explained because Sharland et al. (1992) reported their results 
solely on clinically, and not also genetically, diagnosed children with Noonan syndrome. 
Digilio et al. (2011) also reported on feeding problems by type of mutation (25). Feeding 
problems were reported in 65% of Noonan syndrome children with a PTPN11 mutation, in 
75% with a RAF1 mutation, and in none with a SOS1 mutation. We found feeding problems 
in 59% of children with a PTPN11 mutation, in 50% with a RAF1 mutation, and in 38% with 
a SOS1 mutation, but the latter two are based on small numbers. The effect of feeding 
problems on first-year growth has never been investigated before. Only three studies 
have hypothesized an association between stunted growth and feeding problems in 
Noonan syndrome (16, 18, 25). We found that children with Noonan syndrome and feeding 
problems were on average 290 grams lighter and 0.8 centimeters shorter than children 
without feeding problems at the age of one year. In addition, feeding problems had 
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clinically relevant effects on weight and length SDS at the end of the first year of life (both 
SDS -0.57 from age 2.5 months to one year). 
 Having cardiac surgery in the first year of life may have an independent influence on 
weight and certainly influenced length development (-2.2 centimeters [SDS -0.88]). In 
general, the etiology of growth retardation in children with a congenital heart defect is 
multi-factorial. Known contributing factors associated with growth restriction include 
fluid restriction, hemodynamic impairment, inadequate caloric intake, and hyper 
metabolism (33). A theory could be that in children with Noonan syndrome with a 
congenital heart defect that needs surgery in the first year, weight and especially length 
development are compromised more severely because of the above-mentioned factors. 
As only five children in our study population had cardiac surgery, careful interpretation of 
our results is warranted.    
 We found that children with a mutation other than PTPN11 were on average 264 
grams heavier than children with the PTPN11 mutation at the age of one year. The type of 
mutation had no influence on height development. Malaquias et al. (2012) did not find an 
additional effect of the PTPN11 mutation on height either (15). However, other studies have 
reported that people with Noonan syndrome with a PTPN11 mutation were more often 
and more severely growth retarded than most people with other mutations (8, 17, 18). To 
our knowledge, no one has studied the effects of different mutations on weight only. 
They also found that the body mass index was near normal in people with Noonan 
syndrome with PTPN11 and SOS1 mutations. People with RAF1 and BRAF mutations had the 
highest body mass index, and people with KRAS and SHOC2 mutations had the lowest 
body mass index (15, 17). However, these studies were not restricted to the first year of life, 
in contrast to our study.
 Children with a parent with Noonan syndrome were 331 grams heavier at the age of 
one year. No known literature exists describing the association between having a parent 
with Noonan syndrome and weight gain, so we have no good explanation for this finding. 
Perhaps parents with Noonan syndrome recognize some issues better and earlier because 
of their own experience and choose a parenting approach that is apparently effective. 
 Although a relatively small patient cohort was included in this study, the participants 
can be considered representative of the Noonan syndrome patient population in the 
largest treatment center in the Netherlands. In addition, we used multiple data points per 
participant in our mixed model analyses, which strengthened our results. However, the 
study also had some limitations. Because of the retrospective design, growth 
measurements were obtained from growth charts in hospital files and/or from the growth 
forms provided by parents, which may be subject to measurement errors made  previously. 
It may also have been difficult for the parents to recall the symptoms their children 
experienced earlier in life. Therefore, some misclassification may have occurred regarding 
the absence or presence or the severity of feeding problems. Although SDS values were 
corrected for gender, we found an influence of gender on weight and length in the first 
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2.5 months. This effect was not caused by the used syntax, because SDS values were even 
more deviant when the first two weeks of life were excluded. 
 Because overall birth weight and length can be considered normal, intra-uterine 
growth retardation did not seem to be a factor in the growth retardation in our children 
with Noonan syndrome. In the first year of life, a fast decline in weight SDS and length SDS 
was seen. Variables other than intrinsic growth, which were considered clinically relevant 
for the stunted growth of length and weight, were the presence of feeding problems, 
having a PTPN11 mutation, having cardiac surgery in the first year of life, and having a 
parent with Noonan syndrome; a possible clinically relevant effect was found for birth 
weight, birth length, maternal height, and gestational age. It seems reasonable to conclude 
that feeding problems do not have a major effect on growth in the first year of life.
 In conclusion, growth in children with Noonan syndrome is impaired right after birth 
and only partially associated with feeding problems. In addition, several specific Noonan 
syndrome-related factors seem to influence growth in the first year. With regard to these 
findings, we recommend adequate nutritional intake, as in every other child. 
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Abstract
Studies from a patient perspective on motor performance problems in Noonan syndrome 
in daily life are lacking. The aims of this study were to provide insight into the motor 
performance problems that people with Noonan syndrome and/or their relatives 
experienced, the major consequences they suffered, the benefits of interventions they 
experienced and the experiences with healthcare professionals they mentioned. 
 We interviewed ten adults with Noonan syndrome (two were joined by their parent), 
and 23 mothers (five of whom had Noonan syndrome), nine fathers (one of whom had 
Noonan syndrome) and one cousin who reported on 28 children with Noonan syndrome. 
 People with Noonan syndrome reported particular problems related to pain, 
decreased muscle strength, fatigue and clumsiness, which had an evident impact on 
functioning in daily life. Most participants believed that problems with motor performance 
improved with exercise, appropriate physiotherapy guidance and other supportive 
interventions. Nevertheless, people with Noonan syndrome and/or their relatives did not 
feel heard and supported and experienced no understanding of their problems by 
healthcare professionals. 
 This was the first study from a patient perspective that described the motor 
performance problems in people with Noonan syndrome, the major consequences in 
daily life, the positive experiences of interventions and the miscommunication with 
healthcare professionals. To achieve optimal support, healthcare professionals, as well as 
people with Noonan syndrome and/or their relatives themselves, should be aware of 
these frequently presented problems with motor performance. Research on these 
different aspects is needed to better understand and support people with Noonan 
syndrome. 
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Introduction
Noonan syndrome is an autosomal dominant condition with an incidence of 1:1000–2500 
live births. It is characterized by a typical face, short stature, congenital heart defects, 
skeletal abnormalities, cryptorchidism and variable development delay (1-3). Noonan 
syndrome is genetically heterogeneous and shows considerable clinical overlap with 
other RASopathies caused by germline mutations in genes encoding proteins of the 
Ras-mitogen-activated protein kinase (RAS/MAPK) pathway (4). Excellent literature reviews 
of Noonan syndrome have been published with comments on both clinical and molecular 
findings (3, 5-7). 
 In daily life, many people with Noonan syndrome report motor impairments, decreased 
muscle strength and pain in muscles and joints. However, only a few studies on people 
with Noonan syndrome with a special focus on motor impairments have been published. 
Motor developmental delay has been reported by parents in 26–46 % of infants with 
Noonan syndrome (1, 2, 8). Three studies reported on pain in Noonan syndrome (9-11). 
Reinker et al. (2011) performed a structured orthopedic history prospectively and found 
that people with Noonan syndrome had a high incidence of chronic pain, particularly in 
adulthood (n=26, mean age 14.7 years (range 1–50 years)). Smpokou et al. (2012) used a 
questionnaire and reported onset of chronic muscle pain in childhood, onset of chronic 
back pain in adolescence or adulthood and a variable onset of chronic joint pain (n=35, 
mean age 28 years (range 16–68 years)). Vegunta et al. (2015) also used a questionnaire and 
reported that pain was found as a prevalent symptom in adults and children with Noonan 
syndrome, with the pain being significantly more prevalent in the extremities and joints 
(n=45, mean age 17 years (range 2–48 years)). Results of handgrip strength tests were 
found to be significantly decreased in people with Noonan syndrome (n=15, mean age 21 
years (range 6–47 years)) (12). Many parents classified their children as clumsy (13-15). 
Apart from these problems, many musculoskeletal anomalies have been described in 
Noonan syndrome, such as anterior chest wall anomalies, scoliosis, hypermobility, talipes 
equinovarus, joint contractures and pes planus or cavus (2, 9, 16). 
 Despite the frequently reported problems with motor performance in people with 
Noonan syndrome, as mentioned in literature (2, 9-16), as well as in our outpatient visits 
and Noonan syndrome contact days, the majority of people with Noonan syndrome and/
or their relatives do not feel heard and supported by healthcare professionals. To provide 
more insight into the perceived problems in daily life we evaluated the motor performance 
problems that people with Noonan syndrome and/or their relatives experienced, the 
major consequences they suffered, the benefits of interventions they experienced, and 
the experiences with healthcare professionals they mentioned. These findings will support 
people with Noonan syndrome and healthcare professionals in clinical practice and 
endorse future research on the motor performance and functioning of people with 
Noonan syndrome in daily life. 
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Materials and methods
Design
We performed a qualitative focus group interview study with people with Noonan 
syndrome and/or their relatives, which is an appropriate method when very little is known 
about a phenomenon (17). We expected that the group dynamic and the explicit invitation 
to react to each other would lead to more information (18).
Participants 
The study was conducted in collaboration with the Dutch Noonan syndrome patient 
association. Participants were recruited through an announcement for one of three 
planned focus group interviews on the flyer of the Noonan syndrome contact day in 2013, 
where the focus group interviews were conducted. People with Noonan syndrome and/
or their relatives were free to decide whether to join one of these focus group interviews. 
There were no restrictions on the number of participants. Each participant could attend 
only one of the three focus group interviews. No relationship was established with the 
participants prior to the commencement of the study. Participants might have known 
each other because of peer contact and/or the annual Noonan syndrome contact day. 
Ethical approval and informed consent
The Regional Committee on Medical Research Ethics approved the study, in conformance 
with the Declaration of Helsinki. Participants were informed both by letter and verbally 
about the aim of the study and the focus group interviews. Oral consent was obtained 
from all participants before the audio recording started. 
Data collection
Three moderators chaired the focus group interviews. Two researchers (a pediatrician in 
training (EC) and a physiotherapist (ME)) asked the questions. One researcher (MH), with 
special expertise in qualitative research methods, focused on the quality of the focus 
group interview process. Each focus group interview lasted approximately one hour. 
 The participants were asked about their experiences with motor performance 
problems in daily life: what motor performance problems were experienced, what the 
major consequences were, what the perceived benefits of interventions were and what 
the experiences with healthcare professionals were. To ensure that at least the list of 
predefined topics was covered, an interview guide was used. The aim was to collect a 
wide spectrum of information, until saturation was achieved. We asked participants to 
provide written background information about the presence or absence of a mutation, 
congenital heart defect, hearing impairment and/or visual impairment and type of 
education or profession. 
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Data analysis
The focus group interviews were audiotaped and transcribed verbatim using the 
computer program Atlas.ti 6 (19). Data were analyzed using conventional content analysis, 
which is generally used with a study design that aims to describe a phenomenon (20). 
 After reading each transcript multiple times, descriptive coding was used. The codes 
could be a word or short phrase that expressed the experiences of the participants 
concerning motor performance (21). The codes were based on the checklist of the focus 
group interviews (based on literature and clinical experiences), and extended with new 
input from the focus group interviews. In the next phase, MH checked extracts and codes, 
and suggestions for improvement were made by EC. After consensus was reached, the 
first researcher applied the suggestions. Then, an audit document was composed by MH, 
which consisted of a table linking each quote to each interview topic derived from the 
predetermined code list. Through this document, each code was analyzed on the basis of 
the associated quotes. After this analysis, MH made a second audit document that 
revealed the different codes per quote, in order to visualize the relation between different 
codes. 
 The identified problems with motor performance were grouped into two age groups: 
‘Motor performance problems in children with Noonan syndrome reported by relatives 
and retrospectively by adults’ and ‘Self-reported motor problems by adults with Noonan 
syndrome.’  
 The analyzed data were presented on the Noonan syndrome contact day in 2014. 
All attendees agreed with the results without any additional remark. 
Results
A total of 47 people with Noonan syndrome and/or their relatives were present in one of 
the three focus group interviews. Eight of them did not participate actively in the 
interviews and had not submitted their personal information and information about the 
phenotype of their child and/or themselves. The remaining 39 participants consisted of 
ten adults with Noonan syndrome (aged 25–50 years; two were joined by their parent), 
who reported on the problems experienced in childhood and on the actual health-related 
problems, and 23 mothers (five of whom had Noonan syndrome), nine fathers (one of 
whom had Noonan syndrome) and one cousin who reported together on the problems 
experienced in 28 children with Noonan syndrome (aged 1–17 years). Three sets of parents 
joined our focus groups. Information about their child was only reported once. Table I 
shows the characteristics of the participants, both adults with Noonan syndrome (n=10) 
and healthy relatives (n=29), and the characteristics of the children reported on (n=28).
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Four major problems were mentioned: pain, decreased muscle strength, fatigue and 
clumsiness. They all manifested themselves in childhood as well as in adulthood. In 
general, most people with Noonan syndrome and/or their relatives believed that pain, 
decreased muscle strength, fatigue and clumsiness all improved with exercise (in particular 
swimming) and appropriate physiotherapy guidance. We discuss at length the different 
problems below. Next to these problems of motor performance, to a lesser extent, 
complaints of hypermobility, increased skin sensitivity, and problems with planning and 
organizing activities were mentioned. Participants elucidated on the consequences of 
these symptoms in daily life, the benefits of interventions and the experiences with 
healthcare professionals. Table II gives an overview of the interview topics and themes. 
Table III gives an overview of the themes and corresponding quotes.
Pain 
The presence of pain was mentioned by most of the people with Noonan syndrome and/
or their relatives (four persons with Noonan syndrome did not experience pain). Most 
participants described this pain as muscle ache, particularly in children, where it manifested 
itself predominantly in the legs (quote(q)1). Adults also attributed the pain to joint pain, 
Table I   Characteristics of participants in the focus group interviews and  
the children reported on.
Characteristics Participants – 
Adults with  
Noonan syndrome
Participants – 
Healthy relatives
Children reported  
on – Children with  
Noonan syndrome
Number of participants/children 10 9 fathers
19 mothers
1 cousin
28
Age range (years) 25–50 Unknown 1–17
Mutation known 7/10 (70%) na 24/27 (89%)
Congenital heart defect 6/10 (60%) na 17/25 (68%)
Hearing impairment 1/10 (10%) na 3/25 (12%)
Visual impairment 4/9 (44%) na 11/22 (50%)
Intelligence Quotient (range) 75–110 Unknown 60–118
Current education or profession
     Too young for education
     Regular education
     Regular education with help
     Special education
     Secondary education
     Profession
na
na
na
na
1/9 (11%)
8/9 (89%)
na
3/25 (12%)
6/25 (24%)
5/25 (20%)
8/25 (32%)
3/25 (12%)
0/25 (0%)
na: not applicable
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e.g. knees, ankles, wrists, hips and back. The pain presented often after brief exercise 
during daily activities (such as walking or cycling), as well as during endurance sports 
(mostly team sports), wherein the pain often built up to a point at which the activity/sport 
had to be interrupted (q2). Several children were not able to write because of the 
development of wrist pain, which was interpreted as writer’s cramp. The use of a computer 
at school in such cases was perceived as useful. Because of leg pain, one adult used braces 
to stabilize her knees (q32) and underwent chronic pain rehabilitation for three years (q35). 
Pain was also frequently mentioned at the end of a physically demanding day (such as 
sport, school and work). During the night, many children suffered from leg pain, which 
was interpreted more than once as growing pain (q3). Massaging the legs, or taking 
acetaminophen just before going to bed, helped to relieve the painful legs at night (q33). 
Also, exercise (in particular swimming (q30)) and appropriate physiotherapy guidance 
(q29) could relieve pain. Many relatives mentioned that the children had a high level of 
pain tolerance. It was obvious that complaints of pain could differ considerably within 
families. In some adults, the presence of pain was previously perceived as coincidence, 
but was recognized and acknowledged during the focus group interviews (q4). 
Muscle strength 
Nearly all participants reported decreased muscle strength in childhood, as well as in 
adulthood. One parent stated her child did not have decreased muscle strength. Both 
Table II   Interview topics and results of thematic analysis.
Interview topics Themes
Manifestations and consequences of  
motor performance problems
Cognition
Social consequences
Perceived effect of interventions
Experiences with healthcare professionals
Pain
Muscle strength
Fatigue
Clumsiness
Hyperlaxicity/hypermobility
Sensory symptoms
Behavior
Planning
Memory
School
Work
Sport
Exercise
Aid
Medical intervention
Knowledge/advice
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adults and children with Noonan syndrome experienced problems in daily activities such 
as cycling (q5), opening jars (q6) and swimming, and in doing physical activities at school 
(physical education) and/or work (q7). For example, an electric bike was used by some 
children because they had insufficient strength to move the pedals. One adult even used 
a stair lift. Most adults with Noonan syndrome and relatives of children with Noonan 
syndrome explicitly mentioned that strength improved with exercise, in particular 
swimming (q30). 
Fatigue
Fatigue was also a frequently mentioned complaint in childhood, as well as in adulthood. 
The presence and/or degree of fatigue could differ considerably within families. One 
mother with Noonan syndrome reported she and her daughter did not experience 
fatigue, but her son did (q9). Fatigue generally presented itself after short exercise or 
developed gradually during a normal day. Many children were carried in prams for longer 
than normal (q8), both children and adults used an electric bike (q31), and one adult even 
used a wheelchair when long distances had to be covered. The presence of a congenital 
heart defect seemed to influence the extent of the fatigue, because some relatives 
mentioned that children had increased exercise tolerance after cardiac surgery (q34). 
Many people with Noonan syndrome and/or their relatives benefited from frequent 
pauses during the day (q10). Exercise to build stamina was seen as positive (q30). 
Clumsiness
Clumsiness was the fourth frequently mentioned problem in childhood (q11) and 
adulthood (q16), reported by nearly all participants. It manifested itself in problems with 
fine motor skills (q17), e.g. crafts at school (use of scissors), writing (for which a computer 
was used at school and work) and tying shoelaces (a skill that one adult had not even 
mastered), but also in problems with gross motor skills, e.g. walking (q13), cycling (cycling 
longer with training wheels (q14) and even an electric bike was used by children and 
adults), running (many Noonan syndrome children and adults had a different way of 
running and a stiff gait (q15)), sitting posture (a custom chair and table) and sports (such as 
ball sports). Clumsiness was shown as aberrant movements and was interpreted as being 
the result of poor (trunk) balance (q12), poor coordination and prolonged reaction times. 
Generally, learning gross and fine motor skills took more time in comparison with children 
without Noonan syndrome, for example siblings, or could not be mastered at all. Many 
parents of Noonan syndrome children mentioned that their child had never crawled. 
Exercise, such as swimming (q30), and physiotherapy guidance (q29) were experienced as 
positive. Relatives of children with Noonan syndrome experienced that motor skills could 
be obtained once they had been learned in small steps, but repetition remained important. 
Without repetition, many relatives experienced that mastered skills were lost faster than 
among peers.
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Other complaints
To a lesser extent (in approximately 20%), complaints of hypermobility and increased skin 
sensitivity were recognized in childhood, as well as adulthood. In adulthood, tingling and 
numbness in limbs were also mentioned.
Cognition
Some participants mentioned problems with planning (q20 and q21) and memory (q22 
and 23) in childhood, as well as in adulthood, which manifested in school/work and sports 
activities. Many relatives described their child as inventive in solving the problems they 
encounter (q18) and called them a go-getter (q19). 
Social consequences
The problems mentioned above had enormous consequences on participation in daily 
life. Almost all people with Noonan syndrome and/or their relatives experienced difficulties 
in participation at school (q24 and q25), work (q26) and sport/leisure activities (q27 and 
q28). For example, some people with Noonan syndrome and/or their relatives reported 
moderate to no guidance on secondary and vocational education or on finding an 
appropriate job. These difficulties not only impacted the functioning of the people with 
Noonan syndrome themselves, but also the system in which the people with Noonan 
syndrome lived, such as the family. 
Variation in presented problems
It was obvious that the severity of symptoms was quite different among individuals with 
Noonan syndrome. Moreover, some people with Noonan syndrome experienced many of 
the above-mentioned problems, while some experienced no problems in daily life at all. 
In addition, whereas some adults with Noonan syndrome only experienced problems in 
childhood, others experienced other problems in adulthood, and still others experienced 
the same problems both in childhood and adulthood. Also, in two families with the same 
genotype, the participants mentioned a large difference in symptoms between mother, 
daughter and son, which seemed not to be related to age or gender.
Experiences with healthcare professionals
Many participants were concerned about the unknown prospect in terms of physical 
problems. Moreover, the majority of people with Noonan syndrome and/or their relatives 
did not feel heard and supported by their healthcare professionals. They complained that 
healthcare professionals (in particular physicians and physiotherapists) had ‘no idea’ what 
Noonan syndrome is (q36), were not aware of the problems people with Noonan 
syndrome experienced in daily life and did not present clear intervention plans (q37). 
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r, 
is 
al
re
ad
y 
im
po
ss
ib
le
.’
7.
 
A
:  ‘
H
e’s
 a
tt
en
di
ng
 a
n 
on
-t
he
-jo
b 
tr
ai
ni
ng
 s
ch
oo
l, w
he
re
 h
e 
w
or
ks
 in
 th
e 
ki
tc
he
n.
 B
ut
 h
e 
ca
n’
t e
ve
n 
lif
t a
 li
gh
t c
ra
te
, l
et
 a
lo
ne
 
on
e 
w
ith
 c
up
s 
in
 it
.’
8.
 
C:
 ‘W
al
ki
ng
 w
as
 v
er
y 
st
re
nu
ou
s 
fo
r h
im
; a
fte
r a
 s
ho
rt
 d
ist
an
ce
 h
e 
w
as
 a
lre
ad
y 
tir
ed
. H
e 
w
as
 s
til
l u
sin
g 
th
e 
pr
am
 w
he
n 
he
 w
as
 
5 
ye
ar
s 
ol
d.
’ 
9.
 
C/
A
: ‘I
 d
o 
no
t k
no
w
 w
ha
t i
t’s
 li
ke
 to
 b
e 
tir
ed
, a
nd
 th
e 
sa
m
e 
go
es
 fo
r m
y 
da
ug
ht
er
. B
ut
 m
y 
so
n 
is 
ea
sil
y 
fa
tig
ue
d.
 I 
al
w
ay
s 
fig
ur
ed
 h
e 
w
as
 ju
st
 b
ei
ng
 la
zy
 o
r t
ha
t h
e 
w
as
 e
xa
gg
er
at
in
g,
 s
o 
I’m
 a
ct
ua
lly
 g
la
d 
to
 h
ea
r i
t i
s 
a 
co
m
m
on
 s
ym
pt
om
 o
f N
oo
na
n 
sy
nd
ro
m
e.’
 
10
. 
A
: ‘D
ur
in
g 
th
e 
da
y, 
I t
ak
e 
a 
lo
t o
f p
au
se
s. 
M
y 
lif
e 
is 
re
al
ly
 p
ut
 in
 E
xc
el
 w
ith
 b
lo
ck
s 
of
 “I
 c
an
 w
or
k 
so
 lo
ng
” a
nd
 “I
 c
an
’t 
w
or
k”
.’ 
11
. 
C:
 ‘T
he
y 
bo
th
 re
al
ly
 li
ke
 s
po
rt
s, 
bu
t t
he
y 
ar
e 
ju
st
 c
lu
m
sy
.’ 
12
. 
C:
 ‘H
e 
co
ul
d 
no
t fi
nd
 h
is 
ba
la
nc
e 
to
 s
te
p 
do
w
n 
a 
cu
rb
.’ 
13
. 
C:
 ‘H
e 
us
ed
 to
 fa
ll 
ov
er
 a
 lo
t w
he
n 
he
 w
as
 li
tt
le
; h
e 
co
ul
d 
tr
ip
 o
ve
r t
he
 s
ill
ie
st
 b
la
de
 o
f g
ra
ss
.’
14
. 
C:
 ‘H
e 
on
ly
 le
ar
ne
d 
to
 ri
de
 h
is 
bi
ke
 w
he
n 
he
 w
as
 1
2 
ye
ar
s 
ol
d.
 H
e 
is 
16
 n
ow
. F
or
 a
 lo
ng
 ti
m
e 
he
 u
se
d 
a 
ta
nd
em
. T
ha
t w
as
 
id
ea
l. A
nd
 fo
r a
 lo
ng
 ti
m
e,
 a
 b
ic
yc
le
 w
ith
 tr
ai
ni
ng
 w
he
el
s.’
15
. 
C/
A
: ‘A
ll 
th
re
e 
of
 u
s 
ha
ve
 a
 p
ar
tic
ul
ar
 w
ay
 o
f r
un
ni
ng
. I
t l
oo
ks
 w
ei
rd
.’
16
. 
A
: ‘…
 m
os
tly
 c
lu
m
sin
es
s. 
I p
la
y 
ba
sk
et
ba
ll 
on
ce
 a
 w
ee
k 
an
d 
I n
ot
ic
e 
th
at
 I 
re
al
ly
 h
av
e 
to
 th
in
k 
ab
ou
t t
he
 s
te
ps
 I’m
 ta
ki
ng
, t
he
 
m
ov
es
 I 
ha
ve
 to
 m
ak
e…
 M
y 
te
am
m
at
es
 w
ill
 s
ay
, d
ud
e,
 I 
do
n’
t k
no
w
 w
ha
t y
ou
 a
re
 d
oi
ng
 b
ut
 I 
th
in
k 
yo
u 
sh
ou
ld
 b
e 
do
in
g 
so
m
et
hi
ng
 e
lse
.’
17
. 
A
: ‘M
ot
or
ic
al
ly
, t
he
 h
an
ds
 a
re
 b
ad
, t
he
 fi
ne
 m
ot
or
 s
ki
lls
. S
til
l h
av
en
’t 
su
cc
ee
de
d 
in
 ty
in
g 
sh
oe
la
ce
s.’
Co
gn
iti
on
   
  B
eh
av
io
r
   
  P
la
nn
in
g
   
  M
em
or
y
18
. 
C:
 ‘T
he
 th
in
g 
I n
ot
ic
e 
is 
th
at
 c
hi
ld
re
n 
th
at
 a
ge
 a
re
 re
al
ly
 c
re
at
iv
e.’
19
. 
C:
 ‘T
he
y 
ar
e 
go
-g
et
te
rs
, t
he
y 
do
n’
t w
an
t t
o 
be
 a
n 
ou
ts
id
er
.’
20
. 
C:
 ‘O
ur
 d
au
gh
te
r i
s 
a 
ve
ry
 g
oo
d 
st
ud
en
t a
nd
 g
oe
s 
to
 a
 b
ili
ng
ua
l s
ch
oo
l. B
ut
 p
la
nn
in
g 
is 
a 
di
sa
st
er
. P
eo
pl
e 
at
 s
ch
oo
l t
hi
nk
 s
he
’s 
go
od
 a
t s
ch
oo
l, s
o 
sh
e 
m
us
t b
e 
go
od
 a
t p
la
nn
in
g 
th
in
gs
 a
s 
w
el
l. B
ut
 th
at
 re
al
ly
 h
as
 n
ot
hi
ng
 to
 d
o 
w
ith
 e
ac
h 
ot
he
r.’ 
 
21
. 
A
: ‘L
ot
s 
of
 b
re
ak
s, 
so
 I’v
e 
pu
t m
y 
lif
e 
lit
er
al
ly
 in
 E
xc
el
, w
ith
 b
lo
ck
s 
of
 h
ow
 lo
ng
 I 
ca
n 
w
or
k,
 a
nd
 I 
ca
n’
t w
or
k.’
 
22
. 
C:
 ‘…
an
d 
fo
rg
et
tin
g 
it 
ag
ai
n 
as
 w
el
l, w
hi
ch
 is
 s
om
et
hi
ng
 w
e 
ca
n 
se
e 
ve
ry
 c
le
ar
ly
. A
 n
or
m
al
 c
hi
ld
 w
ill
 ta
ke
 a
bo
ut
 a
 w
ee
k,
 a
 
w
ee
k 
an
d 
a 
ha
lf 
to
 le
ar
n 
so
m
et
hi
ng
 b
y 
he
ar
t. 
In
 h
is 
ca
se
 it
 w
ill
 ta
ke
 a
bo
ut
 8
 to
 9
 w
ee
ks
. A
nd
 o
nc
e 
he
 h
as
 le
ar
ne
d 
it,
 y
ou
 h
av
e 
to
 k
ee
p 
re
pe
at
in
g 
it.’
23
. 
A
: ‘I
 h
av
e 
tr
ou
bl
e 
re
m
em
be
rin
g 
th
in
gs
. A
s 
lo
ng
 a
s 
th
er
e 
is 
so
m
e 
so
rt
 o
f s
tr
uc
tu
re
 it
’s 
al
l g
oo
d,
 b
ut
 if
 it
 g
oe
s 
di
ffe
re
nt
 th
an
 
ex
pe
ct
ed
, I
 th
in
k 
oo
oo
oo
h…
’
So
ci
al
 c
on
se
qu
en
ce
s
   
  S
ch
oo
l
   
  W
or
k
   
  S
po
rt
24
. 
C:
 ‘W
ha
t i
s 
al
so
 a
 p
ro
bl
em
 is
 th
at
 th
e 
sp
ec
ia
l e
du
ca
tio
n 
an
d 
at
te
nt
io
n 
yo
u 
ge
t a
t t
he
 p
rim
ar
y 
an
d 
se
co
nd
ar
y 
sc
ho
ol
 is
 g
on
e 
on
ce
 y
ou
 g
o 
to
 th
e 
vo
ca
tio
na
l s
ch
oo
l. A
nd
 th
en
 th
ey
 d
ro
p 
yo
u.
’
25
. 
C:
 ‘H
e’d
 h
av
e 
ha
d 
so
 m
uc
h 
cr
am
p 
in
 h
is 
ha
nd
s…
 a
nd
 th
en
 th
e 
ho
m
ew
or
k 
ha
d 
to
 b
e 
re
tu
rn
ed
 b
ec
au
se
 it
 w
as
 n
ot
 n
ea
t 
en
ou
gh
. B
ut
 y
es
, I
 d
o 
ho
m
ew
or
k 
at
 h
om
e 
be
ca
us
e 
th
en
 it
’s 
fin
ish
ed
, a
nd
 h
e 
do
es
 n
ot
 h
av
e 
th
at
 m
uc
h 
en
er
gy
.’ 
26
. 
A
: ‘I
’v
e 
al
w
ay
s 
be
en
 a
 n
ur
se
. I
 h
el
pe
d 
pe
op
le
 w
ith
 th
ei
r s
to
ck
in
gs
. M
y 
co
lle
ag
ue
s 
w
ou
ld
 g
o 
on
 th
ei
r k
ne
es
 li
ke
 th
at
, w
hi
ch
 
m
ad
e 
m
e 
th
in
k,
 h
ow
 d
o 
yo
u 
do
 th
at
? T
ha
t h
ur
ts
?!
 If
 I 
ha
d 
ha
d 
an
 o
ffi
ce
 jo
b,
 I 
pr
ob
ab
ly
 c
ou
ld
 h
av
e 
do
ne
 lo
ng
er
 w
ith
ou
t 
sy
m
pt
om
s.’ 
27
. 
C:
 ‘…
bu
t b
ec
au
se
 h
e 
is 
so
 c
lu
m
sy
 in
 h
is 
m
ot
or
 s
ki
lls
…
 A
s 
a 
sm
al
l c
hi
ld
 o
ne
 c
an
 s
til
l j
oi
n 
al
l k
in
ds
 o
f s
po
rt
s, 
bu
t a
bo
ve
 1
2 
yo
u 
sh
ou
ld
 k
no
w
 h
ow
 to
 d
o 
it.
 Y
ou
 d
on
’t 
jo
in
 a
 h
oc
ke
y 
te
am
 if
 y
ou
 c
an
’t 
pl
ay
 h
oc
ke
y.’
28
. 
A
: ‘I
’v
e 
go
t t
hi
s 
ex
er
ci
se
 w
ith
 y
og
a,
 w
he
re
 y
ou
 li
e 
on
 y
ou
r s
to
m
ac
h,
 a
nd
 th
en
 y
ou
 li
ft 
yo
ur
 a
rm
s 
an
d 
le
gs
. I
 c
an
’t 
do
 th
at
. T
ha
t’s
 
a 
re
al
 c
on
tr
as
t w
ith
 m
y 
fe
llo
w
 y
og
a 
st
ud
en
ts
.’
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Ta
bl
e 
III
  Q
uo
te
s 
pe
r t
he
m
e 
co
rr
es
po
nd
in
g 
to
 c
hi
ld
re
n 
an
d 
ad
ul
ts
 w
ith
 N
oo
na
n 
sy
nd
ro
m
e 
(C
on
tin
ue
d)
.
Th
em
es
Q
uo
te
s
Pe
rc
ei
ve
d 
eff
ec
t o
f 
in
te
rv
en
tio
ns
 
   
  E
xe
rc
ise
   
  
   
  A
id
   
  
   
  
   
  M
ed
ic
al
 in
te
rv
en
tio
n
29
. 
C:
 ‘I 
do
 g
et
 th
e 
im
pr
es
sio
n 
th
at
 p
hy
sio
th
er
ap
y 
w
or
ks
…
 M
y 
da
ug
ht
er
 fi
nd
s 
it 
ha
rd
 to
 o
rg
an
iz
e 
th
in
gs
 in
 h
er
 m
in
d 
an
d 
to
 
de
te
rm
in
e 
th
e 
or
de
r. 
H
er
 p
hy
sio
th
er
ap
ist
 h
el
ps
 h
er
 g
oi
ng
 th
ro
ug
h 
th
e 
m
ov
em
en
ts
 in
 a
 c
er
ta
in
 w
ay
, t
o 
m
ak
e 
su
re
 s
he
 le
ar
ns
.’  
30
. 
A
: ‘…
an
d 
sw
im
m
in
g 
is 
ju
st
 re
al
ly
 s
om
et
hi
ng
 y
ou
 s
ho
ul
d 
be
 d
oi
ng
…
 s
w
im
m
in
g 
is 
go
od
 a
nd
 w
or
ke
d 
w
el
l f
or
 m
e.’
 
31
. 
C:
 ‘I 
ju
st
 n
ot
ic
e 
th
at
 m
y 
so
n 
ca
nn
ot
 c
yc
le
 v
er
y 
fa
r. 
H
e 
cy
cl
es
 5
00
 m
et
er
s 
an
d 
th
en
 h
e 
ju
st
 s
ay
s: 
I c
an
’t 
do
 it
 a
ny
m
or
e.
 I 
am
 ti
re
d 
an
d 
m
y 
le
gs
 h
ur
t. 
I h
av
e 
ar
ra
ng
ed
 a
n 
el
ec
tr
ic
 b
ic
yc
le
 th
ro
ug
h 
th
e 
Co
un
ci
l s
o 
he
 c
an
 jo
in
. I
t i
s 
id
ea
l, I
’m
 re
al
ly
 h
ap
py
.’
32
. 
A
: ‘I
 w
ea
r b
ra
ce
s 
fo
r m
y 
kn
ee
s 
to
 s
ta
bi
liz
e 
th
em
 a
 li
tt
le
 m
or
e.’
  
33
. 
C:
 ‘S
ta
nd
ar
d 
pr
oc
ed
ur
e 
is 
a 
pa
ra
ce
ta
m
ol
 b
ef
or
e 
go
in
g 
to
 b
ed
. A
nd
 th
at
 re
al
ly
 h
el
ps
. H
e 
do
es
n’
t w
ak
e 
up
 in
 th
e 
m
id
dl
e 
of
 th
e 
ni
gh
t a
ny
m
or
e.
 If
 w
e 
do
 fo
rg
et
, h
e 
w
ill
 w
ak
e 
up
 fo
r s
ur
e,
 c
ry
in
g 
be
ca
us
e 
of
 th
e 
pa
in
.’ 
34
. 
C:
 ‘M
y 
so
n 
ha
s 
ha
d 
he
ar
t s
ur
ge
ry
, o
nl
y 
th
re
e 
w
ee
ks
 a
go
, a
nd
 h
e’s
 a
 c
om
pl
et
el
y 
di
ffe
re
nt
 b
oy
. B
ef
or
e 
he
 ju
st
 s
at
 o
n 
th
e 
co
uc
h 
an
d 
pl
ay
ed
 a
 b
it,
 a
nd
 n
ow
 a
ll 
of
 a
 s
ud
de
n 
hi
s 
sk
ill
s 
ar
e 
st
ar
tin
g 
to
 d
ev
el
op
.’ 
35
. 
A
: ‘I
’v
e 
do
ne
 p
ai
n 
re
ha
bi
lit
at
io
n 
in
 a
 re
ha
bi
lit
at
io
n 
ce
nt
er
 a
nd
 th
er
e 
I’v
e 
re
al
ly
 le
ar
ne
d 
to
 li
st
en
 to
 m
y 
bo
dy
 a
nd
 to
 e
xp
lo
re
 m
y 
bo
un
da
rie
s.’ 
Ex
pe
rie
nc
es
 w
ith
 
he
al
th
ca
re
 p
ro
fe
ss
io
na
ls
36
. 
C:
 ‘A
 p
hy
sio
th
er
ap
ist
 h
as
 re
al
ly
 n
o 
id
ea
 w
ha
t N
oo
na
n 
sy
nd
ro
m
e 
is 
an
d 
w
ha
t t
o 
do
.’ 
37
. 
A
: ‘…
an
d 
w
he
n 
yo
u 
sa
y “
I’v
e 
go
t N
oo
na
n 
sy
nd
ro
m
e,
 it
 h
as
 to
 d
o 
w
ith
 th
at
”…
 N
o 
on
e 
be
lie
ve
s 
yo
u,
 a
s 
no
 o
ne
 k
no
w
s 
th
e 
sy
nd
ro
m
e.
 P
eo
pl
e 
w
ill
 s
ym
pa
th
iz
e 
w
ith
 D
ow
n 
or
 G
ill
es
 d
e 
la
 To
ur
et
te
, b
ut
 th
ey
 ju
st
 ro
ll 
th
ei
r e
ye
s 
w
he
n 
I m
en
tio
n 
N
oo
na
n.
’ 
C:
 C
hi
ld
 re
po
rt
ed
 o
n;
 A
: A
du
lt
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Discussion
People with Noonan syndrome experienced many problems with motor performance 
during their life, which had an evident impact on functioning in daily life. Nevertheless, 
people with Noonan syndrome and/or their relatives did not feel heard and supported 
and experienced no understanding of their problems by healthcare professionals. 
 The most frequently experienced problems with motor performance in people with 
Noonan syndrome were pain, decreased muscle strength, fatigue and clumsiness. To a 
lesser extent, complaints of hypermobility, increased skin sensitivity, and problems with 
planning and organizing activities were mentioned. We assume that motor performance 
is affected in particular by decreased muscle strength, which in turn is related to pain, 
fatigue, and possibly to motor learning problems and clumsiness. In addition, the latter 
can also be influenced by problems with coordination and planning. The problems 
experienced showed a large interindividual variability, even within one family (from no 
problems at all in some people with Noonan syndrome to wheelchair use in one). No clear 
relation with age was seen. We hypothesize that the way these complaints are experienced 
and handled will depend on the personal capacity, the context and the phase in life. Most 
people with Noonan syndrome and/or their relatives believed that problems with motor 
performance improved with exercise, appropriate physiotherapy guidance and other 
supportive interventions. However, despite these interventions, most people with Noonan 
syndrome still experienced difficulties in everyday activities.
 Although some studies underpinned many findings in the focus group interviews, 
they lacked systematic research focusing on either the subjectively experienced signs and 
symptoms or their impact on daily life (9-15). Moreover, what is lacking is insight into the 
underlying impairments, not only prediction of the natural course, but also appropriate 
focused interventions and treatment of these motor performance problems in Noonan 
syndrome. Pain was one of the most frequently mentioned symptoms in our focus group 
interviews. In particular, the presence of chronic pain has been described in literature 
(9-11). However, ideas about growing pains and effects of interventions are not mentioned 
in literature. Decreased muscle strength has been reported in only one study (12, 22). 
However, in our focus group interviews, decreased muscle strength was a major problem. 
Stevenson and Yang [2011] and Stevenson et al. (2012) suggested that disturbance of RAS/
MAPK signaling leads to muscle weakness, which likely correlates with various clinical 
musculoskeletal findings broadly observed in the RASopathies. The authors hypothesized 
that increasing strength will result in improved ability to participate in physical activities 
with improvement in quality of life. Therefore, assessments by physiotherapy and/or 
occupational therapy should be considered in these people (12). Although many of our 
participants supported this hypothesis, until now, no systematic research into the effect of 
exercises has been found. Clumsiness, which in our study was expressed as a problem 
with learning gross and fine motor skills, coordination and aberrant movements can be 
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interpreted as a developmental motor coordination disorder, as mentioned in literature 
(13, 14). With respect to the last frequently mentioned problem, fatigue, no literature has 
been published. The presence of hypermobility is supported in literature (9, 16). Problems 
with sensitivity are not described in literature. Our people with Noonan syndrome and/or 
their relatives also mentioned problems with planning and organizing activities. Van der 
Burgt et al. (1999) first recognized organizational and planning weakness in children with 
Noonan syndrome. 
 A qualitative approach was used. According to Sandelowski (2010), a sample size 
could not be determined a priori in qualitative descriptive research. In this study, we 
considered the sample size adequate once informational redundancy (data saturation) 
occurred; no new themes or data were elicited during analysis (23). Also, attendees on the 
Noonan syndrome contact day in 2014 recognized the presented results and had nothing to 
add. Although it could be argued that interviewing participants in an Noonan syndrome 
patient association environment might introduce some bias, we did not expect to miss 
information because of saturation and judged such an elaborate overview of complaint 
presentation adequate as a starting point for new quantitative research. Because of the 
small number of participants, no phenotype-genotype correlation could be determined. 
 This is the first study from a patient perspective to describe the motor performance 
problems that people with Noonan syndrome and/or their relatives experience, the major 
consequences in daily life, the positive experiences of interventions and the mis-
communication with healthcare professionals. To achieve optimal support, healthcare 
professionals, as well as people with Noonan syndrome and/or their relatives themselves, 
should be aware of these frequently presented problems with motor performance. 
Since no effect studies regarding interventions and treatment options have been carried 
out, recommendations for interventions can only be made on the basis of experiences 
of people with Noonan syndrome. Research into the cause of problems with motor 
performance is still very limited (12, 24). In addition, motor performance problems have 
never been investigated systematically using valid norm-referenced tests. Therefore, 
research on these different aspects is needed to understand and support people with 
Noonan syndrome.  
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Abstract
Although problems with motor performance in daily life are frequently mentioned in 
Noonan syndrome, the motor performance profile has never been systematically investigated. 
The aim of this study was to examine whether a specific profile in motor performance in 
children with Noonan syndrome was seen using valid norm-referenced tests. 
 The study assessed motor performance in 19 children with Noonan syndrome (12 females, 
mean age 9y 4mo, range 6y 1mo to 11y and 11mo, SDS 1y and 11mo). 
 More than 60% of the parents of the children reported pain, decreased muscle 
strength, reduced endurance, and/or clumsiness in daily functioning. The mean standard 
scores on the Visual Motor Integration (VMI) test and Movement Assessment Battery for 
Children 2, Dutch version (MABC-2-NL) items differed significantly from the reference 
scores. Grip strength, muscle force, and 6-Minute Walking Test (6MWT) walking distance 
were significantly lower, and the presence of generalized hypermobility was significantly 
higher. All MABC-2-NL scores (except manual dexterity) correlated significantly with almost 
all muscle strength tests, VMI total score, and VMI visual perception score. The 6MWT was 
only significantly correlated to grip strength. 
 This is the first study that confirms that motor performance, strength, and endurance 
are significantly impaired in children with Noonan syndrome. Decreased functional motor 
performance seems to be related to decreased visual perception and reduced muscle 
strength. Research on causal relationships and the effectiveness of interventions is 
needed. Physical and/or occupational therapy guidance should be considered to enhance 
participation in daily life. 
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Introduction 
Noonan syndrome is a well-known autosomal dominant disorder with an estimated 
incidence of 1:1000–2500 live births (1). The cardinal features of Noonan syndrome are 
atypical face, congenital heart defects, and short stature, with many other variable 
manifestations, such as cryptorchidism, skeletal abnormalities, and variable developmental 
delay (2-4). Noonan syndrome is genetically heterogeneous and shows considerable 
clinical overlap with other RASopathies, a specific class of disorders caused by germline 
mutations in gene encoding proteins of the Ras-mitogen-activated protein kinase (RAS/
MAPK) pathway (5). Excellent reviews of Noonan syndrome have been published with 
comments on both clinical and molecular findings (2, 6-9). 
 Problems with motor performance are frequently reported in Noonan syndrome. 
As demonstrated in our previously published qualitative research study, many people 
with Noonan syndrome report problems related to pain, decreased muscle strength, 
fatigue, and clumsiness, which have an evident impact on functioning in daily life (10). 
Also, other authors have reported on chronic muscle and joint pain in children and adults 
with Noonan syndrome (11-13), and musculoskeletal anomalies such as anterior chest wall 
anomalies, scoliosis, talipes equinovarus, joint contractures, pes planus or cavus, and 
hypermobility (4, 11, 14). 
 Horiguchi and Takeshita (2003) tested the visual motor integration (VMI) in a 
10-year-old child with Noonan syndrome and found delayed visual motor coordination. In 
contrast, van der Burgt et al. (1999) found average visual motor abilities in children with 
Noonan syndrome, whereas Wingbermuhle et al. (2012) found no differences between 
adults with Noonan syndrome and healthy controls on a test for visuoconstructive ability. 
A motor developmental delay has been reported by parents in 26% to 46% of infants with 
Noonan syndrome (3, 4, 15). In other studies, parents of children with Noonan syndrome 
report clumsiness, often referred to as a developmental coordination disorder (16-18). In 
addition, Lee et al. (2005) tested motor coordination in children with Noonan syndrome 
using the Test of Motor Impairment-Revised (TOMI-R) and found a developmental 
coordination disorder in 51% of the sample. Alfieri et al. (2011) performed the Movement 
Assessment Battery for Children (MABC) in children with Noonan syndrome and found an 
impaired score in 72% of the children. Pierpont et al. (2009, 2010) tested fine motor skills 
through the Purdue Pegboard Test and reported that manual fine motor skills were 
severely impaired (>2 standard deviation score (SDS) below the mean) in 34% and below 
average (>1 SDS below the mean) in 72% of the children with Noonan syndrome. Troyer 
and Joschko (1997) reported on two children with Noonan syndrome and found a 
below-average IQ and a below-average, inconsistent level of performance on sensorimotor 
tasks. Stevenson et al. (2012) found significantly decreased handgrip strength in people 
with Noonan syndrome (range 6–47 years). 
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Despite these frequently reported problems with motor performance in people with 
Noonan syndrome, the motor performance profile has never been systematically 
investigated within a single cohort of children with Noonan syndrome using valid 
norm-referenced tests.  To validate the motor performance problems of children with 
Noonan syndrome in daily life, we investigated whether motor performance in children 
with Noonan syndrome differed from the reference population, and whether a specific 
profile of motor performance in these children could be seen.
Materials and methods 
Participants
We selected all children with Noonan syndrome between the ages of 6 and 11 years who 
had been clinically diagnosed at our tertiary center using the cardinal features delineated 
by van der Burgt et al. (1994) (19). Because Noonan syndrome is genetically heterogeneous 
and shows considerable clinical overlap with other RASopathies (5), we included only 
children with phenotypic and genotypic diagnoses of Noonan syndrome. The children 
and their parents were invited by means of a letter that explained the study aims. After 
informed consent of both parents or guardians was obtained, we sent them questionnaires 
and invited them to visit our clinic with their children for measurements. Results were 
communicated (verbally or by letter) to the parents, and in the case of motor impairments, 
referral to a therapist was provided.
Design
We performed an observational cross-sectional cohort study. No control group was 
included, since (Dutch) reference scores were available for all measurements, which 
allowed comparison of the results from a group under research with a relatively large 
reference population of the same age. 
Ethical approval and informed consent
The Regional Committee on Medical Research Ethics approved the study (no. 2013/149), 
in conformance to the Declaration of Helsinki. 
Methods of measurement
The children visited our clinic for one day. First, three questionnaires were completed. 
Then motor performance was assessed by one of the two experienced pediatric physio-
therapists (ME and MP) in the following areas: VMI, Movement Assessment Battery for 
Children 2, Dutch version (MABC-2-NL), Concise Assessment Method for Children’s 
Handwriting (BHK), grip strengths, muscle force, 6-Minute Walking Test (6MWT), and 
Beighton Hypermobility Score (BHS).
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Questionnaires
The general questionnaire inventoried the phenotypic–genotypic profile: type of mutation, 
presence and type of congenital heart defect, visual and hearing impairments, allied 
health received, type of education, developmental milestones, reported musculoskeletal 
characteristics, and problems in daily functioning. 
 The sports questionnaire contained questions concerning participation in school, 
physical education, sports, and active lifestyle (20). The participants registered which 
sports they participated in in the past year and how many times a week they exercised.
 The Dutch version of the Self-Perception Profile for Children was used to measure 
children’s self-perception of motor performance level based on 12 questions, with higher scores 
indicating higher perceived levels (21). We included the motor domain interest questionnaire 
(10 items) using a four-point scale. Norm references are available for Dutch children (22).
Motor performance measurements
All motor performance tests used were evaluated to conform to the corresponding 
manuals. Dutch norm references were available for the MABC-2-NL (23), BHK (24), muscle 
force tests (25), and the BHS (26). International norm references for children were used for 
VMI (27), grip strength (28), and 6MWT (29).
 To test VMI, the Beery VMI sixth edition was used, together with the subtests for visual 
perception and motor coordination (27). 
 To determine motor performance levels, the MABC-2-NL was used. This test is divided 
into three sections: manual dexterity, ball skills, and static and dynamic balance. Moreover, 
a total score can be calculated (23). 
 To test the presence of handwriting problems, we used the BHK as a screening tool 
to recognize dysgraphia (24). Children had to copy a standardized text on a blank sheet 
of paper within a time frame of five minutes. A total quality score was calculated, and 
copying speed was based on the number of characters written by the child in five minutes.
Grip strength was measured with a Jamar Plus+ Hand Dynamometer (Patterson Medical 
and Sammons Preston). The handle size was adapted to a child’s hand size as per the 
instructions. The peak value obtained during five seconds was noted as the ‘peak grip 
strength’ in pounds. Verbal encouragement was given during the attempts to achieve 
maximal effort. The values of three attempts were averaged for the left side as well for the 
right side, and z-scores were calculated (28). 
 Muscle force was measured with a Hand-held Dynamometer (CITEC, CIT Technics, 
Groningen, The Netherlands). Maximum voluntary isometric muscle strength of elbow 
flexors and knee extensors was measured bilaterally in newtons using the ‘break’ 
technique. Verbal encouragement was given during the attempts to achieve maximal 
effort. The highest value was used as the outcome measurement (25). 
 Physical fitness was assessed with the 6MWT, a submaximal test in which children 
walked at a constant, uninterrupted, unhurried pace as far as they could in six minutes (29). 
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Oxygen saturation and heart rate were determined during the walking. The BHS is most 
widely used to diagnose joint hypermobility in children, with scores ranging from 0 to 9 (30). 
Data analysis
We used the reference norms in the manuals to present the results as normal, at risk, or 
impaired, presented as SDSs or z-scores. Based on the outcome of the Self-Perception 
Profile for Children scale, motor self-perception was dichotomized between ‘abnormal’ 
(≤ 1SDS) and ‘normal’ (> 1SDS). ‘Motor domain’ interest was dichotomized into ‘not important’ 
(≤ -1SDS) and ‘interested’ (> -1SDS). Results for VMI and MABC-2-NL were expressed as 
mean standard scores, which were related to the absolute reference norms and were 
classified to conform to the manuals in ‘normal and good performance’ (> -1 SDS), ‘at risk’ 
(≤ -1 SDS and > -2 SDS), and ‘impaired’ (≤ -2 SDS). Handwriting was categorized as ‘not 
dysgraphic’ (a score of 0–21), ‘ambiguous’ (a score of 22–28), and ‘dysgraphic’ (a score of 29 
or higher) (24). The copying speed score was  categorized as ‘slow writers’ (< 1SDS) and 
‘normal and fast writers’ (> 1SDS) (24). For grip strength, muscle force, and 6MWT, z-scores 
were calculated that were related to the reference norm. Van der Giessen et al. (2001) 
validated the Beighton criteria for Dutch children: generalized hypermobility was present 
if the score was ≥ 5 for children 4 to 9 years of age and ≥ 4 above 10 years of age.
 We used descriptive statistics, one sample T test, and Chi-square or Fischer’s exact 
test to compare results with available norm references. We also performed a correlation 
analysis between the different test results to get insight into the relationship between 
motor performance as measured with the MABC-2-NL and the outcomes in VMI, grip 
strength, muscle force, and 6MWT. We expected a strong relationship between VMI and 
manual dexterity and ball skills, whereas ball skills and dynamic and static balance would 
be more related to muscle strengths. The 6MWT would be expected to be related to 
muscle force tests. Statistical analyses were performed with SPSS 20.0. A probability level 
of P<0.05 (two-tailed) was considered statistically significant. 
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Results
Twenty-nine children with Noonan syndrome between the ages of 6 and 11 years were 
invited to participate in the study, of which 10 could not be included: one had incomplete 
address data, five did not respond to our letters, and four did not want to participate in the 
study. The other 19 children with Noonan syndrome were included in the study. 
Questionnaires
Table I shows the characteristics of the 19 children with Noonan syndrome included in the 
study, obtained from the general questionnaire. Figure 1 shows the number of children 
with Noonan syndrome with pain and the level of performance with respect to peers for 
the characteristics of endurance, strength, and dexterity. Of the 12 children with Noonan 
syndrome with pain (seven not severe, five severe), the pain was characterized as muscle 
and/or joint pain (Figure 1A). Half of these children experienced pain at night and/or at the 
end of the day, and five during and/or after exercise. Five children reported recovery from 
pain after sleep, and four experienced pain for less than one hour. 
 Twelve children with Noonan syndrome reported that they tired (very) quickly 
compared to other children (Figure 1B). Strength compared to other children was reduced 
in 12 children with Noonan syndrome, normal in three, and increased in four children with 
Noonan syndrome (Figure 1C). Dexterity relative to other children was reduced in 13 
children with Noonan syndrome, normal in four, and increased in two children with 
Noonan syndrome (Figure 1D). Skeletal abnormalities were present in 17 children with 
Noonan syndrome. Most of them had pectus deformity, flat feet, hypermobility, and/or 
scoliosis. Other skeletal abnormalities were less common. More than half of the children 
with Noonan syndrome experienced problems in daily functioning. Two children with 
Noonan syndrome did not participate in sports. Three children with Noonan syndrome 
participated less than one time a week in sports, 11 participated one to two times a week 
in sports, and three participated two or more times a week in sports. Of the 14 children 
who participated at least one time a week in sports, two participated in two sports. Of 
those 16 sports, 10 sports were individual sports (such as swimming and judo) and six 
sports were team sports (such as hockey and soccer). All children answered the question 
“sports have a positive influence on…”, namely: 1. developing condition and/or endurance 
(n=16); 2. developing strength (n=15); 3. reducing pain (n=0); 4. reducing excessive 
flexibility and/or stiffness (n=3); 5. something else, namely… (n=0). 
 Self-perception of motor competence in children showed a mean decile score of 
5.05 (range 1–10) (Table II). The distribution in ‘abnormal’ and ‘normal’ scores did not differ 
significantly from the normative score. ‘Motor domain’ interest showed a mean individual 
score of 2.74 (range 1–4), which also did not differ significantly from the dichotomized 
normative score. 
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Table I   General characteristics of the children with Noonan syndrome.
General characteristics Children with Noonan syndrome 
(n=19)
Sex, n (%)
     Male
     Female
7 (36.8)
12 (63.2)
Age 
     Mean age at testing 
     SDS (range)
9y and 4mo
1y and 11mo (6y and 1mo – 11y and 
11mo)
Height
     Mean (cm) 
     SDS (range)
125.2
12.8 (109.0 – 146.5)
Weight
     Mean (kg) 
     SDS (range)
24.2
6.2 (16.5 – 40.0)
Type of mutation, n (%)
     PTPN11 
     SOS1
     KRAS
     RAF1
11 (57.9)
4 (21.1)
2 (10.5)
2 (10.5)
Congenital heart defects, n (%)
     Pulmonary valve stenosis 
     Hypertrophic cardiomyopathy
     Septal defect
     Other 
     Cardiac surgery
14 (73.7)
     10 (71.4)
     1 (7.1)
     2 (14.3)
     2 (14.3)
     6 (42.9)
Visual disorder, n (%) 12 (63.2)
Hearing disorder, n (%) 8 (42.1)
Allied health (in the past or present), n (%)
     Physiotherapy
     Speech therapy
     Occupational therapy
17 (89.5)
12 (63.2)
5 (26.3)
Education, n (%)
     Regular primary education
     Regular primary education with additional support
     Special education
5 (26.3)
9 (47.4)
5 (26.3)
Mean age of achieved developmental milestones (mo), 
SD (range)
     Stacking blocks (n=7)
     Walk independently (n=19)
     Two-word sentences (n=10)
     Bicycle independently (n=18)
17.1, 9.5 (10 – 36)
20.4, 6.1 (13 – 36)
21.1, 8.4 (12 – 36)
65.7, 15.7 (42 – 108)
517840-L-bw-croonen
Processed on: 6-3-2018 PDF page: 135
135
Motor performance in children with Noonan syndrome
8
Motor performance 
Figure 2A illustrates the proportions of children with ‘normal’, ‘at risk’, and ‘impaired’ VMI 
scores. Figure 2B illustrates the proportions of children with ‘normal’, ‘at risk’, and ‘impaired’ 
MABC-2-NL scores. Results of the norm-referenced tests are shown in Table II. The mean 
standard scores on the VMI items and the MABC-2-NL items differed significantly from the 
normative scores. The BHK was not performed by nine children with Noonan syndrome, 
since four children were too young to write and five children wrote only in block letters 
because of handwriting difficulties. Of the remaining 10 children with Noonan syndrome, 
one was ‘ambiguous’ and four were ‘dysgraphic’. The distribution in ‘slow writers’ and 
‘normal/fast writers’ did not differ significantly from the Dutch norm (P=0.114). Grip 
strength measurements in the left and right hand, muscle force of elbow flexors and knee 
extensors, and 6MWT mean walking distance differed significantly from the norm 
references (P<.001). According to the validated BHS, four children with Noonan syndrome 
had generalized hypermobility (P=0.003). Two of them had hypermobility of both hands 
and arms. Sixteen children with Noonan syndrome had only hypermobility of the hands. 
In one child, no hypermobility was found.
Table I   General characteristics of the children with Noonan syndrome (Continued).
General characteristics Children with Noonan syndrome 
(n=19)
Skeletal abnormalities, n (%)
     Pectus excavatum
     Flat feet
     Pectus carinatum
     Hypermobility
     Scoliosis
     Overstretched elbow/knee
     Hammertoe
     Clubfeet
     Curved arms and legs
     Short Achilles tendon
17 (89.5)
     10 (58.8)
     8 (47.1)
     7 (41.2)
     6 (35.3)
     4 (23.5)
     2 (11.8)
     1 (5.9)
     1 (5.9)
     1 (5.9)
     1 (5.9)
Problems in daily functioning, n (%)
     Writing
     Running
     Throwing/catching
     Standing on one leg
     Swimming
     Bicycling
16 (84.2)
     13 (81.3)
     11 (68.8)
     8 (50.0)
     11 (68.8)
     8 (50.0)
     7 (43.8)
n: number; y: years; mo: months; SDS: standard deviation score
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Table III shows the correlation between the different test results. Because only minor 
differences were found between left- and right-sided grip strength and muscle force tests, 
left- and right-sided SD values were averaged. Both VMI and MABC-2-NL item scores 
showed a significant correlation between the different test sub-items. In addition, a 
significant correlation between all MABC-2-NL scores (except for manual dexterity) and 
most muscle strength tests, and VMI total score and VMI visual perception was found. The 
6MWT was only significantly correlated to grip strength. 
Figure 1   Description and classification of self-reported pain (A), endurance with 
respect to peers (B), muscle strength with respect to peers (C), and dexterity 
with respect to peers (D) in children with Noonan syndrome.
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8Figure 2   Distribution of classification of (sub)tests for Visual Motor Integration (A) and 
Movement Assessment Battery for Children 2-NL (B) for reference population 
and children with Noonan syndrome.
RPTBV: Reference Population Total Beery Visual Motor Integration; TBV: Total Beery Visual Motor Integration; VP: Visual 
Perception; MC: Motor Coordination; RPTM: Reference Population Total Movement Assessment Battery for Children 2-NL; 
TM: Total Movement Assessment Battery for Children 2-NL; MD: Manual Dexterity; BS: Ball Skills; SDB: Static and Dynamic 
Balance.
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Discussion
This is the first study that systematically investigated motor performance using valid 
norm-referenced tests within a single cohort of children with Noonan syndrome. Most 
children with Noonan syndrome experienced motor performance impairments, pain, 
decreased strength, and decreased endurance in daily functioning, which was confirmed 
by our test results. However, self-perceived motor performance tests showed a normal 
‘motor domain’ interest with a normal self-perception of motor competence. It was clearly 
demonstrated that overall motor performance was impaired, characterized by significantly 
lower performance of fine motor skills, ball skills, balance, visuomotor tasks, and more 
‘dysgraphic’ handwriting, and that strength and endurance levels in children with Noonan 
syndrome were decreased. A significant correlation between motor skill levels, measured 
with MABC-2-NL scores (except for manual dexterity), and most muscle strength tests, 
VMI total score, and VMI visual perception was found. The 6MWT was only significantly 
correlated to grip strength. 
 VMI mean standard scores differed significantly from the normative scores. Visual 
perception was borderline significant. Our findings are in agreement with the findings of 
Horihuchi and Takeshita (2003). However, van der Burgt et al. (1999) and Wingbermuhle et 
al. (2012) did not find impaired visual–motor abilities in persons with Noonan syndrome. 
Selection bias could have influenced the different findings in comparison with our study. 
In addition, Wingbermuhle et al. (2012) speculated that visuoconstruction might only be 
compromised in Noonan syndrome during childhood, but not in adulthood. 
 The MABC-2-NL mean standard scores differed significantly from the normative 
scores for all items. Our findings are in line with the known literature (17, 31-34). Minor 
differences in percentages might be explained by the different inclusion criteria and 
different tests used. In addition, Lee et al. (2005) found an inverse relationship between the 
degree of motor problems and age. Despite the lower scores on the different MABC-2-NL 
items, the children with Noonan syndrome in this study have a positive self-image with 
respect to motor performance and are not restrained from sports activities. This indicates 
that the motor deficit is not only due to a lack of exercise experience. 
 We found ‘dysgraphic’ writing in a significantly higher percentage than in healthy 
children as mentioned in the literature (35). In addition, five children who wrote in block 
letters because of handwriting difficulties were excluded. So the percentage of children 
with ‘dysgraphic’ writing might even be underestimated. Copying speed did not differ 
significantly from the Dutch norm. However, two children with Noonan syndrome who 
were ‘fast writers’ were also ‘dysgraphic’. It is likely that speed is at the expense of quality. 
 In the questionnaires, reduced strength and reduced endurance were mentioned 
in 63% of the children with Noonan syndrome. These findings were confirmed by our test 
results. Grip strength and muscle force differed significantly from the normative scores, 
which is consistent with the known literature (36). The physical fitness level was significantly 
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lower than the normative scores. Physical fitness has never been evaluated in people with 
Noonan syndrome before. 
 We found generalized hypermobility in 21.1% of the children with Noonan syndrome. 
More than one third of the children with Noonan syndrome reported hypermobility in the 
questionnaire. In the literature, joint laxity and/or hyperextensibility were reported in 50% of 
people with Noonan syndrome (14); however, these were not scored using the Beighton 
Hypermobility Score. Reinker et al. (2011) did not mention hypermobility at all. 
 With regard to the findings from the correlation analysis, decreased functional motor 
performance seems to be related to decreased visual perception but also to reduced 
muscle strength. Because no correlation between VMI and manual dexterity was seen, we 
hypothesize that the reduced visual perception is primarily determined by an abnormal 
spatial perception rather than by reduced vision. Alfieri et al. (2008, 2011) already suggested 
the relation between visual impairments and VMI and MABC test results. Alfieri et al. (2008) 
investigated visual function and found that patients with impaired VMI had abnormal 
stereopsis, suggesting that the difficulties in 3D processing may cause difficulties in VMI. 
However, they used raw VMI scores (which are not corrected for age) instead of standard 
scores as an outcome measure (37). Alfieri et al. (2011) concluded that the poor performances 
on the MABC in their cohort confirmed ventral stream involvement in patients with 
visuomotor perceptual difficulties. However, in contrast to this conclusion, they mentioned 
in their discussion that there was no consistent association between individual tasks on 
the MABC and results on form (ventral stream) and motion (dorsal stream) assessment. 
Unfortunately, no statistical results were added. 
 Noonan syndrome is genetically heterogeneous and shows considerable clinical 
overlap with other RASopathies (5); as a result, we only included children with phenotypic 
Noonan syndrome and a positive mutation analysis. Ten children were excluded (one had 
incomplete address data, five did not respond to our letters, and four did not want to 
participate in the study). This could have led to selection bias, because we hypothesize 
that children without clinical complaints are less likely to participate in research. The tests 
were performed and evaluated according to the manuals by two experienced pediatric 
physiotherapists, so intra- and inter-observer variation was minimized. Most of the current 
manuals do not correct for weight and height. Because short stature is a cardinal feature 
of Noonan syndrome, we hypothesize that results of muscle strength and endurance 
might be underestimated. Ploegmakers et al. (2013) already mentioned that grip strength 
is strongly associated with height, weight, and gender in childhood. However, grip 
strength results in our cohort were more than -2.5 SDS, which is such a large deviation 
from normal that we do not expect it will come in the normal range if corrected for height 
and weight. Nevertheless, we recommend including correction for height in future 
manuals. 
 We did not investigate the relationship with possible confounding health conditions 
related to Noonan syndrome due to the small patient cohort and the scarcity of time and 
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money. However, a relation between the found motor difficulties and Noonan syn-
drome-related impairments is imaginable. For example, the presence of congenital heart 
disease might influence endurance. We did not test intellectual abilities to avoid an 
excessive testing load and because only a mildly lowered average level of intelligence 
score has been found in Noonan syndrome patients (38). In studies on cognitive 
functioning in children with Noonan syndrome, an inconsistent pattern for scores on 
verbal and nonverbal abilities has been found (17, 32, 39). In our cohort, 15 of the children 
had ever undergone an intelligence test, and outcomes were present for 10 of them, with 
a mean total intelligence score of 93 (n=10; range 76–133), which is in the normal range. 
 Few studies have published results on (the relationship between) IQ and motor 
performance. Pierpont et al. (2009, 2011) found that fine motor dexterity was significantly 
associated with language and verbal and nonverbal intellectual functioning. In addition 
to fine motor dexterity, influences such as mutation type, hearing loss, and parental 
education levels accounted for significant variability in cognitive outcomes. Severity of 
cardiac disease was not related to cognitive functioning (32). Alfieri et al. (2011) concluded 
that most of their patients had normal IQ with poor visuomotor perceptual performances 
on the MABC. The level of VMI is associated with the level of cognitive integration and 
maturation and can moderate educational outcome (38). As mentioned above, visual 
impairments themselves seem to be related to decreased functional motor performance. 
 It was not our purpose to elucidate the etiology of the found impairments. However, 
some hypotheses are suggested in the literature. Troyer and Joschko (1997) suggested the 
existence of cerebellar dysfunction, which has been associated with below-average 
intellectual abilities and motor-coordination problems. The specific, but variable, verbal 
and/or visuospatial cognitive deficits of patients with Noonan syndrome might be 
dependent on the location of the focal cerebral abnormality (34). Alfieri et al. (2008, 2011) 
mentioned that visual and visuoperceptual abilities are probably related to a multifactorial 
etiology in which abnormal ocular movements and/or a specific occipitotemporal deficit 
are suggested. A prospective systematic MRI and clinical study may help to fully evaluate 
the integrity of the neural network, including ocular, peripheral, and central structures of 
the visual pathway (31, 37). Stevenson et al. (2011, 2012) provided objective data to suggest 
that disturbance of RAS/MAPK signaling leads to skeletal muscle weakness and increased 
bone resorption. Skeletal muscle weakness likely contributes to musculoskeletal anomalies. 
The authors hypothesized that increasing strength will result in improved ability to 
participate in physical activities with improvement in quality of life and that therefore 
assessments by physical and/or occupational therapy should be considered in these 
patients (14, 36, 40). 
 Taken together, our findings and discussion suggest that problems with motor 
performance in Noonan syndrome in daily life are generated by the interaction of multiple 
systems, including sensory/perceptive functioning (such as visuoperceptual functioning), 
cognitive functioning (such as attention and planning movements), the musculoskeletal 
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system (such as decreased muscle strengths and endurance, pain, and hypermobility), 
and the cardiovascular system, but also the progress of motor performance with age. 
However, the problems with motor performance do not seem to be the result of disuse or 
lack of learning experiences, because children participated in sports and physical activities 
just like their peers. Nevertheless, task-oriented intervention and physical and occupational 
therapies are found to be effective interventions for children with a developmental 
coordination disorder (41). Moreover, from our qualitative study, we learned that parents 
reported positive results from training and physiotherapy treatment (10). It is likely that 
improving motor performance, strength, and endurance through physical and/or 
occupational therapy will result in improved developmental trajectories and the ability 
to participate in physical activities, school, and work activities, with subsequent 
improvement—but no normalization—in functional activities important for quality of life. 
 This is the first study that confirms that motor performance, strength, and endurance 
are significantly impaired in children with Noonan syndrome, with an evident impact on 
functioning in daily life. Decreased functional motor performance seems to be related to 
decreased visual perception but also to reduced muscle strength. Research on causal 
relationships and the effectiveness of interventions is needed. Until then, physical and/or 
occupational therapy assessment and guidance should be considered to enhance 
participation in daily life. 
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In this thesis, we have attempted to answer several clinical questions, from the perspective 
of both doctors and patients, in order to support and improve the recognition of Noonan 
syndrome and the clinical care of people with Noonan syndrome throughout their lives. 
 On the one hand, we have introduced new knowledge with regard to the diagnostic 
process, with emphasis on clinical diagnosis and genetic findings. Based on the findings 
of our research we recommend: a. the use of the clinical diagnostic criteria in diagnosing 
Noonan syndrome, as evidenced by typical Noonan syndrome cases in which the 
underlying genetic defect has not yet been identified or in which the underlying genetic 
defect is an unusual mutation; b. the use of the electrocardiogram (ECG) pattern as a 
useful part of the clinical evaluation of subjects with suspicion of Noonan syndrome who 
have not been genotyped; c. prenatal testing of PTPN11, KRAS and RAF1 in pregnancies 
with an increased nuchal translucency and at least one other specific feature of Noonan 
syndrome. These findings support and improve the diagnostic process and recognition of 
Noonan syndrome.   
 On the other hand, we have introduced new knowledge about problems experienced 
in daily life. We concluded that growth in children with Noonan syndrome is impaired 
right from birth and only partially associated with feeding problems. With regard to these 
findings, we recommend an adequate nutritional intake as in every other child. In an 
interview about problems experienced in motor performance in daily life, people with 
Noonan syndrome reported particular problems related to pain, decreased muscle 
strength, fatigue, and clumsiness, which had an evident impact on functioning in daily life. 
Based on these findings, we tested motor performance in children. We concluded that 
motor performance, strength, and endurance are significantly impaired in children with 
Noonan syndrome, and recommend physical and/or occupational therapy in these 
children to enhance their participation in daily life. 
Diagnosing Noonan syndrome
“Phenotype-first” approach in Noonan syndrome
Prior to the identification of the first Noonan syndrome gene PTPN11 in 2001, the diagnosis 
of Noonan syndrome was solely based on clinical grounds via the observation of key 
features. Van der Burgt et al. published diagnostic criteria for Noonan syndrome in 1994 
and an update in 2007, with a scoring system to guide the diagnostic process (1). 
In subsequent years — after the identification of the PTPN11 mutations, and therefore 
during my PhD — several other germline mutations in different genes of the RAS/MAPK 
pathway have been identified as causal for Noonan syndrome. As we recommend the use 
of clinical diagnostic criteria as the basis for diagnosing Noonan syndrome, in recent years 
the clinical diagnosis of Noonan syndrome has preferably been supported by confirmation 
of a germline mutation in one of the RAS/MAPK pathway genes. 
517840-L-bw-croonen
Processed on: 6-3-2018 PDF page: 154
154
Chapter 9
“Genotype-first” approach in Noonan syndrome
By contrast, recent new technologies in genomics have been used to establish a genetic 
diagnosis, with or without a clear clinical diagnosis.  This “genotype-first” approach is a 
type of strategy used in genetic epidemiological studies to associate specific genotypes 
with apparent clinical phenotypes of a complex disease or trait. The genotyping is 
generated using next-generation sequencing technologies (including whole-genome 
sequencing and exome sequencing) and microarray analyses. As opposed to “pheno-
type-first”, this approach characterizes individuals first by a common genotype based on 
molecular tests prior to clinical phenotypic classification. This method of grouping leads 
to patient evaluations based on a shared genetic etiology for the observed phenotypes, 
regardless of their suspected diagnosis. 
 Currently, the “genotype-first” approach is used primarily for research objectives. 
However, the implications from these studies can have valuable clinical applications, 
including improved diagnosis, counseling, and support groups for individuals with the 
same genetic etiology (2, 3). The “genotype-first” approach has been used to diagnose 
patients with rare diseases (4),  to identify novel disease genotype-phenotype associations 
(5), and to characterize uncommon or heterogeneous diseases based on patient’s 
genotype (2, 6). 
Advantages  of the “Genotype-first” approach 
Possible advantages of the “genotype-first” approach are that multiple other diagnostic 
tests and examinations do not have to be performed. It is unaffected by phenotypic 
heterogeneity, incomplete penetrance and levels of expressivity. Therefore, it is also useful 
in diseases that overlap, enabling the diseases to be distinguished, and specific subtypes 
of the disease based on the genomic content to be determined. A shift towards 
characterizing individuals by a common genotype rather than by clinical presentation will 
allow the classification of new syndromes, and the genetic classification of certain disease 
subtypes/atypical presentations of disease. Last but not least, the identification of 
causative genes has the potential to identify therapeutic targets. 
Limitations of the “Genotype-first” approach 
One of the limitations of the “genotype-first” approach is that the phenotype might 
change over time (e.g. becomes more or less severe) implying that “genotype-first” studies 
make assumptions about the role of a variant in disease manifestation at a specific time 
point. Therefore, longitudinal follow up is important in order for the genotype-phenotype 
association to be evaluated over time and examine the disease prognosis. Genotype- 
phenotype association relies on the presentation of clinically recognizable phenotypes 
(2), as seen in other genome association studies. The “Genotype-first” approach, however, 
can generate variants of unknown significance (VUS). A VUS is an allele, or variant form 
of a gene, which has been identified through genetic testing, but whose significance 
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to the function or health of an organism is not known (7), especially when being used 
diagnostically (8).
“Genotype-first” versus “Phenotype-first” 
In almost 80% of the cases with clinically diagnosed Noonan syndrome a germline 
mutation in one of the known Noonan syndrome genes is found. So, in the remaining 
20% of clinically diagnosed Noonan syndrome patients, no mutation has yet been found. 
Besides their genetic heterogeneity, subjects with Noonan syndrome also have variable 
expression of the disease, with large intra- and inter-mutational variability. In addition, 
Noonan syndrome frequently shows clinical overlap with the other RASopathies, namely 
NF1, Noonan syndrome with multiple lentigines (NSML; formerly named LEOPARD 
syndrome), Costello syndrome (CS), and Cardio-facio-cutaneous (CFC) syndrome. Besides 
these well described syndromes, in recent years Noonan syndrome-like syndromes 
(syndrome with loose anagen hair and CBL-mutation associated syndrome) and NF1-like 
syndrome have also been described. Recently elucidated RASopathy genes are found to 
cause Noonan syndrome that conforms to the diagnostic criteria but also to Noonan 
syndrome-like phenotypes (9). 
 With regard to the “genotype-first” approach, RASopathies and therewith Noonan 
syndrome might be a candidate “disease” because of the known clinically and genetically 
heterogeneity. This could lead to new classified syndromes and more specific and better- 
coordinated follow-up programs. In addition, the identification of causative genes that 
underlie RASopathies could facilitate molecular diagnosis, enabling the evaluation of 
 genotype-phenotype relationships, and aid in the development of possible therapeutic 
approaches. 
 However, which clinical characteristics (phenotype) are required for starting the 
“genotype-first” approach — characteristic facies, congenital heart defects, short stature, 
skeletal abnormalities, cryptorchidism, lymphatic dysplasia OR a variable degree of 
development delay? A characteristic ECG pattern?  An increased nuchal translucency? And 
what if a mutation of a gene of the RAS/MAPK pathway has been identified in a patient 
with only a pulmonary valve stenosis — should hemostatic analysis be performed before 
a tonsillectomy occurs? The variation in clinical expression will become more hetero-
geneous. Do we still call all such presentations Noonan syndrome? Or call them in general 
RASopathy based on genetic confirmation with an additional clinical description? Another 
limitation of the “genotype-first” approach in Noonan syndrome is the generation of 
variants of unknown significance. How do we classify and follow them? And what do we 
do with those where no mutation has been found but the clinical characteristics meet 
the criteria for one or more RASopathy(s)? 
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Recommendations for the future
To find an answer to these questions, we need to know more about the clinical presentation of 
these genetically heterogeneous syndromes. Therefore, longitudinal follow up is needed 
to gain insight into these questions.  Our recommendation for future research is therefore, 
in concordance with a “phenotype-first” approach, the creation of a large database of 
clinically diagnosed RASopathies. These patients should be genotyped for known 
RASopathy genes. If no gene mutation is found in the known RASopathy genes, whole 
exome sequencing of the RAS/MAPK pathway signaling cascade should be performed to 
search for other potential genes. Second, a “genotype-first” database must be created in 
which all known RASopathy genes are included with additional data on phenotype. These 
databases might be the first step in providing some answers to the questions above. 
Best practice in the organization of care in  
Noonan syndrome
Regardless of which diagnostic approach will be preferred in the future, at this time many 
(parents of) subjects with Noonan syndrome share the experience of a time consuming 
and sometimes frustrating journey towards diagnosis.  Physicians in the Netherlands are in 
general unfamiliar with Noonan syndrome. This unfamiliarity leads to failure to recognize 
Noonan syndrome as such.
 However, even after Noonan syndrome is diagnosed, there is still a lack of knowledge 
about Noonan syndrome related problems. Because of this lack of knowledge, problems 
are not recognized as related to Noonan syndrome on the one hand, and on the other 
hand, clinicians do not know how to approach these Noonan syndrome related problems. 
Both issues lead to potential misdiagnosis and inappropriate treatment in subjects with 
Noonan syndrome. 
 In this thesis, we have focused on two problems which were frequently mentioned 
by (parents of) persons with Noonan syndrome: feeding problems and failure to thrive in 
the first year of life; and perceived problems with motor performance in daily life. These 
research results have already led to the use of handles for daily practice. However, also 
with regard to these problems, many questions still remain unanswered, e.g. what is the 
exact cause of the problems with motor performance and (how) can they be treated?
Current organization in the Netherlands
The lack of awareness of Noonan syndrome, and therewith Noonan syndrome tailored 
health services in the Netherlands, led to the establishment of the Dutch Noonan 
syndrome Foundation in 2003. This foundation was initiated by parents of children with 
Noonan syndrome. The objectives of the foundation are: to relieve social concerns of 
people with Noonan syndrome and their environment; to give information to patients, 
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family of patients as well as physicians and other possible therapists, such as physiothera-
pists, occupational therapists, dieticians et cetera; to offer peer support; and to represent 
the interests of people with Noonan syndrome. Dyscerne, a European consortium, 
developed the first management guidelines in 2010 (Noonan Syndrome Guideline 
Development Group 2010). A separate set was also published in 2010 by an American 
consortium working with the Noonan Syndrome Support Group (10). The European 
clinical management guidelines were translated into a Dutch version in 2010. However, in 
2014 a Dutch Standard of Care was composed for primary healthcare providers, and for 
(parents of) people with Noonan syndrome in 2016, initiated by the Dutch Noonan 
Syndrome Foundation (appendices). Special attention was given to early recognition and 
care-related prevention, diagnostics, and treatment including psychosocial support, and 
an individual care plan was added. However, the principles established in the Standard of 
Care are not safeguarded if the organization of health services is not appropriate to carry 
them out. 
A multidisciplinary clinic
Because of the multisystemic problems associated with it, people with Noonan syndrome 
wish for a patient-centered multidisciplinary clinic where all of the healthcare providers 
work together as one team. Team-based approaches to patient care are a relatively recent 
innovation in health care delivery.
 Research into multidisciplinary care has shown that organized, patient centered, 
multi disciplinary clinics are more patient-friendly with better outcomes than the current 
care model where patients with rare diseases see several specialists at different sites and 
on different dates (11). Van Groenendael et al. (2015) found that patients who have access 
to a highly specialized clinical service reported that their care was well organized, 
personalized, and holistic, and that shared decision making was used. Patients reported a 
high level of satisfaction with their care (11). This finding was in agreement with Wen et al. 
(2014), who found some evidence indicating that team-based care is better than usual 
care in improving patient satisfaction (12). On the other hand, evidence suggests that 
 dissatisfaction leads to decreased compliance and poor disease control (13). In line with 
these findings, treatment compliance and clinic attendance were better in the multidisci-
plinary clinic than for the usual standard of care (14). Furthermore, there was a significant 
reduction in the frequency of clinic visits and ordering of investigations after the 
establishment of a national service (11). A patient centered multidisciplinary clinic plays an 
important role as a source of knowledge to patients and healthcare providers about the 
multisystemic disease and its management. On the one hand, healthcare providers 
acquire sufficient knowledge and experience about the disease and about the 
management of the disease, and are able to share knowledge not only with other experts 
in the clinic, but also with the patients themselves (14). A patient centered multi disciplinary 
model prevents an isolated view from the perspective of single healthcare providers. 
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On the other hand, evidence also suggests that patient education empowers patients 
to self-manage and coordinate their care (15). Healthcare providers in patient centered 
multi disciplinary clinics can also convey their knowledge to local healthcare providers. 
A continuity of care between specialist centers and local healthcare providers has been 
shown to improve patient care considerably (16). The involvement of a patient organization 
is also an essential part of the success of a patient-centered multidisciplinary clinic. Patient 
organizations have a clear view on how disease-specific care should be delivered. According to 
patient organizations, rare-disease patient care should always be a patient- centered, inter-
disciplinary and holistic effort (17). In addition, a patient centered multi disciplinary clinic 
offers the opportunity on the one hand for healthcare providers to undertake research to 
improve the care of their own patients and other patients (inter)nationally, and on the 
other hand offers the opportunity for patients to participate in research. 
 Until recently, no patient-centered multidisciplinary care for people with Noonan 
syndrome was available in the Netherlands. In addition, no international studies on the 
effect of treatment in a patient-centered multidisciplinary clinic for persons with Noonan 
syndrome has been performed. 
Noonan syndrome database
As mentioned above, a patient-centered multidisciplinary clinic could meet the care 
needs of the patients with multisystemic problems. In addition, multidisciplinary follow-up 
also provides the opportunity for the collection of longitudinal data in people with 
Noonan syndrome. Registry data can be used to better define disease characteristics; to 
increase the understanding of the natural history of a disease, also with regard to geno-
type-phenotype correlations; to assess the clinical effectiveness of management and 
quality of care; to serve as an evidence base for clinical management; and to aid in the 
identification of opportunities for intervention (18). Furthermore, detailed clinical charac-
terization will allow the inclusion of patients into studies of various issues, such as geno-
type-phenotype correlations and novel treatment interventions. Finally, a registry will also 
encourage international collaborations for the benefit of patients and thereby support 
wider access to genetic testing and probably the identification of novel mutations. 
 In 2010, the European network on Noonan syndrome and related disorders 
(NSEuroNet) started its activities. The project aims to improve the knowledge about 
RASopathies at the levels of basic research as well as in practical clinical care. A RASopathy 
mutation and phenotype database was created, which is a core part of the NSEuroNet 
project. This registry is aimed at providing locus-specific mutation databases for the 
RASopathy genes in combination with standardized phenotype data including long-term 
follow-up. The ultimate goals are to clarify genotype-phenotype correlations; to detect 
rare manifestations (e.g. cancer) and possible associated risk genotypes; to improve 
counseling and individual clinical care; and to develop a platform from which clinical trials 
could be carried out. However, the data collection in this database is incomplete as yet. 
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At present, patients in our clinic and in the Netherlands are not structurally enrolled in a 
(inter)national registry. In this way, patient information will be lost and will not contribute 
to improvement of current patient care or to future research.
Future prospects
Dutch patient-centered multidisciplinary clinic 
Both on the basis of the recommendations made in the section “diagnosing Noonan 
syndrome” and on the basis of the persistent lack of awareness of Noonan syndrome 
(related problems), we believe that a Dutch patient-centered multidisciplinary clinic and 
use of a (inter)national registry are needed to optimize the care of (parents of) subjects 
with Noonan syndrome. This is motivated firstly, in order to meet the demands from the 
patients themselves; and secondly, in order to acquire knowledge using the information 
obtained. Co-operation between the specialists of the multidisciplinary clinic, healthcare 
providers of local centers, the Dutch Noonan syndrome Foundation, and basic scientists, 
but also (inter)national experts are of vital importance to achieve our goals. 
E-Health
Ideally, all of the collected information should be curated in an online Dutch network on 
Noonan syndrome, in which the data will be collected through validated and standardized 
measuring instruments. Such an online network should contain general information 
about Noonan syndrome, the Dutch standards of care for Noonan syndrome, a patient- 
centered section, a patient-forum, an anonymized national registry, information about 
research into Noonan syndrome including enrollment in studies, and a link to the Dutch 
Noonan syndrome Foundation. 
 The patient-centered section should contain the most recently updated individual 
care plan, prepared jointly by the patient and healthcare providers at their last visit, and a 
link to the multidisciplinary clinical files were patients can see the information documented 
by their healthcare providers, the results of investigations and scheduled appointments. 
Some time before the next appointment the patients should be sent an online 
questionnaire in which specific needs besides those scheduled in the individual care plan 
are inventoried. Consequently, follow-up appointments can be adjusted accordingly. This 
part should also contain a forum where patients and healthcare providers may interact 
with each other. It is the patient’s decision whether to provide access to this patient-cen-
tered part to other healthcare providers that are involved, both healthcare providers from 
the multidisciplinary clinic as well as those in local centers. These latter two may also come 
into contact with each other via the forum. Besides this forum, a general patient-forum 
should also be included where patients (and parents) of individuals with Noonan 
syndrome can meet each other. 
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The anonymized national registry should contain genotypic and phenotypic information 
of the subjects with Noonan syndrome seen at the patient-centered multidisciplinary 
clinic and must be accessible to persons associated with the Dutch network on Noonan 
syndrome. In an extension of this network, the registry could be also used for all RAS- 
opathies, to get a better view on the different phenotypes, genotypes and the relationships 
between them, which has not been possible in our studies because of the low number of 
patients in each subgroup. 
 Also, information about research into Noonan syndrome should be included. Here, 
recent research results and ongoing investigations are displayed, and ideas for future 
research can be suggested. From this input, researchers, together with clinicians and 
(parents of) subjects with Noonan syndrome, would be able to influence the direction of 
future research. 
 Finally, a link to the Dutch Noonan syndrome Foundation should be included. This is 
because the Foundation is complementary to the patient-centered multidisciplinary 
clinic, provides important input needed to improve the care of subjects with Noonan 
syndrome, and, last but not least, represents the interests of (parents of) individuals with 
Noonan syndrome. 
Successful achievements
Last year, a start was made with the development of a patient-centered multidisciplinary 
clinic at the Radboud University Nijmegen Medical Centre Amalia Children’s Hospital, 
Nijmegen. This year, the implementation of this patient-centered multidisciplinary clinic 
has begun, whereby an individual care plan will guide the follow-up of each patient. 
Based on the management guidelines developed by Dyscerne, a European consortium, 
and the Dutch Standard of Care, a protocol for follow-up (when and in which disciplines) 
was composed. From here, we want to further improve care for people with Noonan 
syndrome in the Netherlands and to make our future prospects a reality. 
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The aim of this thesis is to support and improve the recognition of Noonan syndrome and 
the clinical care of people with Noonan syndrome throughout life. The studies described 
in this thesis focus on answering clinical questions, from both a doctor’s and a patient’s 
perspective, regarding the diagnosis of Noonan syndrome and perceived problems in 
the daily lives of people with Noonan syndrome. 
 On the one hand, we introduce new knowledge with regard to the diagnostic process 
with emphasis on the clinical diagnosis and genetic findings, namely the differences in 
clinical presentation between mutation-positive (except PTPN11) and mutation-negative 
people with Noonan syndrome, the clinical diagnosis of Noonan syndrome and not 
Neuro fibromatosis type 1 (NF1) in a child with an NF1 gene mutation, a protocol for 
prenatal Noonan syndrome testing, and the role of the electrocardiogram (ECG) in the 
clinical evaluation of subjects with Noonan syndrome. These findings support and 
improve the diagnostic process and recognition of Noonan syndrome.   
 On the other hand, we investigate new knowledge on perceived problems in daily life, 
namely growth deceleration in the first year of life and its relation to feeding problems, 
perceived motor performance problems, and whether a specific profile of motor performance 
in children with Noonan syndrome can be seen. These insights support and improve the 
clinical care of people with Noonan syndrome throughout life. 
Noonan syndrome
In Chapter 1 we introduced Noonan Syndrome as a multisystem genetic disorder with 
an estimated incidence of 1 in 1.000 to 1 in 2.500 live births. Diagnosis of Noonan syndrome 
is primarily based on clinical findings. The cardinal features of Noonan syndrome are 
characteristic facies, congenital heart defects, short stature, skeletal abnormalities, 
cryptorchidism, lymphatic dysplasia, and variable degrees of development delay. In 1994, 
van der Burgt et al. developed a scoring system to diagnose Noonan syndrome based 
on the above-mentioned characteristics.
 In 2001, the first gene, PTPN11, causing Noonan syndrome was identified. The PTPN11 
gene belongs to the Ras/mitogen-activated protein kinase (MAPK) pathway. The RAS/
MAPK pathway plays an essential role in regulating the cell cycle and cellular growth, 
 differentiation, and senescence, all of which are critical to normal development. 
 Mutations in the PTPN11 gene are found in approximately 50% of patients with Noonan 
syndrome. From 2001, much research has been done to elucidate other genetic causes 
of Noonan syndrome. Germline mutations in other genes of the RAS/MAPK pathway 
involved in the pathogenesis of Noonan syndrome are found in subsequent years (KRAS, 
NRAS, BRAF, RAF, SOS1, MAP2K1, RIT1, SOS2, A2ML1, RASA2, LZTR1, and RRAS). Noonan syndrome 
is an autosomal dominant trait. Nowadays, in almost 80% of cases with clinical Noonan 
syndrome, a germline mutation in one of the above-mentioned genes is found. 
517840-L-bw-croonen
Processed on: 6-3-2018 PDF page: 166
166
Chapter 10
Besides Noonan syndrome, other syndromes are also caused by mutations in genes 
encoding proteins of the RAS/MAPK pathway, together known as RASopathies, namely 
NF1 (caused by mutations in NF1), Noonan syndrome-like syndromes (Noonan syndrome 
with loose anagen hair caused by mutations in SHOC2 and CBL-mutation-associated 
syndrome caused by mutation in CBL), Noonan syndrome with multiple lentigines (NSML; 
formerly known as LEOPARD syndrome, caused by mutations in PTPN11 and RAF1), Costello 
syndrome (CS; caused by mutations in HRAS), Cardio-facio-cutaneous (CFC) syndrome 
(caused by mutations in BRAF, MAP2K1 (MEK1), and MAP2K2 (MEK2)), and NF1-like syndrome 
(Legius syndrome; caused by mutations in SPRED1).
 
Doctor’s perspective: The diagnostic process
In Chapter 2 we presented a genotype-phenotype analysis of 33 subjects with a clinical 
diagnosis of Noonan syndrome who did not carry a PTPN11 mutation. The purpose of this 
study was to identify the disease-causing mutation in these subjects and to compare the 
phenotypic presentation of mutation-positive subjects, on the one hand with known 
cases from the literature and on the other hand, to those patients in whom no mutation 
had yet been found. The latter was to ascertain whether there were important clinical 
differences between mutation-positive and mutation-negative subjects with Noonan 
syndrome. DNA from all patients was tested by Sanger sequencing in a routine DNA 
diagnostic setting for mutations in the coding regions of the genes PTPN11, KRAS, HRAS, 
NRAS, BRAF, RAF1, SOS1, MAP2K1, MAP2K2, SHOC2, and CBL. In 14 (42%) subjects with Noonan 
syndrome, a mutation was found: 7 (21%) had a mutation in SOS1, 3 (9%) in RAF1, and 1 (3%) 
each in KRAS, MAP2K2, BRAF and SHOC2. The phenotype of these mutation-positive cases 
corresponded to that described in the literature. In the cases with a BRAF and MAP2K2 
mutation, the diagnosis Noonan syndrome was rejected in retrospect and a diagnosis of 
CFC syndrome was made. The subject with the SHOC2 mutation had features compatible 
with ‘Noonan-like syndrome with loose anagen hair’. The presence of characteristic facies, 
congenital heart defects, and/or short stature was more prevalent in the mutation-posi-
tive subjects than in the mutation-negative subjects with Noonan syndrome. However, all 
mutation-negative cases still met the clinical Noonan syndrome criteria. Based on these 
findings, we concluded that the sensitivity of the criteria of van der Burgt seemed to be 
low; however, specificity was high, which means that no subject with Noonan syndrome 
would be missed according to the criteria. This discrepancy in diagnosis will continue 
because of significant clinical overlap and a large intra- and interfamilial variability of 
expression in each of the RASopathies. In addition, since in several typical Noonan cases, 
the underlying genetic defect has not yet been identified, the involvement of novel genes 
is to be expected.
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NF1 is a well-known genetic condition in which characteristics develop over time. NF1 is 
caused by a mutation of the NF1 gene, which encodes a protein of the RAS/MAPK pathway. 
There is some overlap in the clinical features of Noonan syndrome and NF1. Subjects who 
fulfil the diagnostic criteria for NF1 and have features of Noonan syndrome are described 
in the literature as having the neurofibromatosis-Noonan syndrome (NFNS). In these 
subjects, mutations in NF1 are found. One NFNS subject has been described with both an 
NF1 and a PTPN11 gene mutation. In Chapter 3, we presented the first documented case 
of a person with an NF1 mutation who fulfils the clinical diagnostic criteria for Noonan 
syndrome and not for NF1.  
 Subjects with Noonan syndrome are most frequently diagnosed in childhood. 
However, there are prenatal characteristics that can be seen by ultrasound examination. In 
studies on prenatal testing for Noonan syndrome in fetuses with an increased nuchal 
translucency (NT) and a normal karyotype, mutations have been reported in 9%–16% of 
cases. In Chapter 4, we aimed to provide a protocol for prenatal Noonan syndrome 
testing to serve as a useful aid to facilitate parental counselling and targeted DNA testing. 
DNA of 75 fetuses with a normal karyotype and abnormal ultrasound findings was tested 
in a diagnostic setting for mutations in (a subset of) the four most commonly mutated 
Noonan syndrome genes. A de novo mutation in either PTPN11, KRAS, or RAF1 was detected 
in 13 fetuses (17.3%). Ultrasound findings were increased NT, distended jugular lymphatic 
sacs (JLS), hydrothorax, renal anomalies, polyhydramnios, cystic hygroma, cardiac 
anomalies, hydrops fetalis, and ascites. A second group, consisting of 60 other fetuses with 
sonographic abnormalities of which anonymized DNA was present, was tested for 
mutations in 10 RAS/MAPK pathway genes (PTPN11, KRAS, RAF1, SOS1, BRAF, NRAS, SHOC2, 
MAP2K1, MAP2K2, and HRAS). In this group, five possible pathogenic mutations have been 
identified (in PTPN11 (n = 2), RAF1, BRAF, and MAP2K1 (each n = 1)). We recommended 
prenatal testing of PTPN11, KRAS, and RAF1 in pregnancies with an increased NT and at least 
one of the following additional sonographic features: polyhydramnios, hydrops fetalis, 
renal anomalies, distended JLS, hydrothorax, cardiac anomalies, cystic hygroma, and 
ascites. If possible, mutation analysis of BRAF and MAP2K1 should be considered. 
 Congenital heart defects are present in more than half of all children with Noonan 
syndrome. The ECGs of subjects with Noonan syndrome frequently show a characteristic 
pattern. In Chapter 5, we quantified these characteristic ECG findings and analyzed if the 
ECG characteristics are related to the presence of a PTPN11 gene mutation or cardiac 
abnormality found by echocardiography or if they are an independent diagnostic entity 
to determine the role of ECG in the clinical evaluation of subjects with Noonan syndrome. 
In this cross-sectional study, we evaluated characteristic ECG findings and cardiac 
abnormalities in 84 subjects with Noonan syndrome. In all, 56 (67%) were positive for a 
PTPN11 mutation. The ECG showed at least one characteristic finding in 50% of cases, 
including left axis deviation in 38 (45%), small R waves in the left precordial leads in 20 
(24%) and an abnormal Q wave in 5 (6%) of the subjects with Noonan syndrome. The 
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characteristic ECG findings of subjects with Noonan syndrome were not associated with 
the presence of a PTPN11 gene mutation nor with a (specific) cardiac anomaly. We 
concluded that the ECG pattern is neither a useful tool for the phenotype characterization 
of a PTPN11 mutation nor for the presence or type of cardiac abnormality but is a useful 
part of the clinical evaluation of subjects suspected of having Noonan syndrome who 
have not been genotyped. 
Patient’s perspective: Perceived problems in daily life
Feeding problems and failure to thrive are common problems faced by parents with a 
newborn child with Noonan syndrome. At birth, weight and length are usually normal or 
slightly subnormal. However, in the first year of life, a rapid decline in growth gain is seen. 
In addition, feeding problems are present in more than 50% of infants with Noonan 
syndrome. The aim of the study presented in Chapter 6 was to explore if growth was 
decelerating in the first year of life because of feeding problems, or because of other 
Noonan syndrome-related variables. The answer may support healthcare providers and 
parents with respect to nutrition guidelines in children with Noonan syndrome in daily 
practice. A total of 52 subjects with clinically and genetically determined Noonan 
syndrome were included. The largest decline in weight and length SDS occurred in the 
first 2.5 months after birth (-1.93 and -1.15, respectively), with feeding problems causing a 
decline of 0.57 SDS in the remaining months. At the age of 1 year, children with feeding 
problems were on average 290 g lighter and 0.8 cm shorter than children without feeding 
problems. The possession of a PTPN11 mutation and a higher gestational age also 
negatively influenced weight gain, whereas children of parents with Noonan syndrome 
and those with a higher birth weight gained more weight. Growth (in length) was reduced 
by cardiac surgery and a higher gestational age but was positively influenced by birth 
length and maternal height. We concluded that growth in children with Noonan syndrome 
is impaired right from birth and only partially associated with feeding problems. In 
addition, several specific Noonan syndrome-related factors seem to influence growth in 
the first year. Regarding these findings, we recommend adequate nutritional intake as in 
every other child. 
 In daily life, many people with Noonan syndrome report motor impairments, 
decreased muscle strength, and pain in muscles and joints. Despite the frequently 
reported problems with motor performance, most people with Noonan syndrome and/
or their relatives do not feel heard and supported by healthcare professionals. In addition, 
studies from a patient’s perspective on motor performance problems in Noonan 
syndrome in daily life are lacking. The aims of the study presented in Chapter 7 were to 
provide insight into the motor performance problems people with Noonan syndrome 
and/or their relatives experienced, the major consequences they suffered, the benefits of 
517840-L-bw-croonen
Processed on: 6-3-2018 PDF page: 169
169
Summary
10
interventions they experienced, and the experiences with healthcare professionals they 
mentioned. We interviewed 10 adults with Noonan syndrome (two were joined by a 
parent) and 23 mothers (five of whom had Noonan syndrome), nine fathers (one of whom 
had Noonan syndrome), and one cousin who reported on 28 children with Noonan 
syndrome. People with Noonan syndrome reported particular problems related to pain, 
decreased muscle strength, fatigue, and clumsiness, which had an evident impact on 
functioning in daily life.  Most participants believed that problems with motor performance 
improved with exercise, appropriate physiotherapy guidance, and other supportive 
interventions. Nevertheless, people with Noonan syndrome and/or their relatives did not 
feel heard and supported, and they experienced no understanding of their problems by 
healthcare professionals. This was the first study from a patient perspective that described 
the motor performance problems in people with Noonan syndrome, the major consequences 
in daily life, the positive experiences of interventions, and the miscommunication with 
healthcare professionals. To achieve optimal support, healthcare professionals, as well as 
people with Noonan syndrome and/or their relatives, should be aware of these frequently 
presented problems with motor performance. Research on these different aspects is 
needed to better understand and support people with Noonan syndrome. 
 Despite the frequently reported problems with motor performance in daily life, 
motor performance has never been systematically investigated within a single cohort of 
children with Noonan syndrome using valid norm-referenced tests. In Chapter 8, we 
investigated whether motor performance in children with Noonan syndrome differed 
from the reference population and whether a specific profile of motor performance was 
seen. We assessed motor performance in 19 children with clinically and genetically 
diagnosed Noonan syndrome by using questionnaires and norm-referenced tests: Visual 
Motor Integration (VMI), Movement Assessment Battery for Children 2, Dutch version 
(MABC-2-NL), Concise Assessment method for Children’s Handwriting (BHK), grip strengths, 
muscle force, 6-Minute Walking Test (6MWT), and Beighton Hypermobility Score (BHS). 
More than 60% of the parents of children reported pain, decreased muscle strength, 
reduced endurance and/or clumsiness in daily functioning. The mean standard scores 
on the VMI and MABC-2-NL test items differed significantly from the reference scores 
(all P < 0.001, VMI visual perception P = 0.049). Grip strength, muscle force, and 6MWT 
walking distance were significantly lower (all P < 0.001) and the presence of generalized 
hypermobility was significantly higher (P = 0.003). Four out of ten children with Noonan 
syndrome were dysgraphic based on handwriting accuracy scores. Handwriting speed 
did not differ. All MABC-2-NL scores (except manual dexterity) correlated significantly with 
almost all muscle strength tests, VMI total score, and VMI visual perception score. The 
6MWT was only significantly correlated to grip strength. This is the first study that 
confirmed that motor performance, strength, and endurance are significantly impaired in 
children with Noonan syndrome. Decreased functional motor performance appears to be 
related to decreased visual perception but also to reduced muscle strength. Research on 
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causal relationships and the effectiveness of interventions is needed. Physical and/or 
occupational therapy guidance should be considered to enhance participation in daily life. 
Discussion and future prospects
In Chapter 9 we reflected on the results of our studies and clinical implications. With 
regard to the diagnostic process, we discussed the use of the “Genotype-first” approach 
in Noonan syndrome and made recommendations for the future. We also explained the 
current organization of care in Noonan syndrome in the Netherlands and discussed the 
use of a multidisciplinary clinic and database for subjects with Noonan syndrome. 
 In line with these items, in the future a Dutch patient-centered multidisciplinary clinic 
combined with E-Health will facilitate further the diagnostic process and items regarding 
perceived problems in daily life. 
 Last year, the development of a patient-centered multidisciplinary clinic was initiated 
at the Radboud University Nijmegen Medical Centre Amalia Children’s Hospital, Nijmegen. 
This year, the implementation of this patient-centered multidisciplinary clinic has begun, 
whereby an individual care plan will guide the follow-up of each patient. From here on, 
we want to further improve care for people with Noonan syndrome in the Netherlands 
and to make our future prospects a reality. 
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Met dit proefschrift willen we een bijdrage leveren aan het verbeteren van herkenning 
van het Noonan syndroom en aan het verbeteren van de zorg voor patiënten met het 
Noonan syndroom. De studies die beschreven worden in dit proefschrift richten zich op 
het beantwoorden van klinische vraagstukken,  zowel vanuit het perspectief van de 
dokter als van de patiënt. Het accent ligt op het verzamelen van kennis die de diagnostiek 
bij het Noonan syndroom verbetert en op het vragen van meer aandacht voor de problemen 
welke in  het dagelijks leven worden ervaren door personen met het Noonan syndroom.
 Enerzijds introduceerden we nieuwe kennis ten aanzien van het diagnostisch proces 
met de nadruk op de klinische diagnostiek en de genetische bevindingen, namelijk; de 
verschillen in klinische presentatie tussen mutatie positieve (behalve PTPN11) en mutatie 
negatieve personen met het Noonan syndroom, de klinische diagnose van Noonan 
syndroom en niet Neurofibromatosis type 1 (NF1) in een kind met een NF1-gen mutatie, 
een protocol voor prenataal onderzoek naar het Noonan syndroom, en de rol van het 
electrocardiogram (ECG) in de klinische evaluatie van personen met het Noonan 
syndroom. Deze bevindingen ondersteunen en verbeteren het diagnostisch proces en de 
herkenning van het Noonan syndroom.
 Anderzijds zochten we naar nieuwe kennis ten aanzien van de problemen welke 
worden ervaren in het dagelijks leven, namelijk; groeivertraging in het eerste levensjaar 
en de relatie met voedingsproblemen, ervaren problemen ten aanzien van motorisch 
functioneren in personen met Noonan syndroom en of er een specifiek motorisch profiel 
in kinderen met Noonan syndroom wordt gezien. Deze inzichten ondersteunen en 
verbeteren de zorg van personen met Noonan syndroom gedurende het leven.
Noonan syndroom
Noonan syndroom is een genetische aandoening welke meerdere orgaansystemen betreft, 
met een geschatte incidentie van 1 per 1.000-2.500 levendgeborenen. Voordat genetisch 
onderzoek naar Noonan syndroom beschikbaar was, werd het Noonan syndroom uitsluitend 
op basis van klinische kenmerken gesteld. De belangrijkste klinische kenmerken zijn 
 karakteristieke gelaatstrekken, aangeboren hartafwijkingen, kleine lengte, cryptor chidisme 
(niet ingedaalde testis), lymfatische afwijkingen en een variatie in ont wikkelingsniveau. 
In 1994 ontwikkelden van der Burgt et al. een scoringssysteem voor Noonan syndroom, 
welke is gebaseerd op bovengenoemde kenmerken.
 In 2001 werd het eerste gen welke Noonan syndroom veroorzaakt, PTPN11, 
 geïdentificeerd. Het PTPN11 gen is een van de genen betrokken bij de Ras/mitogen- 
activated protein kinase (MAPK) signaleringscascade. De RAS/MAPK signaleringscascade 
speelt een essentiële rol in de regulatie van celcyclus en cellulaire groei, differentiatie en 
overleving. Dit alles is van belang voor een normale overleving van de cel en daarmee 
ontwikkeling. Mutaties in het PTPN11 gen worden in ongeveer 50% van de personen met 
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Noonan syndroom gevonden. Sinds 2001 zijn er naast het PTPN11 gen andere genen van 
de RAS/MAPK signaleringscascade gevonden welke betrokken zijn bij de pathogenese 
van Noonan syndroom (KRAS, NRAS, BRAF, RAF1, SOS1, MAP2K1, RIT1, SOS2, A2ML1, RASA2, 
LZTR1 en RRAS). Overerving volgt een autosomaal dominant patroon, hetgeen inhoudt 
dat zowel mannen als vrouwen ontvankelijk zijn en dat een kind van iemand met Noonan 
syndroom 50% kans heeft om de aandoening ook te hebben. In bijna 80% van de 
patiënten met klinische kenmerken van Noonan syndroom kan via moleculaire diagnostiek 
een genafwijking worden gevonden.
 Naast het Noonan syndroom zijn er ook andere syndromen welke worden veroorzaakt 
door mutaties in genen betrokken bij de RAS/MAPK signaleringscascade. Deze staan 
bekend als RASopathiën, te weten:
 NF1 (veroorzaakt door mutaties in NF1), Noonan syndroom-achtige syndromen 
(Noonan syndroom met loose anagen hair veroorzaakt door mutaties in SHOC2, en CBL- 
mutatie geassocieerd syndroom veroorzaakt door mutaties in  CBL), Noonan syndroom 
met meerdere pigmentvlekken, ook wel lentigines genoemd (NSML, eerder bekend als 
LEOPARD syndroom; veroorzaakt door mutaties in PTPN11 en RAF1), Costello syndroom 
(CS; veroorzaakt door mutaties in HRAS), Cardio-facio-cutaan (CFC) syndroom (veroorzaakt 
door mutaties in BRAF, MAP2K1 (MEK1) en MAP2K2 (MEK2)), en NF1-achtig syndroom (Legius 
syndroom; veroorzaakt door mutaties in SPRED1).
Dokter-perspectief: Het diagnostisch proces
In hoofdstuk 2 wordt een genotype-fenotype studie beschreven waarbij 33 kinderen 
met een klinische diagnose Noonan syndroom zonder een mutatie in het PTPN11 gen 
werden geanalyseerd. Het doel van de studie was enerzijds om de ziekte veroorzakende 
mutaties in deze patiëntengroep te vinden en anderzijds om het fenotype van mutatie- 
positieve personen te vergelijken met de huidige literatuur alsook met de mutatie- 
negatieve personen. Dit laatste om te bepalen of er een evident verschil in fenotype is 
tussen mutatie-positieve en mutatie-negatieve personen met Noonan syndroom. DNA 
van alle personen werd middels Sanger sequencing getest voor mutaties in de coderende 
gebieden van de volgende genen: PTPN11, KRAS, HRAS, NRAS, BRAF, RAF1, SOS1, MAP2K1, 
MAP2K2, SHOC2, en CBL. In 14 (42%) personen werd een mutatie gevonden: 7 (21%) 
personen hadden een SOS1 mutatie, 3 (9%) personen een RAF1 mutatie en in 4 personen 
werd een enkele mutatie (3%) gevonden, te weten in KRAS, MAP2K2, BRAF en SHOC2. 
Het fenotype van deze mutatie-positieve personen kwam overeen met dat beschreven in 
de literatuur. Bij personen met de BRAF en de MAP2K2 mutatie werd retrospectief de 
diagnose Noonan syndroom verworpen en de diagnose CFC gesteld. De persoon met de 
SHOC2 mutatie had kenmerken overeenkomend met de diagnose ‘Noonan-achtig 
syndroom met loose anagen hair’. De aanwezigheid van een karakteristiek gelaat, een 
congenitale hartafwijking en/of korte lengte was meer voorkomend in de mutatie- 
positieve personen dan in de mutatie-negatieve personen. Echter, alle mutatie-negatieve 
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personen voldeden aan de diagnostische criteria voor het Noonan syndroom. Gebaseerd 
op deze bevindingen achten wij de sensitiviteit van de criteria van van der Burgt als laag, 
maar de specificiteit hoog, wat betekent dat middels deze criteria de diagnose Noonan 
syndroom niet wordt gemist. Gezien de significante overlap alsook de grote variabiliteit 
binnen en tussen families in expressie van de verschillende RASopathiën, blijft de diagno-
sestelling echter uitdagend. Aangezien in enkele personen met typisch Noonan syndroom 
nog geen mutatie is gevonden, is de verwachting dat er in de toekomst nog nieuwe 
genen zullen worden ontdekt.
 NF1 is een genetische aandoening waarbij karakteristieke klinische kenmerken zich 
in de loop van tijd ontwikkelen. NF1 wordt veroorzaakt door een mutatie in het NF1 gen, 
welke codeert voor een eiwit van de RAS/MAPK signaleringscascade. Er is enige overlap 
tussen de klinische kenmerken van Noonan syndroom en NF1. In de literatuur worden 
personen welke voldoen aan de criteria voor NF1 en kenmerken hebben van Noonan 
syndroom beschreven als Neurofibromatosis-Noonan syndroom (NFNS). Bij deze 
personen werden mutaties in het NF1 gen gevonden. Er is 1 NFNS persoon beschreven 
welke zowel een NF1 als een PTPN11 mutatie heeft. In hoofdstuk 3 presenteerden we de 
eerst gedocumenteerde casus van een persoon met een NF1 mutatie welke wel voldeed 
aan de diagnostische criteria van Noonan syndroom maar niet aan de diagnostische 
criteria van NF1.
 De diagnose Noonan syndroom wordt veelal tijdens de kinderjaren gesteld. Echter, er 
zijn ook prenatale afwijkingen welke kunnen wijzen op Noonan syndroom. In studies over 
prenataal onderzoek bij Noonan syndroom werd in 9-16% van de foetussen met een 
verdikte nekplooi en een normaal karyogram een mutatie gevonden duidend op het 
bestaan van Noonan syndroom. In hoofdstuk 4 hebben we een voorstel gedaan ten 
aanzien van prenataal onderzoek bij vermoeden op Noonan syndroom. DNA van 75 
foetussen met een normaal karyogram maar abnormale echografische bevindingen werd 
getest op mutaties in (een deel van) de vier meest voorkomende gemuteerde genen bij 
het Noonan syndroom. In 13 (17.3%) foetussen werd een de novo mutatie in PTPN11, KRAS 
of RAF1 gevonden. De echografische afwijkingen welke werden gevonden waren een 
verdikte nekplooi, gezwollen jugulaire lymfatische zakken, hydrothorax, nierafwijkingen, 
polyhydramnion, cysteuze hygroma, hartafwijkingen, hydrops foetalis en ascites. Een 
tweede onderzoeksgroep, bestaande uit 60 andere foetussen met echografische 
afwijkingen waarvan geanonimiseerd DNA beschikbaar was, werd getest op 10 genen 
betrokken bij de RAS/MAPK signaleringscascade (PTPN11, KRAS, RAF1, SOS1, BRAF, NRAS, 
SHOC2, MAP2K1, MAP2K2 en HRAS). In deze groep werden vijf mogelijke pathogene 
mutaties gevonden (PTPN11 (n=2), RAF1, BRAF en MAP2K1 (elk n=1)). Op basis van deze 
bevindingen adviseerden wij prenataal onderzoek te verrichten naar mutaties in het 
PTPN11, KRAS en RAF1 gen indien bij echografie tijdens de zwangerschap een verdikte 
nekplooi en tenminste 1 van de volgende kenmerken wordt gezien: polyhydramnion, 
hydrops foetalis, nierafwijkingen, gezwollen jugulaire lymfatische zakken, hydrothorax, 
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hartafwijkingen, cysteuze hygroma en ascites. Mutatie analyse van BRAF en MAP2K1 kan 
worden overwogen.
 In meer dan de helft van de kinderen met Noonan syndroom is sprake van een 
aangeboren hartafwijking. Daarnaast toont het ECG bij personen met Noonan syndroom 
vaak een kenmerkend patroon. In hoofdstuk 5 kwantificeerden wij deze kenmerkende 
ECG bevindingen en analyseerden we of de ECG afwijkingen gerelateerd zijn aan de 
aanwezigheid van een PTPN11 mutatie, aan de aanwezigheid van een hartafwijking of een 
onafhankelijke diagnostische entiteit zijn. Dit alles om de rol van het ECG in de klinische 
evaluatie van personen met Noonan syndroom te bepalen. We evalueerden de 
kenmerkende ECG bevindingen en hartafwijkingen bij 84 personen met het Noonan 
syndroom, waarvan 56 (67%) personen een PTPN11 mutatie hadden. Het ECG toonde 
tenminste 1 kenmerkende bevinding bij 50% van de personen met Noonan syndroom. 
De afwijkingen bestonden uit linker as deviatie (n=38; 45%), kleine R golf links precordiaal 
(n=20; 24%) en een afwijkende Q golf (n=5; 6%). De kenmerkende ECG bevindingen waren 
niet geassocieerd met de aanwezigheid van een PTPN11 mutatie of met de aanwezigheid 
van een (specifieke) hartafwijking. We concludeerden dan ook dat het ECG een bruikbaar 
hulpmiddel is in de klinische evaluatie van personen met verdenking op Noonan 
syndroom zonder een aangetoonde mutatie.
Patiënt-perspectief: Ervaren problemen in het dagelijks leven
Veel ouders van pasgeborenen met Noonan syndroom ervaren problemen ten aanzien 
van voeding en groei. Bij de geboorte is er veelal sprake van een (laag) normaal gewicht 
en lengte. Echter, in het eerste levensjaar wordt vaak een afbuiging van de groei gezien. 
Ook worden voedingsproblemen bij meer dan 50% van de zuigelingen met Noonan 
syndroom gemeld. Het doel van de studie gepresenteerd in hoofdstuk 6 was om te 
onderzoeken of de afbuigende groei in het eerste levensjaar gerelateerd is aan voedings-
problemen of aan andere Noonan syndroom gerelateerde factoren. Het antwoord hierop 
kan zorgverleners en ouders ondersteuning bieden ten aanzien van voedingsrichtlijnen 
bij kinderen met Noonan syndroom. Totaal werden 52 kinderen met een genetische en 
klinische diagnose van Noonan syndroom geïncludeerd. De grootste daling in gewicht en 
lengte SDS was te zien in de eerste 2.5 maanden na de geboorte (-1.93 en -1.15, respectie-
velijk), waarbij voedingsproblemen zorgden voor een daling van 0.57 SDS in de overige 
maanden. Op de leeftijd van 1 jaar waren kinderen met voedingsproblemen gemiddeld 
290 gram lichter en 0.8 cm korter dan kinderen zonder voedingsproblemen. Gewichts-
toename werd ook negatief beïnvloed door de aanwezigheid van een PTPN11 mutatie en 
door een langere zwangerschapsduur, terwijl kinderen van ouders met Noonan syndroom 
en kinderen met een hoger geboorte gewicht meer gewichtstoename lieten zien. 
Lengtegroei werd negatief beïnvloed door een langere zwangerschapsduur en door een 
doorgemaakte hartoperatie in het eerste jaar, maar positief beïnvloed door geboortelengte 
en lengte van de moeder. We concludeerden dat kinderen met Noonan syndroom direct 
517840-L-bw-croonen
Processed on: 6-3-2018 PDF page: 179
179
Nederlandse samenvatting
na de geboorte een afbuigende groei laten zien welke slechts gedeeltelijk is geassocieerd 
met voedingsproblemen. Andere Noonan syndroom gerelateerde factoren lijken deze 
groei in het eerste jaar ook te beïnvloeden. Gezien deze bevindingen bevelen we een 
adequate voedingsintake aan zoals bij elk ander kind.
 Veel personen met het Noonan syndroom ervaren in het dagelijks leven problemen 
ten aanzien van motorisch functioneren, spierkracht en pijn in spieren en gewrichten. 
Ondanks de frequent gerapporteerde klachten voelt een meerderheid van de personen 
met Noonan syndroom en/of verzorgers zich niet gehoord en gesteund door zorg- 
verleners. Studies vanuit een patiënten-perspectief over het dagelijks motorisch 
functioneren bij Noonan syndroom ontbreken. Het doel van de studie gepresenteerd in 
hoofdstuk 7 was inzicht te verkrijgen in de problemen welke personen met Noonan 
syndroom en/of verzorgers ervaren ten aanzien motorisch functioneren in het dagelijks 
leven, de gevolgen die hiervan worden ondervonden, het effect van interventies en de 
ervaring met zorgverleners. Er werden 10 volwassenen met Noonan syndroom (2 vergezeld 
door een ouder), en 23 moeders (5 met Noonan syndroom), 9 vaders (1 met Noonan 
syndroom) en 1 neef geïnterviewd die informatie verstrekten over totaal 28 kinderen 
met Noonan syndroom. In deze interviews kwamen met name problemen gerelateerd 
aan pijn, verminderde spierkracht, vermoeidheid en onhandigheid naar voren. Deze 
problemen hadden een duidelijke impact op het functioneren in het dagelijks leven. 
De meeste deelnemers waren van mening dat de problemen in het motorisch 
functioneren verbeterden door training, gerichte fysiotherapeutische begeleiding en 
andere ondersteunende interventies. Echter, personen met Noonan syndroom en/of hun 
verzorgers voelden zich vaak niet gehoord en gesteund door zorgverleners. Daarnaast 
werden gemelde problemen vaak niet begrepen. Dit was de eerste studie welke beschrijft 
wat de motorische problemen in het dagelijks leven zijn en welke gevolgen hiervan 
worden ondervonden, dat er een positief effect is van ingestelde interventies en welke 
ingaat op de miscommunicatie met zorgverleners vanuit een patiënten-perspectief. 
Zowel zorgverleners als personen met Noonan syndroom en/of hun verzorgers moeten 
zich bewust zijn van de frequent voorkomende problemen in motorisch functioneren om een 
optimale ondersteuning te kunnen bereiken. Onderzoek van deze verschillende aspecten is 
nodig om personen met Noonan syndroom beter te begrijpen en te ondersteunen.
 Ondanks de frequent gerapporteerde problemen in het dagelijks motorisch functioneren 
is het profiel van motorisch functioneren bij kinderen met Noonan syndroom nooit 
systematisch onderzocht in één en hetzelfde cohort middels gevalideerde tests. 
In hoofdstuk 8 onderzochten we of kinderen met Noonan syndroom een andere 
motorische functie hebben dan de referentie populatie en of er een specifiek profiel van 
motorisch functioneren bestaat. 19 kinderen met een klinische en genetische diagnose 
van Noonan syndroom werden beoordeeld middels vragenlijsten en gevalideerde tests: 
Visuele Motorische Integratie (VMI),  Movement Assessment Battery for Children 2, 
Nederlandse versie (MABC-2-NL), Beknopte Beoordelingsmethode voor Kinderhandschriften 
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(BHK), knijpkracht, spierkracht, 6 Minuten Wandel Test (6MWT) en de Beighton Hyper-
mobiliteit Score (BHS). Meer dan 60% van de kinderen met Noonan syndroom ervaarden 
klachten van pijn, verminderde spierkracht, verminderde conditie en/of onhandigheid in 
het dagelijks functioneren. De gemiddelde standaard scores op de verschillende VMI en 
MABC-2-NL test items verschilden significant van de referentie score (allen P < 0.001, 
behoudens VMI visuele perceptie P = 0.049). Knijpkracht, spierkracht en 6MWT loopafstand 
waren significant lager (allen P < 0.001) en aanwezigheid van gegeneraliseerde hyper-
mobiliteit was significant hoger (P = 0.003) bij de kinderen met Noonan syndroom 
vergeleken met de referentie populatie. Vier van de tien kinderen waren dysgrafisch, 
maar de snelheid van het schrijven was niet verschillend ten opzichte van de referentie 
populatie. Alle MABC-2-NL scores (behalve handvaardigheid) waren significant gecorreleerd 
met bijna alle spierkrachttesten, VMI totaal score en VMI visuele perceptie score. De 6MWT 
was alleen significant gerelateerd aan knijpkracht. Dit was de eerste studie die bevestigde 
dat motorisch functioneren significant afwijkend is bij kinderen met Noonan syndroom. 
Een verminderd motorisch functioneren lijkt gerelateerd te zijn aan verminderde visuele 
perceptie, maar ook aan verminderde spierkracht. Onderzoek naar causale relaties en 
effectiviteit van interventies is nodig. Tot die tijd moeten fysiotherapie en/of ergotherapie 
als screening en begeleiding worden overwogen om ondersteuning te bieden in het 
dagelijks functioneren.
Discussie en toekomstige perspectieven 
In hoofdstuk 9 reflecteerden we op de resultaten van onze studies en de klinische 
implicaties. Ten aanzien van het diagnostisch proces bediscussieerden we het gebruik van 
de “Genotype-first” benadering in Noonan syndroom en maakten we aanbevelingen 
voor de toekomst. Daarnaast bespraken we de huidige organisatie van de zorg voor 
Noonan syndroom patiënten in Nederland. We bediscussieerden het gebruik van een 
multidisciplinaire kliniek en database voor personen met Noonan syndroom. 
 Ten aanzien van deze items zal in de toekomst een Nederlands patiëntgecentreerde 
multidisciplinaire kliniek, gecombineerd met E-health, faciliteren in het toekomstige 
diagnostische proces en in het vinden van antwoorden op vraagstukken ten aanzien van 
problemen welke in  het dagelijks leven worden ervaren. 
 In 2016 is een start gemaakt met de ontwikkeling van een patiëntgecentreerde multi-
disciplinaire kliniek in het Radboud Universitair Medisch Centrum Amalia kinderziekenhuis 
te Nijmegen. In 2017 is gestart met de implementatie van deze patiëntgecentreerde 
multi disciplinaire kliniek, waarbij een individueel zorgplan de follow-up van elke patiënt 
zal leiden. Vanaf dit punt willen we de zorg voor personen met Noonan syndroom in 
Nederland verder verbeteren en onze toekomstperspectieven realiseren. 
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Wat een bijzonder moment is dit. Het schrijven van het dankwoord. De echte laatste 
loodjes van een lange reis naar dit proefschrift! En die lange reis heb ik gelukkig niet alleen 
gemaakt, maar met veel mensen om me heen die me bleven motiveren, inspireren en me 
door dik en dun hebben gesteund! Ik wil iedereen hiervoor hartelijk bedanken; een aantal 
mensen in het bijzonder.
Mijn eerste woorden van dank gaan uit naar het bestuur en leden van de Stichting Noonan 
syndroom én de personen met Noonan syndroom en hun ouders die aan de beschreven 
onderzoeken hebben meegewerkt. Ik wil jullie danken voor de manier waarop jullie mij 
kennis hebben laten maken met Noonan syndroom. De aanwezigheid op jullie jaarlijkse 
familiedagen en contactdagen heeft mijn kennis over het Noonan syndroom enorm 
verrijkt. Ik heb meer dan bewondering voor jullie motivatie en passie waarmee jullie de 
kennis over Noonan syndroom willen vergroten. Dank voor jullie bijdrage en het in mij 
gestelde vertrouwen. Onze kennismaking en hetgeen ik van jullie heb geleerd, heeft mij 
gevormd tot de arts die ik nu ben.
En dan met wie het allemaal begon. Beste dr. J.M.Th. Draaisma, beste Jos. Bedankt voor 
jouw onvoorwaardelijke steun vanaf dag één. Ik maakte kennis met je via mijn weten-
schappelijke stage in 2006. Deze stage leidde tot mijn eerste publicatie over Noonan 
syndroom. Door jouw enthousiasme werd een in de basis klinische dokter geïnteresseerd 
in het doen van wetenschappelijk onderzoek. En zo volgden jaren waarin nieuwe artikelen 
omtrent Noonan syndroom werden gepubliceerd, waarbij het gaandeweg een promotie-
traject werd. Dankzij jou. Jij wist mij telkens te enthousiasmeren en de juiste mensen 
op deze weg te betrekken om tot het proefschrift te komen zoals deze nu is. De titel 
van promotor had je dan ook meer dan verdiend! Naast copromotor ben je ook erg 
belangrijk voor me geweest als opleider kindergeneeskunde. Een opleider waar elk 
ander cluster jaloers op was en die me heeft gevormd tot de kinderarts die ik nu ben. 
Dank Jos!
Daarnaast wil ik mijn andere copromotor bedanken. Beste Dr. I. van der Burgt, beste Ineke. 
Samen met Jos heb jij een hele belangrijke rol gespeeld in de totstandkoming van dit 
proefschrift. Via Jos kwam ik vanaf het eerste onderzoek in contact met jou. Jij liet me voor 
het eerst kennismaken met een kind met Noonan syndroom. Een waardevolle ontmoeting. 
Ook jij hebt mij onvoorwaardelijk gesteund en wist altijd tijd voor me vrij te maken. 
Niet alleen voor onderzoek gerelateerde gesprekken, maar ook voor luchtige gesprekken 
over onze families en hobby’s. Met altijd wel een beschikbare werkplek was jouw afdeling 
een heerlijk thuis om stapels artikelen uit te printen en te lezen, om statussen door te 
spitten en om te schrijven, schrijven en nog eens te schrijven. Gelukkig heb ik snel genoeg 
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geschreven om mijn proefschrift af te hebben voordat je met pensioen gaat. Ga genieten 
van de tijd die komen gaat. Dank voor de fijne samenwerking die we hebben gehad! 
Beste Prof. dr. K. Noordam, beste Kees. Bedankt voor je rustige aanwezigheid, eeuwige 
vriendelijkheid, nuchtere adviezen, humorvolle inbreng en kort maar krachtige gesprekken. 
‘Ons’ artikel heeft een erg lange bevalling gekend, maar met alle inspanningen en geduld is 
het toch gelukt haar op deze wereld te zetten! Dank voor al je tijd die jou heel kostbaar was!
Beste Prof. dr. R. Nijhuis – van der Sanden, beste Ria. Bedankt voor je kritische en toegewijde 
inbreng bij de onderzoeken die we samen hebben gedaan. Ondanks je dramatische 
agenda wist ook jij altijd tijd voor me vrij te maken. Onze gesprekken leidden vaak 
tot alleen maar tot meer werk door jouw onuitputtelijke enthousiasme en nieuwe 
ideeën..., maar ik heb er enorm veel van geleerd. Dank daarvoor! Ook bedankt voor 
de mooie cadeautjes die je me stuurde bij de geboorte van mijn mannen. Dat heb ik erg 
gewaardeerd!
Jos, Ineke, Kees en Ria. Jullie hebben alle vier een enorm belangrijke bijdrage geleverd aan 
het succesvol afronden van dit proefschrift. Met jullie hulp is het iets geworden waar ik 
trots op ben! Enorm bedankt! 
En o ja…Jos, Ineke en Kees, sorry dat ik twee afspraken ben vergeten. Ik had er zelf wel 
‘goede’ verklaringen voor (de eerste keer was ik jarig en op vakantie in Oostenrijk en de 
tweede keer was de afspraak gewoon te vroeg, waardoor hij buiten de weergave van mijn 
agenda viel). Gelukkig heb ik me niet driemaal aan dezelfde steen gestoten.
Beste dr. L. Kapusta, beste Livia. Bedankt voor het mede beoordelen van de ECG’s tijdens 
mijn wetenschappelijk stage. Leuk je vorig jaar in de wandelgangen nog te zijn tegen 
gekomen!
Beste dr. Ir. N. Roeleveld, beste Nel. Dank voor al je inspanningen bij de statistische analyses 
van mijn langst verwachte artikel. Het heeft even geduurd, maar het resultaat mag er 
wezen!
Beste Marlou Essink. Bedankt voor al je hulp omtrent de onderzoeken naar het motorisch 
functioneren van personen, en in het bijzonder kinderen, met Noonan syndroom. Het 
contact dat we hadden was altijd fijn en laagdrempelig. Ik heb erg veel van je geleerd. 
Bedankt voor de fijne samenwerking!
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Beste Maaike Pelsma. Bedankt voor je inzet bij de onderzoeken naar het motorisch 
functioneren bij kinderen met Noonan syndroom. Ik heb veel aan je gedacht… Wat fijn je 
laatst weer te hebben gezien!
Beste Miriam Harmsen. Van jou heb ik geleerd hoe een kwalitatief focus groep interview 
opgezet en geanalyseerd moet worden. Dank voor je enorme inzet om dit onderzoek tot 
een mooi artikel te maken!
Beste dr. H. Yntema, beste Helger. Dank voor de sequentieanalyses die je hebt verricht van 
de Noonan genen voor ons onderzoek naar de prenatale afwijkingen bij Noonan 
syndroom. Met jou als onderzoeksbegeleider hebben we een heel mooi artikel weten te 
publiceren! De afspraken met jou waren altijd erg leerzaam. Zo leerde je me meer omtrent 
de genetisch diagnostische mogelijkheden. Naast onderzoek gerelateerde gesprekken 
konden we ook over alledaagse dingen kletsen en was onze reis ‘even op en neer’ naar 
een RASopathie meeting in Neurenberg naast leerzaam ook erg gezellig!
Beste mw. ing. W. Nillesen, beste Willy. Ook jou wil ik bedanken voor het uitvoeren van de 
sequentieanalyses van de Noonan syndroom genen. Ondanks dat we niet intensief 
hebben samengewerkt heb ik nog steeds een fijn contact met je. Met regelmaat kom ik je 
tegen in het trappenhuis, waar we dan vluchtig een gezellig praatje maken. 
Ik dank de leden van de manuscriptcommissie, Prof. dr. A.R.M.M. Hermus, Dr. C.M. Verhaak 
en Prof. dr. V.V.A. Knoers, voor het kritisch lezen en beoordelen van het manuscript en het 
deelnemen aan de oppositie.
Daarnaast ben ik veel dank verschuldigd aan alle secretariaten die mij op welke wijze dan 
ook hebben geholpen. Het secretariaat kindergeneeskunde en secretariaat IQ Healthcare 
voor het plannen van de onmogelijke afspraken met de (co)promotoren. Het secretariaat 
klinische genetica voor alle hulp bij het opsporen van verdwenen statussen, het bieden 
van een fijne werkplek en de gezellige gesprekken. Het secretariaat fysiotherapie voor het 
zorg dragen voor het versturen van de uitnodigingsbrieven en voor het inplannen van de 
kinderen voor de motorische tests.  
Dank aan alle oud arts-assistenten kindergeneeskunde van het CWZ, waar ik voor het 
eerst werkzaam was als arts-assistent. Bedankt voor jullie onvoorwaardelijke steun tijdens 
mijn onderzoeksperiode, maar bovenal voor de fijne jaren die we samen hebben gehad 
en de vriendschap die we nog steeds delen. Marieke, Anne en Anneke, jullie zie ik minder 
vaak dan de andere dames, maar elke ontmoeting voelt weer vertrouwd en als vanouds. 
Marije en Hylke, dank voor de fijne CWZ tijd, maar met name ook voor jullie steun tijdens 
mijn verdere opleiding tot kinderarts en nu kinderlongarts in het Amalia kinderziekenhuis. 
517840-L-bw-croonen
Processed on: 6-3-2018 PDF page: 186
186
Addendum
Jullie aanwezigheid voelt als vertrouwd en we weten elkaar dan ook nog steeds te vinden 
als we elkaar nodig hebben. Of gewoon voor een gezellig kopje thee. Kim, dank voor alle 
bijzondere momenten die we samen hebben gedeeld en de adviezen die je me hebt 
gegeven. Mede dankzij jou sta ik waar ik nu sta. Marlijn, mijn vriendschap met jou is er één 
uit duizenden. Ondanks dat we ieder onze eigen weg zijn ingeslagen, hebben we elkaar 
nooit uit het oog verloren. Integendeel, sinds we zelf kinderen hebben is onze vriendschap 
alleen maar sterker geworden. Ik ben je dan ook dankbaar dat je vandaag als paranimf 
aan mijn zijde staat!
Daarnaast dank ik ook alle (oud) arts-assistenten van het Amalia kinderziekenhuis voor de 
fijne opleidingstijd die ik heb gehad. In het bijzonder dank ik Rosa, Lara en Imke. Rosa, 
bedankt voor je gezelligheid als kamergenoot en je nuttige adviezen tijdens mijn onder-
zoeksstage. Ik heb veel van je nuchtere blik geleerd. Lara, bedankt voor je luisterende oor 
als pulmo-collega. Imke, we zijn samen aangenomen voor de opleiding kindergenees-
kunde. Bij onze gezamenlijke start in het Amalia kinderziekenhuis op 1 januari 2012 zijn 
we echte maatjes geworden. Bedankt voor al je steun gedurende de opleiding en mijn 
 onderzoeksperiode. Jouw nuchtere blik als echte klinische dokter heeft me vaak doen 
relativeren. En mocht er dan toch nog ooit een moment komen dat we het niet meer zien 
zitten, dan gaan we alsnog worsten verkopen bij de HEMA. 
In het bijzonder wil ik mijn naaste collega’s van de kinderlongziekten bedanken voor het 
in mij gestelde vertrouwen en de fijne opleidingsplek welke jullie mij bieden. Peter en Jolt, 
fijnere naaste collega’s kan ik me werkelijk niet wensen. Wat voel ik me thuis bij jullie. 
Dank dat jullie mij de ruimte hebben gegeven dit proefschrift af te ronden, inclusief 
nuttige adviezen. Coosje, wat ben jij een bijzonder mens. Dank voor je altijd luisterende 
oor. Ik kan alles met je delen, zowel een lach als een traan. Marian, wat ben je toch een 
heerlijk mens. Soms lekker chaotisch, maar bovenal erg gezellig. Peter en Marianne, 
bedankt voor de opleidingsplek welke jullie mij in het CWZ bieden en de kennis die 
jullie met mij delen. Ik voel me een gewaardeerd collega. Petra, bedankt voor de fijne 
samenwerking die we hebben. Cindy, Marijke, Imke en Sonja, bedankt voor het leerzame 
jaar kinderlongziekten op Dekkerswald en de tijd die ik ook bij jullie aan de afronding 
van mijn proefschrift kon besteden. Werken op de dinsdag was werkelijk een feest. 
Maar wat wil je met zo’n lieve Jolanda die er echt alles aan doet om je thuis te laten voelen. 
Bedankt voor alle theetjes en koekjes die je me hebt gebracht en het helpen bij de 
allerlaatste loodjes voor mijn promotie. 
Naast bovengenoemde collega’s wil ik ook alle collega kinderartsen, A(N)IOS, specialisten, 
teamleiders, verpleegkundigen en polikliniek medewerkers van het Amalia Kinderziekenhuis en 
het CWZ danken voor de steun tijdens mijn onderzoeksperiode en de fijne samenwerking. 
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Lieve familie en vrienden. Ik wil jullie danken voor alles wat jullie voor mij betekenen en de 
rol die jullie direct of indirect hebben gehad bij het tot stand komen van dit proefschrift. 
Ook al was het soms lastig te begrijpen wat ik nu precies deed, ik heb me telkens begrepen 
en gesteund gevoeld. 
Mijn lieve basisschool vriendinnetjes, Noortje, Mandy en Sanne. Wat is het bijzonder al 
dertig jaar vriendschap met jullie te mogen delen. Bedankt voor de onvoorwaardelijke 
liefde, ook als ik weer eens geen tijd had. Lieve middelbare school vriendinnetjes, Marloes, 
Ankie, Sabine en Sanne. Dank dat jullie er altijd voor mij zijn. Sanne, dank voor het kritisch 
lezen van de Nederlandse teksten. Sabine, dank voor het kritisch lezen van de Engelse 
samenvatting. En dan nog de andere vriendjes en vriendinnetjes. Bij jullie hoef ik even 
nergens aan te denken. Geen werk, geen onderzoek, gewoon heerlijk kletsen, buurten 
met de kinderen en gezellig jaarlijks een weekendje weg! 
Beste pedel mw. N. Lepoutre-Föllings, lieve tante Nolda. Wat een eer om jou als pedel te 
hebben. Bedankt voor alle adviezen die je me hebt gegeven en de druk die je hebt 
opgevoerd. Vóór je pensioen moest ik gepromoveerd zijn... En dan is het moment eindelijk 
daar. Hora est voor ons allebei!
Lieve Jeanne en Tiny, Gerard en Carla, Marion, Fenne en Dimm. Met jullie heb ik er een 
geweldige familie bij gekregen. Jeanne en Tiny, jullie zijn voor mij een tweede thuis. 
Ook al hebben jullie je nooit inhoudelijk bezig gehouden met mijn onderzoek, ik heb 
me altijd enorm gesteund en gewaardeerd gevoeld. Dank daarvoor!
Lieve Janneke, wat ben ik trots dat jij mijn zus bent. Wat jou typeert? ‘Wat ze in de kop 
heeft, heeft ze niet in haar kont’. Je gaat regelrecht op je doel af en hebt hiermee weten 
te bereiken waar je nu staat. Jouw zijn heeft ook mij gevormd. Onze hechte band is mij 
enorm dierbaar. Ik ben dan ook supertrots dat je vandaag als paranimf aan mijn zijde staat! 
Paul, zwager, met jou heb ik er niet alleen een zwager bij, maar ook een broer. Je bent 
een familiemens en een enorme goedzak. Dank voor jullie twee koters, Elsje en Wimke. 
Een trotsere tante bestaat er niet!
Lieve papa en mama. De allermeeste dank ben ik aan jullie verschuldigd. Jullie hebben 
werkelijk alles mogelijk gemaakt wat ik heb bereikt. Dankzij jullie heb ik een geweldige 
jeugd gehad, heb ik kunnen studeren en sta ik waar ik nu sta. Dank voor al de kansen die 
jullie me hebben gegeven, jullie warmte en trots die ik altijd heb gevoeld, en het feit dat 
jullie er altijd voor mij zijn, dag en nacht!
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En dan het beste voor het laatst bewaard. Mijn drie mannen. Lieve Martijn, jou ontmoeten 
is het beste wat me is overkomen. Je bent mijn steun en toeverlaat. Bedankt voor je 
eeuwige geduld, het accepteren van de ongezellige avonden achter mijn laptop, 
de frustraties die je hebt aangehoord, de adviezen die je hebt gegeven en de heerlijke 
chocolade voor bij de thee. Bedankt voor het levensgeluk dat je me geeft en onze twee 
mannen die je me hebt gegeven! Hoe trots kan een moeder zijn. Hopelijk is er nu iets 
meer tijd om lekker met z’n vieren te genieten en te blijven dromen van onze wereldreis. 
Lieve Geert, jouw komst maakte mij een enorm trotse mama en heeft me leren relativeren. 
Er is inderdaad echt iets veel belangrijker dan werk en onderzoek! Wat geniet ik elke dag 
van je. Jouw opgewektheid, energie, humor, maar ook koppigheid maakt van elke dag 
weer een feestje. Lieve Teus, jij maakt ons gezinnetje meer dan compleet. Wat ben je toch 
een heerlijk ventje! Jouw vrolijkheid en ontspannenheid geeft mij ruimte deze woorden 
op papier te zetten, met jou heerlijk tevreden slapend aan mijn zijde. Hou-jullie lieve 
toppers van me!
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Ellen Antoinette Croonen werd geboren op 18 december 1983 in Nijmegen en groeide op 
in het Gelderse Afferden. Na het behalen van haar VWO diploma aan het Pax Christi College 
te Druten ging zij in 2002 geneeskunde studeren aan het Leids Universitair Medisch 
Centrum (LUMC) te Leiden. 
 Gedurende de studie geneeskunde heeft Ellen profilering gezocht binnen de kinder-
geneeskunde door middel van keuzevakken. Voordat de co-schappen begonnen heeft 
Ellen twee wetenschappelijke stages gedaan binnen de kindergeneeskunde. De eerste 
wetenschappelijke stage verrichtte zij in het Canisius Wilhelmina Ziekenhuis te Nijmegen 
onder supervisie van Dr. Ben A. Semmekrot (kinderarts). Ellens wist tijdens deze stage 
overplaatsing naar de Radboud Universiteit Nijmegen te realiseren, op voorwaarde van 
een extra wetenschappelijke stage. Zij kwam in contact met Dr. Jos M. Th. Draaisma 
(kinderarts) in het Radboudumc Amalia kinderziekenhuis te Nijmegen. Aldaar startte zij, 
tevens in samenwerking met Dr. Ineke van der Burgt (klinisch geneticus) en Dr. Livia 
Kapusta (kindercardioloog), een onderzoek naar de karakteristieken van het electro-
cardiogram bij personen met het Noonan syndroom. Na deze wetenschappelijke stages 
begon Ellen aan haar co-schappen in Nijmegen en volgde onder andere een senior 
co-schap kindernefrologie in het Radboudumc Amalia kinderziekenhuis te Nijmegen.
 Eind 2008 behaalde Ellen haar artsdiploma, waarna zij in januari 2009 startte als 
ANIOS (arts niet in opleiding tot specialist) Kindergeneeskunde in het Canisius Wilhelmina 
Ziekenhuis te Nijmegen. In juni 2010 ging Ellen in opleiding tot kinderarts in het cluster 
Nijmegen en bleef zij tot januari 2012 werkzaam in het Canisius Wilhelmina Ziekenhuis te 
Nijmegen (opleider Dr. Ben A. Semmekrot, kinderarts). Per januari 2012 vervolgde Ellen 
haar opleiding tot kinderarts in het Radboudumc Amalia kinderziekenhuis te Nijmegen 
(opleider Dr. Jos M. Th. Draaisma, kinderarts). Ellen heeft haar opleiding tot kinderarts 
afgerond in augustus 2016. Gedurende haar profileringstage is zij reeds gestart met de 
opleiding tot kinderlongarts, een functie waarin zij nu zowel werkzaam is in het 
Radboudumc Amalia Kinderziekenhuis alsook in het Canisius Wilhelmina Ziekenhuis. 
 Sinds haar wetenschappelijke stage bij dr. Jos M. Th. Draaisma heeft Ellen zich naast 
haar werkzaamheden als A(N)IOS kindergeneeskunde en kinderarts in opleiding tot 
kinderlongarts actief ingezet in onderzoek naar Noonan syndroom. Dit alles heeft, 
onder begeleiding van Prof. Dr. Kees Noordam (kinderarts-endocrinoloog), Prof. Dr. Ria 
W.G. Nijhuis-van der Sanden (kinderfysiotherapeut), Dr. Jos. M. Th. Draaisma (kinderarts) 
en Dr. Ineke van der Burgt (klinisch geneticus), geresulteerd in de totstandkoming van dit 
proefschrift.
 Ellen is sinds 2013 gelukkig getrouwd met Martijn Janssen Steenberg en samen zijn zij 
de trotse ouders van hun zoons Geert (2014) en Teus (2017). 
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ALL Acute lymphoblastic leukemia
ASD Atrial septal defect
AVSD Atrio ventricular septal defect
BMI Body Mass Index
CA Coarctatio aortae
CFC Cardio-Facio-Cutaneous 
CHD Congenital heart defects
CS Costello syndrome 
ECG  Electrocardiogram 
FDA Food and Drug Administration
GA  Gestational age
GEF Guanosine nucleotide exchange factors
GDP Guanosine diphosphate
GRB2 Growth factor receptor-bound protein 2 
GTP Guanosine triphosphate
HCM Hypertrophic cardiomyopathy
HLH Hypoplastic left heart
HOCM Hypertrophic obstructive cardiomyopathy
IQ Intelligence quotient 
JLS Jugular lymphatic sacs
JMML Juvenile myelomonocytic leukaemia 
LVH Left ventricular hypertrophy
NA Not applicable
ND Not determined
NF1  Neurofibromatosis type 1
NS Noonan syndrome
NSML Noonan syndrome with multiple lentigines
NT Nuchal translucency
PDA   Patent ductus arteriosus
PE Pericardial effusion
PTP Phosphotyrosine phophatase
PVS Pulmonary valve stenosis
RAS/MAPK  Ras-mitogen-activated protein kinase
RTK Receptor tyrosine kinase
RV Right ventricle
SD Standard deviation
SDS Standard deviation score
SOS Son of sevenless
TOP Termination of pregnancy
TR Tricuspid regurgitation
VSD Ventricular septal defect
517840-L-bw-croonen
Processed on: 6-3-2018 PDF page: 196
